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CHAPTER 1. INTRODUCTION 
1.1 General introduction 
Spatial distribution and temporal release of specific biologically active molecules by 
light activated compounds help researchers to study how various chemical events mediate 
different biological processes. This thesis is directed towards developing new tools for 
achieving spatial and temporal control for enzyme inhibitors using light and caged 
complexes. An effort has also been made to introduce various aspects involved in developing 
caged compounds for biological applications. This chapter also outlines the applications of 
light, metals and photocages in biology. Current work involves developing light-activated 
metal-based complexes for caging enzyme inhibitors. A brief introduction of cathepsins is 
provided, because we wanted to develop caged cathepsin inhibitors. We have shown that 
ruthenium-based caged cathepsin inhibitors can be used for achieving spatial and temporal 
control over enzyme inhibition.  
1.2 Light in therapeutics 
The electromagnetic spectrum consists of oscillating electric and magnetic waves 
whose wavelengths range from a few picometers to thousands of kilometers. Based on the 
frequency of vibrations, the electromagnetic spectrum is subdivided into different waves. 
These waves are made of the same kind of vibrations but differ in their frequencies. While 
different waves have different applications, light has been widely used in therapeutics against 
many disease states.1 Light has numerous effects on animal and plant life; it acts as a vital 
stimulant and has numerous effects on the skin, nervous system, blood circulation and 
cutaneous glands. Light also increases the hemoglobin content of the blood. Apart from 
stimulating eyes, which sends signals to our brain and enables to see things around us, light 
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has also found its application in therapeutics. In the late 18th century, patients were advised 
by physicians to sunbathe for health benefits. Later light therapy, exposure to artificial light, 
gained therapeutic importance. The first electric light bath was developed in 1891 for treating 
patients at the Battle Creek sanitarium. Since then the electric light bath was introduced in 
many hospitals for treating various diseases such as acne vulgaris, ulcerating lupus, 
dermatitis and neck abscesses. Light therapy affects neurotransmitters and helps in treatment 
of physiological conditions like depression and sleep disorders.2 Numerous book chapters 
have been dedicated towards explaining the importance of light in medicine and provide a 
better understanding of the topic.3-5  
Absorption of light by various molecules can dramatically influence their reactivity. 
This unique feature can be used in numerous applications, as molecules in their excited states 
have different electronic properties compared to their ground states. Photo-excitation can also 
cause changes in geometries, bond angles and bond lengths in the molecule. Thus light can 
also be used in the activation of many molecules such as photosensitizers for photodynamic 
therapy, metal complexes for anticancer applications and caged complexes for drug delivery 
systems. These applications of light are directly related to this dissertation topic and will be 
briefly discussed in subsequent sections of this chapter.  
1.3 Metals in medicine 
Metal ions play a very crucial role in numerous biological processes, which include 
gene regulation, neurotransmission, respiration, synthesis of antibiotics and DNA repair.6,7 
Bioinorganic chemistry, which deals with the study of metals in biology, is a rapidly growing 
area of research with a high potential for developing metal complexes as therapeutic agents 
with novel mechanisms of action.  While organic molecules dominate the pharmaceutical 
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industry and drug market, novel drugs containing metal ions are finding their way into 
medicine. The first metal-based drug, Salvarsan (Arsphenamine), introduced in 1910 was an 
organoarsenic agent developed for treatment of syphilis.8 The initial structure proposed for 
Salvarsan was a bimetallic compound 1 containing an As=As double bond.  More recently 
the structure of Salvarsan was proposed with As-As single bonds and containing a mixture of 
cyclic-As3 (2) and cyclic-As5 (3) species (Figure 1).9  
 
Figure 1: Structures proposed for Salvarsan 
Medicinal inorganic chemistry received its largest breakthrough with the success of 
cisplatin, which is renowned as the best selling anticancer drug.10 Fifty percent of cancer 
chemotherapy uses cisplatin for inducing cell apoptosis by interacting with DNA.11 Apart 
from platinum complexes, numerous polynuclear platinum (II) complexes were also 
developed for anti-cancer applications.12 Despite being widely used for cancer treatments, 
cisplatin has many neurotoxic and nephrotoxic effects. These drawbacks have driven 
researchers to develop new platinum and other metal ion containing drugs for oncology. 
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10,11,13-20 Apart from oncology, bioinorganic chemistry has produced innovative drugs for 
numerous therapeutic applications such as silver-containing antimicrobial agents, iron 
chelators as antimalarial agents,21 vanadium complexes as insulin mimetics and gadolinium 
complexes for diagnostic purposes.10 More recently, Au(I) and Au(III), two different classes 
of gold-containing compounds have been developed for anticancer applications.22 
Thermodynamically both Au(I) and Au(III) oxidation states are unstable when compared to 
Au(0) and can act as oxidizing agents causing cytotoxic effects.  
Compared to organic small molecules, metal complexes have distinct electronic, 
chemical and photophysical properties, which could be utilized in many biological 
applications. Biology utilizes numerous inorganic elements for various functions such as Na+, 
K+ and Ca2+ for charge balance,23 Ca2+ and Zn2+ for propagation of biochemical signals, Fe 
and Cu complexes for electron transport24 and various metals for redox catalysis.25 In addition 
to naturally bioavailable inorganic elements, researchers have applied transition metals and 
lanthanide elements to biology. Ru- and Pt–based complexes are used for interactions with 
biomolecules such as DNA.26,27 Iron, copper and zinc chelators are developed to alter 
bioavailability of metal ions in cell biology for studying the effects of metal ions in cell 
processes.28 Mn- and Ru-based complexes were developed for releasing small molecules 
such as NO (4 and 5, Figure 2) and CO (6, 7 and 8, Figure 2) by breaking M-NO or M-CO 
bonds in vivo.29,30 Gd and Mn complexes are being developed as MRI agents.25 Research in 
the area of metals in medicine is abundant; therefore in subsequent sections focus will be laid 
on ruthenium complexes in medicine as it is directly related to the projects described in this 
dissertation. 
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Figure 2: Mn- and Ru-based complexes as NO and CO releasing metal complexes. 
Ruthenium complexes are developed for many medicinal applications where they act 
as anticancer, antibiotic, immunosuppressant and antimicrobial agents.31,32 Excess NO can 
result in physiological conditions such as stroke, epilepsy and septic shock. Nitric oxide 
forms stable ruthenium (II) mononitrosyls when they are treated with different Ru(III) 
complexes. Thus ruthenium compounds can act as nitric oxide scavengers.33 Properties like 
rates of ligand exchange and range of accessible oxidation states make ruthenium-based 
complexes suitable for medicinal applications. While cisplatin has revolutionized the 
bioinorganic field, drug resistance and toxicity arising from platinum drugs has fueled the 
screening process for discovering other metal ion based anticancer drugs. Similar to platinum 
drugs, ruthenium compounds also cause DNA interaction and damage.34 FDA approved 
platinum-containing anticancer drugs are cisplatin (9), carboplatin (10) and oxaliplatin (11) 
(Figure 3). NAMI-A (12) was the first ruthenium-based anti-cancer drug to enter clinical 
trials. NAMI-A contains inert Ru(III), which upon entering into tumor cells is reduced to 
Ru(II), which is the active anti-cancer agent. KP1019 (13) was the second ruthenium-based 
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anti-cancer drug to enter clinical trials. KP1019 induces apoptosis by bending and untwisting 
DNA.35 Ruthenium complexes are also used for photocaging applications of bioagents.36-40 
Applications of ruthenium complexes in biology are well summarized by Tomasz 
Respondek, a fellow graduate student from our group, in his thesis.41  
 
Figure 3: Platinum- and ruthenium-based anticancer agents.   
1.4 Photocages for biological applications 
Photolabile caging groups (photocages) are molecules that can be cleaved using light. 
Light can be controlled both spatially and temporally with great precision; thus it can be used 
in activation of biomolecules leading to targeted release. Based on the target biomolecules, 
either the caging group or the caged molecule interacts with the biomolecules (Figure 4).  
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Figure 4: Photocaging approach for two different biological applications; A) ligand 
acts as biological agent and B) caging group acts as therapeutic agent.  
 
Many different photocages are being developed for bioagents, including enzymes, 
neurotransmitters, fluorophores, insecticides and enzyme inhibitors for different biological 
applications. Initially, organic groups were developed for photocaging applications. Different 
functionalities such as amines, carboxylic acids, alcohols, amides, and phosphates can be 
caged using organic photocages, which was summarized in a recently published review 
article.42 Factors such as high quantum yields for the release of bioagents, strong absorption 
of light of λ > 300 nm (to prevent damage of biological entities by light), solubility of the 
photocages in the targeted media, distribution and nontoxic byproducts govern the usefulness 
of the organic photocaging groups. Numerous caged bioagents (14 - 19) are commercially 
available and used. For example, the widely used o-nitrobenzyl organic protecting group can 
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be cleaved using long wave UV light to give uncaged compound (23) and nitroso byproducts 
(24) (Scheme 1).43   
 
Figure 5: Common functional groups caged using organic and inorganic photocages. 
Organic photocages can be cleaved using single-photon UV excitation or two-photon 
excitation, which uses less energetic light, typically ranging between the visible to near-IR 
region. Both of these strategies have their own advantages and disadvantages. While single-
photon excitation has higher spot precision, two-photon excitation possesses greater depth 
discrimination.42,44,45 More recently, organic photocages that can be cleaved by visible light 
have been developed.46 
 
Scheme 1: Organic molecules as photocages - Carboxylic acid functionality protected 
with organic photocaging group and its corresponding photolysis products. 
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More recently metal complexes are being developed for photocaging applications. 
With single-photon excitation, most of the organic photocages are uncaged using UV light, 
but metal complexes show photo-cleavage in visible region. Also, metal complexes can be 
used for caging functional groups such as nitriles,47,48 thioethers49 and pyridines,50 which 
cannot be caged using standard organic photocaging groups (20 and 21 in Figure 5). Thus, 
metal complexes provide an orthogonal approach for researchers in caging bioactive 
molecules.  
 
Scheme 2: Metal complexes as photocages - Ru-based photocaging group and its 
corresponding photolysis products. 
 
An advantage of using metal-based photocages is the reduction of risk of damage to 
biomolecules due to the usage of less energetic visible light. In biology, metal-based 
photocages are utilized for two different applications. First, they can be developed for 
targeting biomolecules, where the metal complex itself acts as a bioagent after photo-
excitation (Figure 4B). Here photocaged complexes act as prodrugs, and light of a suitable 
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wavelength serves the purpose of converting the prodrugs into their active forms.10,31,51-55 
Numerous platinum- and ruthenium-based complexes can act as anticancer agents after 
photodissociation (Figure 6).31 Secondly, ruthenium complexes act as protecting groups for 
biomolecules (Figure 4A). One area where metal complexes acting as protecting groups has 
proven particularly useful is neuroscience. Researchers have utilized ruthenium complexes 
for caging neurotransmitters such as tryptamine, tyramine, serotonin, GABA and butylamine 
using the Ru(bpy)2 caging group 34 (Figure 7). 36 They showed that introducing a phosphine-
based ligand alters the MLCT and quantum yield of the reaction. Complex 35 shows a higher 
quantum yield and faster ligand exchange when compared to [Ru(bpy)2(GluH2)2]2+. The 
photorelease of glutamate from 35 occurs at 532 nm (single-photon excitation) or at 800 nm 
(two-photon excitation).56 This dissertation will focus on developing ruthenium complexes 
for caging enzyme inhibitors for achieving spatial and temporal control over enzyme 
inhibition.  
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Figure 6: Examples of platinum- and ruthenium-based photocages used as 
therapeutic agents that are anticancer agents similar to cisplatin. 
 
Figure 7: Ruthenium-based photocages used for caging bioagents. 
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1.5 Photodynamic therapy (PDT) 
For decades light has been used for therapeutic applications against many disease 
states such as depression, vitiligo, rickets and psoriasis. Light therapy involves patient 
exposure to sunlight or light of a particular wavelength. More recently light has been used for 
photodynamic therapy (PDT).57-65 The first example of PDT was reported in the early 1900s 
in which scientists observed that light in combination with other chemical agents could 
induce apoptosis.66 In photodynamic therapy, three nontoxic components; light, a 
photosensitizer and oxygen; are used for inducing cell death.67 
 
Figure 8: Photosensitizers used in PDT 
Photosensitizers are organic molecules that are photosensitive and can be excited 
using light. Many photosensitizers have been developed for different malignant diseases.57,68 
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Most of the sensitizers are porphyrin-based compounds such as 36, 37 and 38 (Figure 8). 
Porphyrin precursors such as 5-ALA 39 and 5-ALA esters 40 are also used for PDT 
applications where they are transformed into porphyrins inside human cells. Once the 
photosensitizers reach the target cells or tissues, they can be activated using light of a suitable 
wavelength. Due to this unique feature, different photosensitizers and wavelengths of light 
are used for different malignant diseases. Once the photosensitizers are irradiated with light, 
the ground state sensitizer is transformed into its corresponding singlet excited state. Through 
intersystem crossing (ISC) the singlet excited state is transformed into a low-lying triplet 
excited state.  The activated triplet photosensitizer then follows one of the two major reaction 
pathways for inducing cell death using tissue oxygen. The two pathways are (i) direct 
reaction with substrate to generate radicals, which can then react with tissue oxygen to 
generate oxygenated products, or (ii) direct energy transfer to tissue oxygen to generate 
reactive oxygen species (ROS) (Figure 9). These ROS can then oxidize the surrounding 
substrates, leading to cell toxicity and cell death.57 
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(b) 
Figure 9: (a) Pictorial representation of PDT and (b) Jablonski diagram of PDT 
showing energy transfer to tissue oxygen for the generation of ROS.  
 
Reactive oxygen species induce phototoxicity by oxidizing biomolecules such as 
proteins, lipids and DNA.69 ROS can also inhibit enzyme activity by oxidizing enzyme 
cofactors. Singlet oxygen formed during PDT can oxidize fatty acids and amino acids, which 
are the building blocks for lipids and proteins. They can also react with double bonds or with 
C-H bonds of DNA.70 Oxidation of DNA can induce cell toxicity through modifications such 
as strand breakage, removal of nucleotides, nucleotide mismatching and DNA-protein 
crosslinking.71 Numerous PDT sensitizers are being developed and are currently under 
clinical trials. Presently PDT is being tested and used in treatment of many cancers such as 
advanced esophageal tumors, lung cancer, bladder cancer, brain tumors, head and neck 
cancers and intrathoracic tumors.58  
While PDT has found many therapeutic applications, it cannot be used for treating 
hypoxic tumors. In PDT, tissue damage and cell death are highly dependent on sensitizer 
distribution, as the formed ROS have very short lifetimes and limited migration from the site 
of formation.58,72,73  
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1.6 Photoactivated ligand dissociation 
 Light is also used in photoactivated ligand dissociation of metal complexes. This 
novel strategy is being used in developing many therapeutic agents. Utilizing this strategy, 
numerous platinum and ruthenium complexes are being developed for anticancer 
applications. This strategy does not require tissue oxygen and can be used against hypoxic 
tumors. Research has shown that various photolabile Ru complexes can cause DNA damage 
after photodissociation. For example cis-[Ru(bpy)2(NH3)2]+2 (31) undergoes 
photodissociation when irradiated with visible light and can then interact with DNA, causing 
cytotoxicity.15 The mechanism of photodissociation of Ru(bpy)3+2 was reported in the 1980s, 
when they suggested that Ru(bpy)3+2 undergoes ligand dissociation by forming a 
pentacoordinated intermediate, which forms from thermal activation of d-d excited states.74 
The metal complex reaches the d-d excited state through the triplet charge transfer state, 
which is formed from initial excitation. The same mechanism is extended to the metal 
complexes of Ru(bpy)2(X)2+2 type (Figure 10). Upon absorbing light of a suitable 
wavelength, metal complexes from their ground state reach their corresponding singlet metal 
to ligand charge transfer state (1MLCT). These 1MLCTs reach their 3MLCTs through 
intersystem crossing (ISC), which upon internal conversion (IC) give triplet metal center 
states (3MC). Triplet MCs can then facilitate ligand dissociation, leading to photolability. 
More recently, photocleavage of Ru(bpy)2(X)2+2 type complexes are also shown to proceed 
via a pentacordinated Ru species that quickly traps solvent molecules.75 Photodissociation 
opens up coordination sites on the metal center, which can then bind to DNA. Chemists have 
utilized photoactivated ligand dissociation for developing novel platinum- and ruthenium- 
based anticancer agents.15,51  
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 This strategy can also be used for spatially controlled delivery of bioagents. 
Researchers utilize the photoactivated ligand dissociation mechanism for delivery of 
neurotransmitters38 and NO76. More recently it was shown that [Ru(bpy)2(5CNU)]2+ 25 can be 
used as a dual therapeutic agent (Scheme 2), where photodissociation leads to the release of 
the biologically active agent (5-cyanourasil) and generation of a DNA-binding agent.47 They 
have also shown that [Ru(bpy)(dppn)(CH3CN)2]2+ can be used as a dual therapeutic agent 
which can generate ROS and also produce [Ru(bpy)(dppn)(H2O)2]2+ through ligand 
dissociation, which can interact with DNA.77 One area of research in Kodanko group is 
utilizing this photoactivated ligand dissociation mechanism in developing new tools for 
achieving spatial control over enzyme inhibitors.  
 
Figure 10: Jablonski diagram of photoactivated ligand dissociation.  
1.7 Cysteine cathepsins proteases 
Biological systems are extraordinarily complex and posses high levels of spatial and 
temporal control. This includes enzymes, which carry out many different functions. One such 
class of enzymes is proteases, which are distributed all over the body. Proteases are a class of 
enzymes that facilitate hydrolysis of polypeptides by cleaving the peptide bonds between 
amino acid residues.78-80 Proteases are further classified into endopeptidases and 
exopeptidases depending on the site of hydrolysis of a protein chain. Endopeptidases cleave 
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the peptide bonds at nonterminal positions while exopeptidases cleave terminal peptide 
bonds. Based on the residues involved in the catalytic cycle, proteases are classified into six 
different groups.81 The six different groups are serine, threonine, cysteine, aspartate, glutamic 
acid proteases and metalloproteases. Cysteine proteases have a nucleophilic cysteine thiol in 
the catalytic cycle for the hydrolysis of peptide bond. The catalytic triad of cysteine proteases 
is composed of an asparagine residue, a histidine residue and a cysteine residue. Peptide bond 
cleavage occurs through enzyme acylation formed from the tetrahedral intermediate. The 
acylated enzyme (acyl ester) undergoes hydrolysis to regenerate the free enzyme (Scheme 
3).82  
 
Scheme 3: Proteolysis mechanism by cysteine protease 
Cysteine cathepsins, which are lysosomal proteases, belong to the papain family. 
Eleven different human cysteine cathepsins (cathepsin B, C, F, H, K, L, O, S, V, X and W) 
have been identified and studied.83,84 Cathepsins F, K, L, O, S, V and W are endopeptidases 
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while cathepsins B, C, H and X are exopeptidases. These enzymes are intracellular and are 
mainly located inside the lysosomal vesicles.  
While cathepsins are distributed all over the body, a few cathepsins, like cathepsin K 
(CTSK), cathepsin W (CTSW) and cathepsin S (CTSS), are more tissue specific.85 In 
osteoclasts, epithelial cells and the synovial fibroblasts of rheumatoid arthritis joints, high 
levels of CTSK were reported. CTSL is ubiquitously expressed, but CTSV, which is 
homologous to CTSL, is expressed only in the thymus and testis.86 Apart from cellular 
protein degradation and turnover, cathepsins are found to play a role in bone resorption and 
remodelling,87 brain and skin development,88,86 keratinocyte differentiation and other 
biological processes. CTSS helps in protein loading, as it controls MHC class II antigen 
presentation pathway.89 CTSL localized to the nucleus is associated with the regulation of 
cell-cycle progression and also shows interactions with histones, opening a new role for these 
enzymes.90 CTSL also helps in regular hair-follicle morphogenesis and its deficiency leads to 
periodic hair loss.91 In normal conditions, well-coordinated signaling pathways regulate the 
production and activity of cathepsins but during abnormal malignancies, well-coordinated 
signaling systems get altered. These irregularities can lead to overproduction of cathepsins. 
Increased levels of cathepsin activity are related to various disease states such as obesity, 
cancer, inflammation and neurological disorders.85 
For further reading, researchers are referred to many review articles, which are 
dedicated to understanding the role of cathepsins in relation to various pathological 
conditions.83-85,92-96 Instead, only their role (cathepsins in general, and CTSK and CTSB, in 
particular) in cancer growth and metastasis will be briefly discussed as they are directly 
related to the topic of this dissertation. 
  
	
19 
Cysteine cathepsins were previously thought to function primarily intracellularly 
inside lysosomal vesicles until recently, when evidence was found to show them functioning 
both extracellularly and intracellularly in cancer.97,98 Researchers have shown through 
experimental models and results that increased cathepsin activity has an important role in 
tumor growth and progression.99-102 Extracellular cathepsins help in tumor progression 
through collagen degradation,85,103 and intracellular cathepsins assist in tumor invasion 
through proteolysis.104 
Cathepsin B promotes cell migration during wound healing by helping in remodeling 
the extracellular matrix.105-108 Overexpression and dysregulation of CTSB is correlated to 
cancer growth and progression.106 Aberrant CTSB activity is associated with many kinds of 
cancers including brain, prostate, breast, colorectal, and lung cancer.105,109,110 Studies show 
that tumor cells secrete CTSB into the extracellular matrix, which then leads to matrix 
degradation, facilitating tumor progression.94,111-113 Numerous research articles have been 
published summarizing aberrant CTSB activity in tumor invasion and progression, and thus 
will not be discussed further.85,92,100,102,105-107,109-111,114-117  
CTSK, which is predominantly expressed in osteoclasts, plays an important role in 
bone resorption and remodeling.118-120 CTSK is responsible for collagen I degradation. 
Studies relate osteoporosis and tumor-induced bone resorption to aberrant CTSK 
activity.118,120-122 Taken together, these data suggest that aberrant expression and/or activity of 
CTSB and CTSK is critical for tumors and other related conditions, and they could be viable 
therapeutic targets.93,123-127  
Different classes of small molecule inhibitors targeting cathepsins have been 
developed by both academia and industry.92,93,128,129 All these inhibitors react with the thiol of 
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the cysteine residue lying in the enzyme active site. Depending upon the warhead present, 
cathepsin inhibitors react with the thiol either in a reversible fashion or irreversibly.93 
Cathepsin inhibitors usually contain a peptide segment, which helps in enzyme recognition, 
and an electrophilic warhead, which reacts with the cysteine residue. The electrophilic 
warhead can include, but is not limited to, nitriles, aldehydes, semicarbazones, ketones and 
epoxysuccinyl derivatives (Figure 11).93 Though overexpressed in the tumor 
microenvironment, cathepsins are required for normal cell growth and function, and a major 
drawback with most of the cathepsin inhibitors in vivo is their offsite reactivity as small 
molecules lack spatial control. 
 
 
Figure 11: Examples of cathepsin inhibitors with different warheads  
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Numerous review articles have been published describing the use of nitrile-based 
inhibitors for cysteine proteases.127,130-136 Acetamidoacetonitrile (46) and 
benzamidoacetonitriles (47) were the first nitrile-based inhibitors developed for cysteine 
proteases (Figure 12).137 
 
Figure 12: First discovered nitrile-based cathepsin inhibitors. 
 
 
Scheme 4: Interaction of cysteine proteases with nitrile-based inhibitors. 
Based on their electrophilic properties, nitrile inhibitors are further divided into (i) 
aminoacetonitriles, (ii) aromatic nitriles and (iii) cyanamides. Cyannamides were reported to 
have the highest electrophilicity, whereas benzonitriles were least electrophilic.132,138 
Cathepsin inhibitors with nitrile functionality reversibly react with the thiol of the cysteine 
residue to give thioimidiate intermediates (Scheme 4).131,133 Numerous research articles have 
been published dealing with the development of dipeptide nitriles as potent and selective 
inhibitors of cathepsins.127,130-132,139 Dipeptide inhibitors can either inhibit many different 
cathepsins or they can specifically inhibit one type of cathepsin. For example, compound 51 
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are being developed, no molecule has reached the market.135 Clinical trials of Odanacatib 
(54), a nitrile-based CTSK inhibitor developed by Merck, have shown promising results for 
the treatment of osteoporosis, but side effect profiles from phase III clinical trials have forced 
Merck to delay FDA filing.141,142 Odanacatib is a reversible covalent modifier and reacts with 
thiolates through a Pinner-type mechanism.135 Another nitrile-based inhibitor to reach clinical 
trials is Balicatib (53), which was developed by Novartis. Balicatib is a highly selective 
CTSK inhibitor with an IC50 of 1.4 nM. Although promising results were seen initially, phase 
II trials were discontinued due to numerous nonselective off-target effects.143 Compounds 55 
and 56 are examples of cyanamide-based cysteine protease inhibitors. 
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Figure 13: Nitrile-based inhibitors of cathepsins with their corresponding IC50 values. 
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cathepsins lack spatial control. Small molecules lack the ability to selectively inhibit 
cathepsin activity in tumor microenvironment. If normal small molecules are used they 
inhibit cathepsins in normal cells as well, leading to toxicity. Thus new tools for achieving 
spatial control over enzyme inhibitors should be explored.  
     1.8 Proof of concept (background work) 
While researchers have used Ru(bpy)2 for caging neurotransmitters, the Kodanko 
group, in collaboration with the Turro group, has caged nitrile-based cathepsin inhibitors 
using the same caging group.146 The compound cis-[Ru(bpy)2(Inh)2]+2 (57) was synthesized 
where Inh (59) was a CTSK inhibitor (Ac-Phe-NHCH2CN) which binds to ruthenium 
through the nitrile functional group.  
 
Scheme 5: Photodissociation of cis-[Ru(bpy)2(Inh)2]+2  
Complex 57 shows excellent stability in the dark, and fast dissociation of the caged 
inhibitor in the light (Scheme 5). Photodissociation proceeds through formation of a 
monoaqua complex with ΦRèI = 0.080(4), which upon further irradiation gives complex 58 
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than in the dark (IC50 = 170 μM) against papain, where the IC50 value for free inhibitor (Inh) 
was 12 μM. This method of caging cathepsin inhibitors with a ruthenium complex provides a 
novel approach to achieve control over enzyme activity.  
Though photocaging of bioactive agents is being explored for different biological 
applications, current Ru-based cages utilize planar heteroaromatic ligands such as bpy, phen 
and terpy. Cages derived from other multidentate nonplanar ligands are under-investigated. 
The complex [Ru(bpy)3]+2 is known to lose a bpy ligand upon photoactivation, so 
multidentate ligands should be developed for caging biomolecules to avoid 
photodecomposition in the biological system. The ligand structure directly impacts MLCTs 
and photoreactivity of the caged complexes. Research has recently shown that sterically 
bulky bidentate ligands enhance photodissociation of a pyridine ligand. 50,147 Thus, 
modulating ligand structure opens a window for developing novel ruthenium complexes with 
high quantum yields for dissociation and photocleavage using less energetic light.    
1.9 Thesis statement 
Biological systems, which are extraordinarily complex, possessing high levels of 
spatial and temporal control, sometimes have dysregulations in enzyme activity. Though 
numerous inhibitors are being developed, their off-target reactivity and lack of spatial control 
cut back their in vivo applicability.  Therefore, new strategies for selective activation of 
bioactive molecules in desired areas need to be developed. Also, the caging strategy provides 
spatial and temporal control over biological molecules, which could help in understanding 
various biological processes. One such strategy is the photocaging strategy where the 
bioactive molecules would be activated only in the desired area by light. While different 
metal ions can be used for developing caged groups for bioactive molecules, we sought to 
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use ruthenium-based caging groups as a platform for releasing inhibitors in a spatially 
controlled fashion. Recently this ruthenium-based caging strategy has been demonstrated for 
caging neurotransmitters and simple cathepsin inhibitors bearing amine, pyridine and nitrile 
functionality. The goal of this dissertation is to further explore various ruthenium-based 
groups for caging different agents and studying their biological applications.  
The first goal of this dissertation is to cage nitrile-based cathepsin inhibitors with 
higher activity using a Ru(bpy)2 caging group. The caged complexes, cis-[Ru(bpy)2(L)2]2+, 
with L being the nitrile-based inhibitor, were synthesized and fully characterized. 
Photodissociation and various enzyme inhibition studies were performed on isolated enzymes 
and also on 2D and 3D assays under both dark and light conditions. Stability studies were 
undertaken to show the compatibility of the caged complexes in biological media. Toxicity 
studies with caged complexes in dark and light were performed to rule out any toxic effects 
on cell viability.  
The second goal of this dissertation is to develop novel ruthenium-based caging 
groups using multidentate ligands and to study ligand effects on photodissociation of caged 
ruthenium complexes. We proposed a solid phase-based synthesis and screening method of 
various metal complexes for caging applications.  
The last section of this dissertation deals with studying excited state properties of 
ruthenium complexes. Efforts were made toward developing novel ruthenium-based 
photosensitizers with exceptionally long-lived excited states for different applications. 
Background and strategies implemented for achieving each goal are discussed in the 
following chapters along with experimental procedures and data. Lastly, conclusions and 
future directions for each goal are discussed at the end of this dissertation.  
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CHAPTER 2. INHIBITION OF CATHEPSIN K ACTIVITY IN A CELL- 
BASED ASSAY BY LIGHT ACTIVATED CAGED RUTHENIUM 
COMPLEXES1 
2.1 Introduction 
Caging biomolecules and releasing them through a light activated ligand dissociation 
pathway provides an excellent strategy to manipulate biological activity with spatial and 
temporal control.42,148,149 The first example of caged nitrile-based protease inhibitor was 
described in the last part of the previous chapter, where a nitrile-based cathepsin K inhibitor 
was caged using the Ru(bpy)2 caging group.146 In this approach, the cathepsin K inhibitor was 
protected from a reactive cysteine thiol by covalently binding to a ruthenium center. The 
Ru(bpy)2 caging group was used because pioneering work demonstrated its application in 
caging neurotransmitters and using it in biological research.36,37,40,150-152 Importantly, these 
ruthenium complexes and their corresponding photolysis byproducts showed no toxic effects. 
Cathepsin K inhibitors were chosen for caging because numerous reports outline the 
relationship between aberrant cathepsin K activity and metastatic bone disease.97,118,119,144,153,154 
Cathepsin K plays a crucial role in osteoclastic bone resorption,119 macrophage invasion and 
tumor growth.155,156 High levels of cathepsin K activity in bone metastates, when compared to 
primary tumors and soft tissues, make it a viable target for chemotherapy. Also, growth and 
progression of prostate carcinoma cells (PC3) implanted into CTSK knock-out mice 
significantly decreased in comparison to tumors implanted into wild-type mice, suggesting 
the importance of CTSK activity in bone tumor progression. While numerous small 																																																								1	Portions of the text in this chapter were reprinted and adapted with permission from Respondek, 
T.; Sharma, R.; Herroon, M. K.; Graner, R. N.; Knoll, J. D.; Cueny, E.; Turro, C.; Podgorski, I.; 
Kodanko, J. J. Chem. Med. Chem. 2014, 9, 1306.	
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molecules were developed for CTSK inhibition, lack of spatial control and off-target 
reactivity lead to side effects and subsequent failure in clinical trials.83,142 For this reason, new 
tools may be needed for achieving localized protease inhibition. 
Towards this goal, photoactivated CTSK inhibitors were developed. In the “proof of 
concept” approach, Ac-Phe-NHCH2CN, (59)  (IC50 = 12 μM) was used for testing the caging 
strategy. Two equivalents of 59 were caged using Ru(bpy)2 and subsequently both the 
equivalents were released in 10 min using visible light irradiation. Initial success motivated 
us to develop a new class of Ru-based caged compounds with more potent inhibitors of 
CTSK. Herein, two new CTSK inhibitors (60 and 61) with higher activity and their 
corresponding Ru-caged complexes were developed. We also demonstrated that our strategy 
could be used for protease inhibition in living cells. Subsequent sections in this chapter will 
provide convincing evidence that our caged inhibitors are nontoxic and can be further 
developed as chemical tools for understanding the role of different proteases within living 
systems, including animal models of human disease states.  
2.2 Results and discussions 
2.2.1 Synthesis and characterization of [Ru(bpy)2(L)2](X)2 (62 and 63) 
complexes 
Literature data show that subtle modifications of compound 59, which was used in the 
previous study, can lead to significant enhancements for inhibition of CTSK activity.127,139 
Compounds 60 and 61 were chosen for caging; IC50 values were roughly three orders of 
magnitude lower than compound 59 (Figure 14).   Compound 60 was chosen because it was 
structurally similar to 59 and was known to inhibit CTSK activity in live cell assays.139 
Compound 61 was chosen because it had more drug-like properties, possessing longer 
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plasma stability and around ten-fold longer half-life in vivo than 60. Also, 61 had an alpha-
substitution that we were interested in studying to see its effects on properties of the caged 
complex. Compounds 60139 and 61127 were synthesized by following published procedures 
from enantioenriched Cbz-Leu-OH and Boc-Ser(OBn)-OH respectively.  
 
Figure 14: Nitrile-based CTSK inhibitors with their corresponding IC50 values. 
Upon treating cis-[Ru(bpy)2Cl2] with 60 (6.0 equiv) in EtOH at 80 oC for 5 h, in the 
presence of silver tetrafluoroborate, a color change from violet to orange occurred. The 
reaction mixture was cooled to –20 oC, filtered through celite and concentrated under reduced 
pressure to obtain an orange solid. Spectroscopic analysis of the crude reaction mixture 
confirmed that 60 was bound to ruthenium with high conversion, as there were no metal-
based byproducts. To remove excess 60 and purify the complex 62, the crude solid was 
dissolved in ethyl acetate and treated with nBu4NCl. Upon cooling to –20 oC, an orange oily 
residue was observed, which was washed with ethyl acetate and toluene several times to 
remove excess nBu4NCl. Subsequent precipitation (layering) from acetone and diethyl ether 
for multiple cycles, followed by drying in vacuum, gave the caged inhibitor 62 in analytically 
pure form. Complex 63 was prepared by following a similar procedure; however, the 
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tetrafluoroborate salt was purified using silica gel chromatography, giving directly the pure 
caged complex 63 without anion metathesis.   
 
 
Scheme 6: Synthesis of caged inhibitor complexes 62 and 63. 
Compounds 62 and 63 were isolated as 1:1 mixtures of Δ and Λ isomers, because cis-
[Ru(bpy)2Cl2], 60 and 61 are chiral (Figure 15). Spectroscopic analysis confirms the 
formation of two diastereoisomers, as two distinct peaks corresponding to amide protons for 
each of the diastereoisomers were split.   
 
Figure 15: Structure of Δ -62 or 63 and Λ -62 or 63 
The IR spectrum for 60 shows the characteristic CN stretching at 2258 cm-1.  This 
resonance is shifted to 2274 cm-1 in the complex 62, which is consistent with the nitrile 
binding to the metal center.146,157 The UV-Vis spectrum of 62 shows maxima at 281 nm (ε = 
cis-[Ru(bpy)2Cl2]
60 (6.0 equiv)
AgBF4, EtOH
80 oC, 5 h
then nBu4NCl
cis-[Ru(bpy)2(60)2]Cl2
62
cis-[Ru(bpy)2Cl2]
61 (6.0 equiv)
AgBF4, EtOH
80 oC, 6 h
cis-[Ru(bpy)2(61)2](BF4)2
63
Ru
N
N
N
N
Inh
Inh
2+
Inh
Inh
N
N
N
N
Ru
2+
Mirror
Inh = 60 or 61
  
	
31 
55,600 M-1 cm-1), associated with ligand-centered bpy ππ* transitions, and at 412 nm (ε = 
9,600 M-1 cm-1), associated with metal-to-ligand charge transfer (1MLCT) transitions, i.e 
Ruèbpy. These observations are consistent with electronic absorptions of other related 
complexes such as cis-[Ru(bpy)2(MeCN)2]+2 and cis-[Ru(bpy)2(59)2]+2 (57). The electrospray 
ionization mass spectra of 62 in water shows a prominent peak at m/z = 1055, along with a 
suitable isotopic pattern, consistent with the monocation of the formula [Ru(bpy)2(60)2](Cl)+.  
The IR spectrum for 61 shows the characteristic CN stretching at 2257 cm-1.  This 
resonance is shifted to 2270 cm-1 in the complex 63. The UV-Vis spectrum of 63 shows 
maxima at 284 nm (ε = 50,600 M-1 cm-1) and at 418 nm (ε = 9,810 M-1 cm-1). The 
electrospray ionization mass spectra of 63 in water shows a prominent peak at m/z = 1348, 
along with a suitable isotopic pattern, consistent with the monocation of the formula 
[Ru(bpy)2(61)2](BF4)+.  
2.2.2 Stability and photolysis of [Ru(bpy)2(L)2](X)2 complexes 
The half-life of both the complexes was determined spectrophotometrically in 
phosphate-buffered saline (PBS, pH = 6.5).  The half-life for 62 was about 8.0 days at 293±2 
K, as determined by using the rate constant for decomposition of 62 obtained from the slope 
of a ln A vs. t graph (kobs = 1.0 × 10-6 s-1). Decomposition was also studied in the dark in pure 
water and in solutions containing 1% DMSO to mimic the conditions used in the biological 
assays. Complex 63 was more stable than 62, giving kobs = 5.0 × 10-9 s-1 in PBS buffer 
corresponding to a half-life of >1800 days. 
The Turro group characterized the photochemistry of 62 and 63. Photoactivated ligand 
dissociation of 62 in water (1% DMSO) results in the sequential exchange of the two 
monodentate ligands (60) for solvent molecules, generating cis-[Ru(bpy)2(H2O)2]2+. The changes 
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in the electronic absorption spectrum of 62 (52 µM), which was measured as a function of 
irradiation time (λirr ≥ 395 nm), show the decrease of the starting material peak at 412 nm and the 
formation of an intermediate species in tirr = 0-3 min with a maximum at around 450 nm (Figure 
16A, inset). During this time, two isosbestic points at 322 and 364 nm are apparent, as well as a 
pseudo-isosbestic point at 427 nm. The intermediate at tirr = 2-3 min has been shown to 
correspond to the product formed after the exchange of one CH3CN ligand for a H2O molecule in 
the CH3CN complex, i.e. cis-[Ru(bpy)2(CH3CN)(H2O)]2+, and is denoted by * in Figure 16.75,146 
Further irradiation of 62 from 3 min to 15 min leads to the formation of the final photolysis 
product, cis-[Ru(bpy)2(H2O)2]2+, with the known absorption maxima at 340 nm and 486.158 Three 
isosbestic points are seen during the final step of photolysis (tirr = 3-15 min) at 332, 384, and 463 
nm (Figure 16). 
 Despite complex 63 showing excellent stability in many solvents, photolysis of 63 is 
much less efficient than 62. Photolysis of 63 in water (2 % acetone) results in a similar trend, 
where sequential exchange of the two 61 ligands with H2O was observed to be much slower than 
62. Formation of the intermediate cis-[Ru(bpy)2(61)(H2O)]2+ can be inferred from a decrease in 
the absorbance at 412 nm and an increase in absorbance at 440 nm that occurs with irradiation 
(λirr ≥ 395 nm) up to 10 min. The isosbestic point at 424 nm is similar to that observed for the 
first ligand dissociation in 62. The second dissociation of 61 to provide the final 
photodissociation product, cis-[Ru(bpy)2(H2O)2]2+ is very slow. From 13 to 60 min of irradiation, 
the intermediate absorbance decreases and a new cis-[Ru(bpy)2(H2O)2]2+ product transition 
evolves at 486 nm with an isosbestic point at 462 nm. 
 The quantum yields for all the conversions were also measured, where for the conversion 
of the reactant (R) 62 to the intermediate (I) cis-[Ru(bpy)2(60)(H2O)]2+ (ΦR→I) and to the product 
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(P) cis-[Ru(bpy)2(H2O)2]2+ (ΦR→P) were 0.050(6) and 0.0067(4), respectively (λirr = 400 nm). The 
corresponding ΦR→I and ΦR→P values for the photoaquation of 63 were measured as 0.021(2) and 
0.0045(6), respectively. 
 
(a) 
 
(b) 
Figure 16: Changes to electronic absorption of (a) 62 (52 μM) in a 1% DMSO 
aqueous solution irradiated at 0, 2, 3, 4, 5, 6, 7, 8, 10 and 15 min (λirr ≥ 395 nm); inset 
0 and 1 min; and (b) 63 (51 μM) in a 2% acetone solution at irradiation times 0, 10, 
13, 16, 20, 25, 30, 40, 50 and 60 min (λirr ≥ 395 nm); inset 0, 1, 2, 3, 5 and 7 min. 
*Absorption maxima of the intermediate.  
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2.2.3 Light-activated inhibition of cathepsin K 
To study the biological assays, first light-activated inhibition of cathepsin K was 
performed for parent inhibitors 60 and 61 against purified human cathepsin K under both 
light and dark conditions. Then we performed similar experiments for caged complexes 62 
and 63 (Figure 17). Solutions of cathepsin K (2 nM) in assay buffer solutions (400 mM 
sodium acetate, pH 6.0, 4 mM EDTA, 8 mM DTT, 0.01% Triton X-100) were treated with 
varying amounts of 60 and 61. Experiments were performed either in dark by leaving the 
solutions covered in aluminum foil or in light by irradiating with a tungsten halogen lamp 
(250 W, λirr > 395 nm, H2O filter). Irradiation times were shorter for 60 and 62 (tirr = 15 min) 
than 61 and 63 (tirr = 40 min) because photolysis of 63 was much slower when compared to 
62. Z-Gly-Pro-Arg-AMC was the fluorogenic substrate used for measuring enzyme activity. 
Data indicate that 60 and 61 inhibit CTSK in the low nanomolar range under these 
conditions, giving IC50 values of 36 nM and 28 nM, respectively. Data were identical within 
error under light vs. dark conditions for both of the parent inhibitors, suggesting that light 
had no effect on enzyme inhibition. In contrast, significant enhancements in cathepsin K 
inhibition were observed with 62 and 63 upon irradiation. IC50 values for 62 under dark vs. 
light conditions were 560 nM and 16 nM respectively, which gives a dark to light IC50 ratio 
of 35:1 (Figure 17a). Similarly, IC50 values for 63 under dark vs. light conditions were 2.2 
µM and 25 nM, respectively, giving a dark to light IC50 ratio of 88:1 (Figure 17b). As 
expected, when irradiated with light, 62 is more potent than the parent inhibitor 60, because it 
carries 2 equivalents of the inhibitor molecule per ruthenium complex, and both are released 
upon irradiation. Enzyme inhibition data for 63 are consistent with results from the 
photochemical experiments, demonstrating that although 2 equivalents are available, release 
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of the second ligand is very slow, giving the same potency for 61 as for 63 under light 
conditions. Nonetheless, both compounds 62 and 63 show a considerable improvement over 
light-activated inhibition by our previous compound cis-[Ru(bpy)2(59)2](PF6)2, whose IC50 
value was only 5.4 µM under light conditions.146  
 
(a) 
 
(b) 
Figure 17: (a) IC50 curves for inhibitor 60 (red = dark; green = light) and cis-
[Ru(bpy)2(60)2]Cl2 (62) (black = dark; blue = light) and (b) IC50 curves for inhibitor 
61 (red = dark; green = light) and cis-[Ru(bpy)2(61)2]Cl2 (63) (black = dark; blue = 
light) against isolated cathepsin K. 
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2.2.4 Toxicity studies 
One important goal with this project was to show that the caged molecules and their 
corresponding photolysis byproducts had no toxic effects on cell viability. In order to gain 
insight into the biological behavior of the caged inhibitor 62 and 63, effects of the complexes and 
their photochemical byproducts on cell viability in murine BMM and human PC-3 cells were 
determined under light and dark conditions by the Podgorski group. The osteoclast cells could 
not be utilized for determination of viability because of their terminal nature. BMM or PC3 cells 
were treated with either cis-[Ru(bpy)2(MeCN)2](PF6)2 as a control, 62 or 63 (1 nM-100 mM), 
incubated for 30 min either in the dark or irradiated with a tungsten halogen lamp for light 
experiments. The irradiation times were different; complexes 62 and cis-
[Ru(bpy)2(MeCN)2](PF6)2] were irradiated for 15 min, whereas complex 63  was irradiated for 40 
min due to its slow photolysis rate. After 24 h, viabilities were determined using the MTT assay 
(Figure 18). To our delight compounds 62 and cis-[Ru(bpy)2(MeCN)2](PF6)2, which both release 
cis-[Ru(bpy)2(H2O)2]2+ upon irradiation, showed no effects on viability within error over the full 
concentration range, up to 100 µM. Compound 63 showed no toxic effects at lower 
concentrations, but did start to affect cell viability at concentrations of 10 µM and higher.   
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Figure 18: Cytotoxicity of cis-[Ru(bpy)2(60)2]Cl2 (62) (A and D), cis-
[Ru(bpy)2(61)2](BF4)2 (63) (B and E)  and the control compound cis-
[Ru(bpy)2(MeCN)2](PF6)2 (C and F) on BMM cells (A-C) and prostate cancer PC3 cells 
(D-F).  
 
2.2.5 Light activated inhibition of cathepsin activity in cells. 
To show the full potential of our caging strategy, we wanted to study the possibility of 
inhibiting CTSK activity in live cells along with isolated enzymes with caged inhibitor 
complexes. Compound 62 was chosen as the lead compound to evaluate in cell-based assays for 
light activated inhibition of cathepsin activity because 62 showed a lower IC50 value under light 
conditions than 63, required a shorter irradiation time and demonstrated no effects on cell 
viability. Bone marrow macrophage cells (BMM) express high levels of CTSK activity and their 
aberrant proteolysis is found to play an important role in inflammatory, osteolytic and tumor 
cell-driven processes in bone tumor microenvironments.120 For this reason we initially decided to 
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use BMM cells for performing live cell assays.  Results from Western blot analyses on murine 
BMM and BMM-derived osteoclast cells suggested that both the cell types are a significant 
source of CTSK and CTSB. Finally, we decided to use osteoclast cells, which had significantly 
higher levels of CTSK compared to BMM cells. Also, if cathepsin K inhibition were to be 
studied in BMM cells, the enzyme activity would be difficult to distinguish from noise in the 
presence of cathepsin B inhibitor CA-074Me because it is very close to the baseline.  
 
 
 
 
 
 
 
 
 
Figure 19: Expression of cathepsins B and K in BMM and BMM derived osteoclast 
cells. Western blots analysis (A and C) and densitometric analysis of CTSB (B) and 
CTSK (D) performed using Fuji Multimodal Imager. 
 
Based on their cathepsin K expression pattern, osteoclasts were chosen as the cell line to 
examine the light activated inhibition of cathepsin activity in live cells in all subsequent 
experiments.  First, the parent inhibitor 60 was studied for its ability to block proteolysis of two 
fluorescent cathepsin K substrates, Z-Gly-Pro-Arg-4-methoxy-β-naphthylamide (Z-GPR-
4MβNA)153 and Z-Leu-Arg-4-methoxy-β-naphthylamide (Z-LR-4MβNA).159 In both cases 4-
methoxy-β-naphthylamine is formed after hydrolysis. The formed 4-methoxy-β-naphthylamine 
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can then form a precipitate with nitrosalicylaldehyde that can be detected and quantified by 
fluorescence measurements. By following a literature protocol,127 cells were preincubated with 
inhibitor 60 (1 nM to 1000 nM), in the presence of the selective CTSB inhibitor CA-074Me (1 
µM) to knock down CTSB activity, which is known to compete with cathepsin K for cleavage of 
these substrates.97,160 Confocal microscopy was used for visualizing enzyme activity and 
intensities of green fluorescence were integrated and averaged over 3 data sets in order to make a 
quantitative assessment of cathepsin inhibition. Results showed that hydrolysis of Z-LR-4MβNA 
were reduced up to 50% with 60 (10-1000 nM) in a dose dependent fashion (Figure 20). 
However, by further increasing the concentration no further reduction in substrate hydrolysis was 
observed, suggesting another protease, not inhibited by 60, might be cleaving the same substrate. 
Although 60 also inhibited hydrolysis of Z-GPR-4MβNA, Z-LR-4MβNA was used as the 
substrate in following rounds of experiments because results were less pronounced and less 
consistent between independent experiments with Z-GPR-4MβNA.  
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Figure 20: Confocal microscopy images of mouse osteoclast cells treated with 60 at 
different concentrations. The intensity of green fluorescence is a direct measure of the 
quantity of hydrolyzed and precipitated substrate (A-D) also visible on DIC images 
(E-H).  The quantified data are shown as column (I) and dot (J) plots. * Indicates 
p<0.05 and ** indicates p<0.001. 
 
Having performed live cell assays with the parent inhibitor and developed a method, 
experiments with the caged complex 62 were performed in dark and in the presence of light 
under similar conditions. Osteoclasts were treated with two concentrations of 62 over the same 
concentration range where 60 was active. Vehicle and cis-[Ru(bpy)2(MeCN)2](PF6)2 were used as 
controls.  Results showed that 62 was able to produce the same response as 60 in the presence of 
light, but did not show inhibition in the dark, consistent with data against purified cathepsin K 
(Figure 21). Importantly, a strong, light-activated response at 1000 nM was observed with 62. 
Also 62 showed a 25% reduction in activity at 100 nM under light conditions. No differences of 
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inhibition were observed with 62 when cells were washed between preincubation and irradiation, 
indicating that 62 might either be cell permeable or cell associated. Vehicle and cis-
[Ru(bpy)2(MeCN)2](PF6)2 showed no difference in inhibition between light and dark 
experiments. A slight reduction in Z-LR-4MβNA hydrolysis was noted with cis-
[Ru(bpy)2(MeCN)2](PF6)2 at high concentrations (1000 nM). However, these data were well 
outside the range of error for inhibition by 62 using light conditions, indicating that the release of 
60 from the caged inhibitor 62 is responsible for the observed inhibition.  
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Figure 21: Confocal microscopy images of mouse osteoclasts cells treated with the 
ruthenium-caged inhibitor 62(A-D) or cis-[Ru(bpy)2(MeCN)2](PF6)2 (E-H) .  Cells were 
preincubated with either complex (0-1000 nM) for 30 min at 37 °C in the presence of 
cathepsin B inhibitor CA-074Me (1 μM), then exposed to dark (no irradiation) or light 
(irradiation; 250W, 395-750 nm) conditions for 15 min. ** indicates p<0.001. 
 
2.3 Discussions 
In this study, we have shown that cathepsin activity in a cell-based assay can be 
controlled by compound 62, which is a light-activated enzyme inhibitor. This approach was 
validated against cathepsin K in osteoclasts cells, one of the key sources of this proteolytic 
enzyme in the bone tumor microenvironment.120 Given the availability of numerous potent and 
selective nitrile-based inhibitors developed for a range of cathepsin and caspase targets,127,133,135,139 
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our method has great potential to control spatial aspects of many biological processes in cells, 
including apoptosis, inflammation and cell signaling.  
Despite having the same caging group, compounds 62 and 63 showed a notable 
difference in photochemical behavior, indicating that not only the caging group but also the 
ligand structure plays a role in caged complex properties. The quantum yields for 62 were 
significantly lower than those reported for the photoaquation of the related complex 
[Ru(bpy)2(CH3CN)2]2+,75 but are similar to those measured for cis-[Ru(bpy)2(59)2](PF6)2. The 
quantum yields for 63 are significantly lower than both of these complexes. Because these 
steady-state measurements determine the overall yield of the reaction, it is possible that the 
initial dissociation of the ligand is relatively efficient, but that it quickly recombines with the 
metal before a water molecule is able to access the open coordination site.  The steric bulk of the 
peptide-containing ligands may prevent water from quickly reaching the metal.  Alternatively, 
the peptides may not be as water soluble as acetonitrile, such that solvation of the uncaged 
product may have a detrimental effect on the overall separation of the photoproducts, and 
therefore the overall reactivity.  The significant decrease in efficiency for the photorelease of 61 
from 63 may be due to the larger size and lower polarity of 61 compared to 59 and 60. 
One important result of this study is the lack of observed toxicity for 62. Neither 62, nor 
the control compound cis-[Ru(bpy)2(MeCN)2](PF6)2 caused growth inhibitory effects in BMM or 
PC3 cells under our experimental conditions. Compound 63, however, did cause growth 
inhibitory effects at higher concentrations, confirming that the biological behavior of these 
ruthenium-caged compounds is not just dependent on the nature of the caging group, but on the 
overall structure of the complex. The caging group Ru(bpy)2 has been used successfully without 
causing deleterious side effects, as mentioned previously by others.37,38,161 Also, the effective 
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concentrations for light-activated inhibitors are dictated by the concentration of the target 
enzyme, as well as inhibitor potency, selectivity and cell permeability. Thus, toxicity may be 
prevented, because protease inhibitors are often effective in culture at low concentrations, 
typically below 5 µM,118,162,163 where 63 caused no growth inhibitory effects. Taken together, 62 
can be categorized as a caged nitrile-based inhibitor that, at the concentrations required for 
inhibition, employs a non-toxic metal center, rather than a bioactive ruthenium complex.  
 Our data confirm that the caged inhibitor complex 62 was able to produce the same 
results as the parent inhibitor 60 under light conditions, whereas in the dark 62 caused no 
inhibition.  Thus spatial control over inhibition in a cell-based assay was realized, which was the 
goal of this study. Despite this achievement, neither compound 60 nor 62 were able to fully 
suppress hydrolysis of the substrate Z-LR-4MβNA in osteoclast cells, where a maximum 
inhibition of 50% was achieved. Given the nanomolar potencies measured against cathepsin K in 
purified enzyme assays, these data suggest that cathepsin K was fully inhibited and that another 
enzyme, not inhibited by 60, was responsible for the remainder of Z-LR-4MβNA hydrolysis. 
Indeed, there are limitations with fluorescent substrates in detecting specific cathepsin 
activities.162 In addition to cathepsin K,159 Z-LR-4MβNA is a substrate for other cathepsins, 
namely S and V. Although greater levels of inhibition were observed with Z-GPR-4MβNA, a 
substrate described to be selective for cathepsin K,163 data were not as consistent between 
independent experiments. Another factor to consider is that nitrile-based inhibitors are less 
potent and selective against mouse cathepsins than human cathepsins, which provides an extra 
level of complexity in correlating pharmacological data from animal cells with human 
enzymes.164 Unfortunately, human osteoclasts were not available for this study.  
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Confocal microscopy experiments indicated that intracellular inhibition was achieved 
with 62. Previous studies have established that inhibitor 60 is highly cell permeable.165 Washing 
cells after preincubation had no effect on the level of inhibition observed with 62, suggesting that 
62 is either cell permeable or membrane associated. Because 62 is not luminescent,166 we are not 
currently able to understand its mode of action, which could either be 62 releasing 60 upon 
irradiation or 62 permeating the cell membrane and releasing inhibitor upon irradiation. Further 
studies will be needed to determine the exact mode of inhibitor uptake.  
2.4 Conclusions 
In conclusion, we demonstrated for the first time that the ruthenium caging approach can 
be used for intracellular light-activated enzyme inhibition. New photoactivated inhibitors of 
cathepsin K were reported that release inhibitors with potencies in the nanomolar range.  
Importantly, our studies confirm that the ruthenium caging approach can be carried out with no 
apparent toxicity. These data strongly support the translation of this technology to other enzyme 
targets and live cell systems.  
2.5 Experimental procedures 
2.5.1 General considerations 
  All reagents were purchased from commercial suppliers and used as received. 
Compounds 60139 and 61127 were prepared by literature procedures. NMR spectra were recorded 
on a Varian FT-NMR Mercury-400 Spectrometer. Mass spectra were recorded on a Waters 
ZQ2000 single quadrupole mass spectrometer using an electrospray ionization source. IR spectra 
were recorded on a Perkin Elmer Spectrum 2000 FT-IR Spectrometer. Enzymatic assays were 
conducted on a Tecan Infinite M200 or Tecan SPECTRAFluor Plus microplate reader. UV-vis 
spectra were recorded on a Varian Cary 50 spectrophotometer. The photolysis experiments were 
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conducted using a 250 W Tungsten Halogen lamp (Osram Xenophot HLX) powered by a 24 V 
power source. The irradiation wavelength was selected by placing a bandpass filter (395 nm 
cutoff) between the lamp and the sample, along with a 10 cm water cell to absorb infrared light. 
All reactions were performed under ambient atmosphere unless otherwise noted. The reaction 
solutions were purged with Ar or N2 for performing anaerobic reactions. 
2.5.2 Synthesis of Complexes and tabulated data 
2.5.2.1 Δ- and Λ-cis [Ru(bpy)2(60)2]Cl2 (62): 
  In the glove box, a sealable tube was charged with cis-Ru(bpy)2Cl2 (0.1 mmol, 48.4 mg), 
AgBF4 ( 0.4 mmol, 77.9 mg) and (S)-benzyl (1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate (60) (0.6 mmol, 91.0 mg) and of freshly distilled EtOH (20 mL). The resulting 
solution was wrapped in aluminum foil and heated to 80 °C for 5 h during which it turned from 
dark violet to bright orange. After cooling the crude solution to RT, it was placed in the freezer at 
–20 °C for 16 h. The precipitated silver salts were filtered off using celite and the filter cake was 
washed with cold EtOH. The solvents were removed under reduced pressure and the crude 
mixture was analyzed by 1H NMR spectroscopy. The resulting yellow solid was dissolved in 
acetone (2 mL) and layered with Et2O (10 mL) and placed in the freezer at –20 °C for 16 h. The 
reaction mixture was filtered and the filter cake washed with cold Et2O. The resulting solid was 
dissolved in EtOAc (15 mL) and extracted 3 times with H2O (15 mL). The organic layer was 
then precipitated with sat.	n-Bu4NCl in EtOAc  (0.1 mL) at –20 °C. The resulting oily residue 
was isolated by centrifugation; the mixture was decanted and the residue was washed with cold 
EtOAc (3 × 5 mL), and then cold toluene (3 × 5 mL). The residue was dissolved in a minimum 
amount of acetone and layered with Et2O. The resulting solid was washed with Et2O. Layering 
and washing were repeated four times to give the title compound as an orange solid in 
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analytically pure form as a hydrate salt (21.0 mg, 0.019 mmol, 19%). 1H NMR (400MHz 
CD2Cl2-d2 δ) 9.93 (s, br, 2H), 9.54 (d, J = 4.9 Hz, 1H), 9.51 (d, J = 4.9 Hz, 1H), 8.53 (d, J = 8.1 
Hz, 1H), 8.45 (d, J = 8.1 Hz, 2H), 8.36 (d, J = 8.1 Hz, 1H), 8.15 (m, 2H), 8.02 (m, 2H), 7.93 (m, 
2H), 7.54 (d, J = 5.9 Hz, 2H), 7.32 (m, 8H), 7.25 (m, 2H), 6.86 (d, J = 9.7 Hz, 1H, NH), 6.74 (d, 
J = 8.1 Hz, 1H, NH), 5.04 (m, 3H), 4.16 (d, J = 12.2, 1H), 4.28 (m, 6H), 1.08 (under the H2O 
peak, m, 4H), 0.91 (m, 12H); IR (KBr) νmax (cm-1): 3419, 3029, 2957, 2870, 2347, 2274, 1714, 
1676, 1604, 1523, 1466, 1446, 1424, 1386, 1337, 1246, 1170, 1122, 1047, 917, 771, 731, 698, 
670; LRMS (ESMS) calculated for C52H58N10O6Ru [M]2+: 510.2, found: 510.1; Anal. Calculated 
for C52H65Cl2N10O9.5Ru ([Ru(bpy)2(60)2]Cl2·3.5H2O): C, 54.12; H, 5.68; N, 12.14. Found: C, 
54.16; H, 5.46; N, 12.13.167  
2.5.2.2 Δ- and Λ-cis [Ru(bpy)2(61)2](BF4)2 (63): 
In the glove box, a sealable tube was charged with cis-Ru(bpy)2Cl2 (60 mg, 0.12 mmol), 
compound 61 (314.7 mg, 0.74 mmol), and AgBF4  ( 96.6 mg, 0.49 mmol)) in dry EtOH (28 mL) 
under inert atmosphere. The resulting solution was wrapped in aluminum foil and heated to 80 
°C for 6 h during which it turned from dark violet to bright orange. After cooling the crude 
solution to RT, it was placed in the freezer at –20 °C for 16 h. The precipitated silver salts were 
filtered off using celite and the filter cake was washed with cold EtOH. The solvents were 
removed under reduced pressure and the crude mixture was analyzed by 1H NMR spectroscopy. 
The reaction mixture was concentrated and the orange solid was stirred with Et2O (3 × 20 mL) to 
remove excess 61. The orange solid was purified using silica gel (acetone). Fractions were 
concentrated and the yellow solid was stirred with Et2O (2 × 20 mL), filtered and dried under 
reduced pressure to get the caged complex as pale orange solid in analytically pure form (64 mg, 
51%): Mp = 206 oC (decomp); 1H NMR (400MHz C3D6O) δ 9.53 (d, 1H, J = 5.2 Hz), δ 9.49 (d, 
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1H, J = 5.2 Hz), δ 8.78-8.75 (m, 2H), δ 8.65 (t, 2H, J = 8.8 Hz), δ 8.36 (t, 2H, J = 7.6 Hz), δ 
8.23 (t, 1H, J = 7.2 Hz, NH), δ 8.13-8.08 (m, 2H), δ 7.86 (t, 2H, J = 6 Hz), δ 7.81 (t, 1H, J = 6.4 
Hz, NH), δ 7.46-7.22 (m, 14H, J = 5.2 Hz), δ 6.72 (d, 1H, J = 7.6 Hz, NH), δ 6.67 (d, 1H, J = 
7.6 Hz), δ 9.53 (d, 1H, J = 5.2 Hz), δ 5.24-5.00 (m, 6H), δ 4.53-4.44 (m, 4H), δ 4.28-4.16 (m, 
2H), δ 3.87-3.74 (m, 4H), δ 1.75-1.45 (m, 8H), δ 0.97-0.85 (m, 12H); IR (KBr) νmax (cm-1) 3360, 
3117, 3087, 3064, 3034, 2957, 2871, 2269, 1719, 1687, 1605, 1524, 1468, 1449, 1389, 1366, 
1316, 1246, 1057, 769, 743, 732, 698; ESMS calculated for C68H74 F4N10O8BRu (M+1) 1347.5, 
found 1347.9; UV-vis λmax = 284 nm (ε = 50,600 M-1cm-1) and 418 nm (ε = 9,810 M-1cm-1); Anal. 
Calculated for C68H74F8N10O12B2Ru (63· 4 H2O): C, 54.23; H, 5.49; N, 9.30. Found: C, 54.39; H, 
5.22; N, 9.20. 
2.5.3 Stability of 62 and 63. 
Solutions of 62 or 63 in 0.1 M pH 6.5 phosphate buffer (1.0% DMSO) were monitored 
by UV-Vis spectroscopy for 24 h. Ln A was plotted vs. time and the line was fit to give a first 
order reaction rate constant kobs = 1.0 × 10-6 s-1, corresponding to a half-life > 8.0 days (t1/2 = -
0.693/kobs) for 62 and kobs = 5.0 × 10-9 s-1 (t1/2 > 1800 days) for 63.  
 
2.5.4 Photochemical quantum yields. 
Photosubstitution quantum yields were determined using ferrioxalate actinometry as 
previously described in detail.168 A 150 W Xe lamp in a Milliarc compact arc lamp housing and 
powered by a PTI model LPS-220 power supply was used in the steady-state photolysis 
experiments; the wavelength of the light reaching the sample was controlled with colored glass 
long-pass and band-pass filters (Newport). 
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2.5.5 Cell assays and imaging. 
The live-cell cathepsin K activity staining assays were performed following a method 
described previously.153 Briefly, bone marrow macrophages (BMMs) were derived from FVBN 
mice as previously described and cultured on sterile petri dishes in MEMα media (Sigma) 
containing 20% fetal bovine serum (FBS) and 30% L929-conditioned media169 as the source of 
macrophage colony stimulating factor (M-CSF). After 96 hours, cells had differentiated into 
BMMs, were washed with PBS (phosphate buffered saline), and gently scraped using osteoclast 
media (MEMα media containing 10% FBS, 10 ng/ml M-CSF (R&D Systems), and 10 ng/ml 
RANKL (R&D Systems)). Roughly 5 × 105 cells were plated per well into 24-well plates 
(Corning Costar) on acid-washed glass coverslips (Electron Microscope Sciences) re-treated 
after 48 hours, and cultured for additional 48 hours until visible osteoclasts are formed. For 
cathepsin inhibition assays, cells were incubated for 30 min at 37 °C with 200 μL of reaction 
buffer (0.2 M sodium acetate, pH 6.0, 0.1 mM EDTA and 0.125 mM BME) containing 60, 62, or 
cis-[Ru(bpy)2(MeCN)2](PF6)2 control complex  (1-1000 nM, +/- 1mM CA-074-Me, a cathepsin B 
inhibitor) in 2% DMSO.  Cells were then treated with 100 μL of substrate solution in reaction 
buffer (0.2 M sodium acetate, pH 6.0, 0.1 mM EDTA, 5% DMSO) containing either 1.0 mM Z-
Gly-Pro-Arg-4MβNA or 0.25 mM Z-Leu-Arg-4MβNA (cathepsin K substrates), and 100 µl of 
the precipitating agent, 1.0 mM nitrosalicylaldehyde, in reaction buffer. The reaction was 
allowed to occur for 30 min at 37 °C in the dark. Controls were incubated in the same manner 
but without substrate (with or without 1.0 µM CA-074-Me). For assays involving photolysis of 
62 or cis-[Ru(bpy)2(MeCN)2](PF6)2 control complex, prior to substrate addition, plates were 
wrapped in aluminum foil (“dark”) or exposed to visible light (“light”) for 15 min (with gentle 
shaking of the plate every 2-3 min). Photolysis was conducted with a 250W tungsten halogen 
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lamp (Osram Xenophot HLX) powered by a 24V power supply, using bandpass and water filters, 
as described previously.146 Following the reaction with substrate and precipitating agent, cells 
were washed with PBS, fixed with 1% formaldehyde for 20 min at RT, washed again, and air-
dried. Coverslips were mounted on microscope slides and viewed with a confocal laser-scanning 
microscope (Zeiss LSM 780) using a 40× oil immersion lens. Each image captured featured a 
mature osteoclast (minimum of 6 images/treatment). Intensity of green fluorescence per 
osteoclast area (indicative of the amount of hydrolyzed substrate) was analyzed using ImageJ 
software (NIH).  
2.5.6 Cathepsin K inhibition studies. 
Cathepsin enzyme activity was determined from kinetic measurements performed by 
fluorimetric detection of the hydrolysis product AMC at 37 °C every 2 min for 14 min (8 
measures). The excitation and emission wavelengths were 360 and 485 nm respectively. The 
selective fluorescent substrate Z-Gly-Pro-Arg-AMC was used at a final concentration of 100 μM 
(obtained from Bachem, Torrance, CA). Enzyme activities are expressed as a percentage, with 
100% equal to activity in the absence of inhibitor. 
Recombinant cathepsin K (human) was obtained from Enzo Life Sciences (Farmingdale, 
NY). An 880 nM stock solution was prepared in 50 mM sodium acetate, pH 5.5, 50 mM NaCl, 
0.5 mM EDTA and 5 mM DTT and kept at –80 °C. For each experiment the stock solution was 
diluted 440 times and activated for 15 min at 37 °C with a 400 mM sodium acetate, pH 5.5, 4 
mM EDTA, 8 mM DTT assay buffer solution. The inhibitor was prepared as a 1% DMSO 
solution in the activated enzyme buffer solution and plated (Corning® 96 Well Flat Clear 
Bottom Black Polystyrene TC-Treated Microplates, 50 μL/well). Three experiments in triplicates 
(60-63, light or dark) were carried out on the different 96 well plates. The wells containing 
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“dark” were carefully wrapped in aluminum foil and the light plate was exposed to visible light. 
The photolysis was conducted for 15 min (60 and 62) or 40 min (61 and 63) (with gentle shaking 
of the plate every 2-3 min) using a 250W tungsten halogen lamp (Osram Xenophot HLX) 
powered by a 24V power supply. The irradiation wavelength was selected by placing a bandpass 
filter (395 nm cutoff) between the lamp and the sample, along with a 10 cm water cell to absorb 
infrared light. After photolysis, the reaction was initiated by addition of 50 μL of 200 μM Z-Phe-
Arg-AMC solution in the assay buffer (final volume 100 μL, final enzyme concentration 1 nM). 
Cathepsin enzyme activity was determined from kinetic measurements performed by fluorimetric 
detection of the hydrolysis product AMC at 37 °C every 2 min for 14 min (8 measures) and 
MAX RFU slope values used for plotting. 
2.5.7 Toxicity (cell viability) studies. 
The cell viability of BMM and PC3 prostate carcinoma cells in the presence of 62, 63 and 
the control compound cis-[Ru(bpy)2(MeCN)2](PF6)2 were measured using the MTT assay 
according to the manufacturer’s instructions (Invitrogen, Grand Island, NY). Briefly, the cells 
were grown in a 96 well plate for 48 h. After removing the media, the cells were treated with 50 
μL solutions of 62, 63 or cis-[Ru(bpy)2(MeCN)2](PF6)2 in the appropriate culture media and 
incubated for 30 min at 37 °C. The media was then removed, and the cells were washed 3 times 
and left in PBS buffer. The “dark” plate was wrapped in aluminum foil while the “light” plate 
was exposed to visible light. The photolysis was conducted for 15 min (with gentle shaking of 
the plate every 2-3 min) using a 250W tungsten halogen lamp (Osram Xenophot HLX) powered 
by a 24V power supply, using bandpass and water filters, as described previously. The cells were 
washed 6 times with PBS buffer. New media was then added and the cells were incubated for 24 
h or 72 h in the dark under a 5% CO2 atmosphere and 37 °C. After the incubation time, the media 
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was removed and 100 μL of new media was added. 10 μL of a 12 mM MTT stock solution (5 mg 
of MTT dissolved in 1.0 mL of sterile PBS) was then added to each well. The cells were covered 
and incubated for 4 h. A negative control consisting of 10 μL of stock MTT solution added to 
100 μL media in empty wells was also prepared. 85 μL was then removed form each well and 
was replaced by 50 μL of DMSO, and thoroughly mixed. Absorbance measurements at 540 nM 
were collected on a microplate reader. Cell viabilities were expressed as a percentage, with 100% 
equal to activity in the absence of 62, 63 and the control compound cis-
[Ru(bpy)2(MeCN)2](PF6)2. 
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CHAPTER 3. IMAGING INHIBITION OF CATHEPSIN B ACTIVITY 
IN REAL-TIME IN SITU 3D MAME CULTURES 
3.1 Introduction 
Light can be controlled both spatially and temporally with great precision and can be 
used in numerous therapeutic applications.2 One such application is cleavage of photocages that 
leads to targeted release of small molecules. Photocages, which release biologically active agents 
upon irradiation with light, can be used to garner spatial and temporal control over biological 
activity.42,148,149 This method is being explored for basic research applications in vitro and in 
vivo.170 Photocaging also shows great potential in photochemotherapy, where therapeutically 
relevant compounds are released only in a desired location, reducing off target reactivity.53 
Amongst the numerous metal-based protecting groups, Ru(bpy)2 has been widely used, due to its 
excellent visible light absorption and photoreactivity, to allow release of neurotransmitters, 
36,38,40,150,152 cytotoxic agents47 and nitrile-based cysteine protease inhibitors.146,171  
The major focus of this dissertation is to develop Ru-based photocages for numerous 
biological applications. Initially we have utilized photocages for achieving spatio-temporal 
control over inhibition of cathepsin K. We have shown that nitrile-based CTSK enzyme 
inhibitors can be neutralized using Ru(bpy)2 protecting group which can be photoactivated using 
light. To broaden the scope of photocages against proteases, we wanted to develop new caged 
inhibitors for other cathepsin enzymes. 
Cathepsin B is one of the lysosomal proteases belonging to the papain family. These 
proteases, under normal physiological conditions, are tightly regulated by complex signaling 
pathways at multiple levels.172 In numerous pathological and oncogenic processes, aberrant 
CTSB activity has been reported. Cathepsin B has been causally linked to progression and 
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metastasis of numerous tumors. Studies have shown that aberrant CTSB activity leads to 
numerous cancers such as brain, prostate, lung and breast cancers.100,102,107,114,145 Cathepsin B plays 
an important role in tumor progression by degrading the extracellular matrix.111 Apart from 
acting as a scavenger and neuro-protector, CTSB helps in maintenance of physiological 
functions under normal conditions.173-175 Although CTSB can be a viable target for 
chemotherapy, enzyme inhibition in normal cells could lead to serious side effects. Therefore, 
site-specific enzyme inhibition would be useful.  This chapter is aimed at developing ruthenium-
caged CTSB enzyme inhibitors as tools to achieve enzyme inhibition in specific locations, which 
could not be done using normal small molecule CTSB inhibitors. 
In the previous chapters, we have shown that photocaged cathepsin inhibitors can be used 
in enzyme inhibition against purified enzymes and in tumor cells using 2D models. The tumor 
microenvironment, which is much more complex, has a major role in modulating the metastatic 
capacity of most cancers. 176 The in vivo characteristics of the tumor microenvironment are not 
represented in studies using purified enzymes or cancer cells cultured in two-dimensional (2D) 
monolayers. In contrast, three-dimensional (3D) cell cultures take into consideration interactions 
of cells with the extracellular matrix (ECM), cell polarity and cell-to-cell contacts, providing a 
more accurate context for evaluating compound activity and protease inhibition.177-179 Here we 
show the importance of studying enzyme inhibition using two distinct approaches (2D and 3D 
cell culture models), which demonstrates the value of evaluating compounds in more advanced 
cell culture models. 
Herein, we describe inhibition of CTSB by a dipeptidyl nitrile-based inhibitor caged 
using a Ru(bpy)2 fragment. We used a photoactivation strategy against activity assays of purified 
enzyme, human TNBC (triple negative breast cancer) cell lysates and live-cell proteolysis assay 
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of TNBC cell lines grown in 3D MAME (mammary architecture and microenvironment 
engineering) cultures.180,181 In MAME cultures, TNBC cells form structures resembling in vivo 
tumors182 and the live-cell proteolysis assay developed by the Sloane laboratory allows one to 
visualize, localize and quantify proteolysis in real time.183 The ability to quantify and monitor 
with respect to time the proteolytic degradation of ECM (extracellular matrix) proteins by living 
tumor cells is important in designing protease inhibitors that will be efficacious in cancers.183,184 
For the first time we demonstrate that photoactivation of a caged CTSB inhibitor can block 
proteolysis at the surface of living cancer cells. Living breast cancer cells grown in 3D MAME 
models used for the study recapitulate the in vivo microenvironment of human breast 
tumors.180,181  
3.2 Results and discussions 
3.2.1 Synthesis and characterization of [Ru(bpy)2(L)2](BF4)2 (65) 
Dipeptidyl nitrile 64 was chosen for caging in this study, because it was identified 
previously as a potent, selective and reversible inhibitor of recombinant human cathepsin B 
expressed in baculovirus (Scheme 7).131 Caging of inhibitor 64 was accomplished by treating 64 
(6.0 equiv) with cis-[Ru(bpy)2Cl2] (1.0 equiv), and AgBF4 (4.0 equiv) in EtOH at 80 °C, resulting 
in a color change from violet to orange. Cooling of the crude reaction mixture to –20 °C, 
followed by filtration and concentration gave crude 65, which was obtained as the major 
ruthenium-based product, as judged by 1H NMR spectroscopic analysis. Compound 65 was 
purified further by multiple cycles of stirring with diethyl ether to remove unreacted 65, 
precipitation from a solution of acetone by diethyl ether vapor diffusion, treatment with 
QuadraSil® MP (a thiol-based Ag-scavenging silica gel) and washing with EtOAc and Et2O, 
which provided 65 as a hydrate salt in an analytically pure form.  
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Scheme 7: Synthesis of ruthenium-based CTSB inhibitor 65 and structure of 64 
Caged inhibitor 65 was characterized by 1H NMR, IR and UV-Vis spectroscopies, mass 
spectrometry and elemental analysis. Spectroscopic data were consistent with 65 being isolated 
as a 1:1 mixture of Δ- and Λ stereoisomers, consistent with other previously synthesized 
complexes.146,171 This was expected because cis-[Ru(bpy)2Cl2] was used as a racemic mixture of 
Δ- and Λ stereoisomers. The IR spectrum of 65 shows a νCN stretch at 2278 cm-1, diagnostic of 
nitrile-binding to Ru(II). The electrospray ionization mass spectrum of 65 shows prominent 
peaks at m/z = 1281.2, along with a suitable isotopic pattern, consistent with a monocation of the 
formula [Ru(bpy)2(64)2](BF4)+. The electronic absorption spectrum of 65 is highly consistent 
with other dications of the general formula cis-[Ru(bpy)2(RCN)2]2+, where RCN is MeCN, 5-
cyanouracil, and protease inhibitors structurally related to 64.42,148 Data for 65 in water containing 
2 % acetone show a maximum at 420 nm (ε = 10,360 M-1cm-1) assigned to a singlet metal-to-
ligand charge transfer (1MLCT) transition.  
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3.2.2 Stability and photolysis of [Ru(bpy)2(L)2](BF4)2 (65) 
The half-life for 65 in the dark was determined spectrophotometrically using the rate 
constant for decomposition, obtained from the slope of a ln A vs. t graph in DMSO (kobs = 1.6 ± 
0.1 × 10-7 s-1) and in phosphate buffered saline (PBS, pH 6.5, kobs = 1.2 ± 0.1 × 10-6 s-1) as 
described previously,146,171 to be ~70 and ~10 days, respectively at 293 ± 2 K.  
The photochemical reactivity of ruthenium-caged complex 65 was evaluated by 
monitoring the changes to the electronic absorption spectrum of the complex as a function of 
irradiation time (λirr ≥ 395 nm) in a 2 % acetone aqueous solution (Figure 22). The Turro group 
performed the photolysis studies and quantum yield calculations for complex 65. The changes to 
the absorption spectrum of 2 are consistent with those of the related [Ru(bpy)2(L)2]2+ 
complexes.47,75,146,171 A decrease of the reactant 1MLCT transition at 412 nm and evolution of a 
new transition at 446 nm at early irradiation times (up to 3 min) can be assigned as arising from 
the photoinduced substitution of one nitrile ligand, 64, by a solvent H2O molecule to form a 
mono-aqua intermediate, [Ru(bpy)2(64)(H2O)]2+ (I). This process exhibits an isosbestic point at 
427 nm indicative that consumption of the reactant is directly correlated to intermediate 
formation. Further irradiation up to 15 min results in formation of the bis-aqua product, 
[Ru(bpy)2(H2O)2]2+ (P) via substitution of the remaining 64 ligand with H2O. This process is 
indicated by a decrease of the peak of the intermediate at 446 nm, the appearance of a new 
transition at 487 nm, and isosbestic points at 383 and 460 nm. The quantum yield of ligand 
exchange for the first step, reactant R to intermediate I (ΦR→I) was determined to be 0.026(4), 
while the second step, from intermediate I to product P (ΦI→P) was measured to be 0.0045(9) in 
water (λirr = 400 nm). The relatively low quantum yield values can be attributed to the low 
solubility of 64 in H2O, such that following photoinduced nitrile dissociation, the ligand does not 
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exit the solvent cage efficiently and recombines with the pentacoordinate ruthenium fragment to 
regenerate the starting material. Because 64 is more soluble in acetone, the photosubstitution 
reaction was repeated in an acetone solution containing 0.25 M tetrabutylammonium chloride 
(TBACl). In this system, irradiation of 65 forms the intermediate [Ru(bpy)2(64)Cl]+ followed by 
a second ligand substitution to form [Ru(bpy)2Cl2]. The quantum yields in this solvent are greatly 
enhanced, with ΦR→I and ΦI→P of 0.056(9) and 0.032, respectively. This experiment clearly 
shows that increasing the water solubility of the nitrile inhibitor can enhance ligand exchange 
quantum yields of caged compounds, such as 65. 
 
Figure 22: Changes to the electronic absorption of 65 (25 μm) in a 2 % acetone aqueous 
solution at irradiation times, tirr, of 0, 3, 5, 7, 10, and 15 min (λirr ≥ 395 nm); the * denotes 
the mono-aqua intermediate. Inset: tirr = 0.0, 0.5, 1.5, and 3.0 min. 
 
3.2.3 Evaluation of 64 and 65 on purified CTSB and breast tumor 
cell lysates 
The dipeptidyl nitrile cathepsin B inhibitor (64) and its caged version 
[Ru(bpy)2(64)2](BF4)2 (65) were evaluated against CTSB purified from human liver and IC50 
values were determined by the Sloane group. Compound 64 showed IC50 value of 0.33 µM, 
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consistent with literature data reported for inhibition of recombinant human cathepsin B 
expressed in baculovirus.131 The IC50 values for the caged variant 65 under light (λirr > 395 nm) 
vs. dark conditions were 0.28 and 3.4 µM, respectively, corresponding to a dark/light IC50 ratio 
of 12 (Table 1). As expected, caged 65 became more active under irradiation than in the dark, 
consistent with the dissociation of the dipeptidyl nitrile molecules from the ruthenium photocage. 
The potency of the uncaged 64 was very similar to that of 65 under light, i.e., 0.33 and 0.28 µM, 
respectively. The strong similarity between the IC50 values for the uncaged and caged inhibitors 
in light could be related to the lower efficiency for the release of the second molecule of inhibitor 
from 65 (evident from its low ΦI→P), as shown previously for caged inhibitors of cathepsin 
K.146,171 
We evaluated the ability of compounds 64 and 65 to inhibit proteolytic activity in lysates 
of two TNBC cell lines grown in monolayer cultures on plastic dishes: MDA-MB-231 and 
Hs578T. The substrate used was Z-Arg-Arg-AMC, a substrate that under the conditions of our 
assay is highly selective for CTSB.182,185 In MDA-MB-231 cell lysates the photocaged compound 
65 was significantly more potent when irradiated than it was in the dark with a dark/light ratio of 
80 (Table 1). Similar results were obtained with Hs578T cell lysates although the dark/light ratio 
was lower, which was 13. Besides the fact that both cell lines are TNBC, they present different 
behavior and express different amount of proteases, which could be related with the higher ratio 
for MDA-MB-231 cell lysates. The IC50 values for inhibitor 64 and for light-activated inhibitor 
65 were comparable in each cell line. These analyses of both cell lysates and purified human 
CTSB confirmed the efficiency of light activation of the photocaged inhibitor. 
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Experiment 64 (μM) 65 dark (μM) 65 light (μM) Dark/light ratio 
Purified cat B 0.33 3.40 0.28 12 
MDA-MB 231 lysate 1.54 126 1.58 80 
Hs578T lysate 0.91 11.2 0.89 13 
Table 1: IC50 values (µM) for 64 and 65 and dark/light ratio (with and without 
irradiation) against human cathepsin B, MDA-MB 231 lysate and Hs578T lysate. 
 
3.2.4 3D MAME cell culture assay for Breast Cancer Cell Lines 
 
We tested the ability of the inhibitors to reduce cathepsin B activity in intact human 
TNBC cells grown in 3D MAME cultures. The Sloane group performed these 3D assays. Studies 
using 3D human pathomimetic models have demonstrated the importance of evaluating 
molecular and cellular function in a model that mimics disease progression by approximating 
organ structure. Such models encompass cell–cell and cell–matrix interactions.177,184 According 
to Schmeichel and Bissell, 3D models have the potential when used for drug screening to 
identify and validate molecules that will sustain efficacy in clinical trials.184 We employed a live-
cell proteolysis assay developed in the Sloane laboratory186 in which dye quenched fluorescent 
proteins are the proteolytic substrates (Figure 23). The fluorescent signal in this gain-of-function 
assay allows us to localize the site of degradation and is proportional to the proteolytic activity.186 
The protein substrate can be cleaved by many proteases allowing the analysis of proteolytic 
networks rather than a single protease or protease class as is the case with assays employing 
selective synthetic small molecule substrates. We grew MDA-MB-231 and Hs578T TNBC 
breast cancer cells in 3D MAME cultures containing DQ-collagen IV 182 and assessed the 
formation of degradation products of DQ-collagen IV (green fluorescence) in real-time. We 
found that the uncaged inhibitor 64 reduced degradation of DQ-collagen IV (Figure 23A and B). 
Quantification of the intensity of fluorescent degradation products per cell in the entire 3D 
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volume of TNBC structures revealed significantly less degradation of DQ-collagen IV in the 
presence of uncaged inhibitor 64 (Figure 23C). As a positive control, we confirmed that a 
mixture of highly selective cathepsin B inhibitors (CA-074 and CA-074Me)187  resulted in a 
reduction in degradation of DQ-collagen IV comparable to that observed with uncaged inhibitor 
64 (Figure 23). In breast carcinoma cells, cysteine cathepsins degrade collagen IV and this 
process can be suppressed by selective cysteine cathepsin inhibitors CA-074 and CA-074Me, 
described as non-permeable and cell permeable, respectively. CA-074Me can also inhibit 
cathepsin L activity,187 which is considered a target for treatment of cancer.188 
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Figure 23. The uncaged inhibitor 64 (30 µM) reduces degradation of DQ-collagen IV 
(green) by MAME cultures of MDA-MB-231 (A) and Hs578T (B) breast carcinoma 
cells. Top views at 4 days of culture were reconstructed in 3D with Volocity software 
from optical sections of 16 contiguous fields acquired on a Zeiss LSM780. Fluorescent 
intensity per cell (C) was quantified in the entire volume; nuclei were stained with 
Hoechst 33342 (blue) at the time of imaging and counted. DMSO and CA-074/CA-
074Me (5 µM each) are negative and positive controls, respectively. Data shown are from 
3 independent experiments; * ≤ 0.05; mean ± SD 
 
In cancers, the cellular localization of cathepsin B is often altered such that the enzyme is 
redistributed to the cell surface or secreted rather than being in lysosomes.83,92,99 Processes 
associated with malignancy such as acidosis accelerate this redistribution and result in increases 
DMSO																	CAO74										64	(30	μM) 
DMSO							 		 		 CAO74		 	 												64	(30	μM) 
DMSO																	CAO74										64	(30	μM) 
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in pericellular proteolysis. Thus, when assessing the efficacy of protease inhibitors it is important 
to determine the site at which a protease is inhibited.114,182 This is an advantage of the live-cell 
proteolysis assay used here, i.e., degradation fragments can be localized to pericellular or 
intracellular compartments.182,186,189 This allowed us to determine potential differences in the 
ability of the uncaged inhibitor 64 to reduce total, pericellular or intracellular proteolysis by the 
MDA-MB-231 and Hs578T 3D MAME cultures. We observed significant reductions in total 
proteolysis and pericellular proteolysis, but not in intracellular proteolysis, in the presence of the 
uncaged inhibitor 64 and comparable results with highly selective cathepsin B inhibitors (Figure 
24). These results are consistent with the uncaged inhibitor 64 acting through inhibition of 
pericellular cathepsin B.  
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Figure 24:  The uncaged inhibitor 64 (30 µM) reduces total and pericellular degradation, 
but not intracellular degradation of DQ-collagen IV by 3D MAME cultures of MDA-
MB-231 and Hs578T breast carcinoma cells imaged at 4 days of culture. Quantification 
of total proteolytic fragments (black bars) and segmentation into pericellular (open bars) 
and intracellular (gray bars) fragments were performed by image arithmetic in Volocity 
software. DMSO was used as negative control and CA-074/CA-074Me (5 µM each) were 
used as positive controls. Data shown are from 3 independent experiments; * p < 0.05; 
mean ± SD. 
In order to prove the efficacy of the caging strategy, the caged compound 65, a light-
activated enzyme inhibitor, was evaluated in live-cell proteolysis assays in the dark and the light 
(Figure 25). At a concentration of 1 µM, photoactivated compound 65 significantly reduced the 
degradation of DQ-collagen IV (green fluorescence) in 3D MAME cultures of TNBC cells 
DMSO												CAO74	/Me							64	(30	μM) 
DMSO															CAO74	/Me							64	(30	μM) 
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exposed to visible light. Initially the assay was carried out with higher concentrations of 
compound 65; however, significant inhibition of proteolysis was observed in the dark (data not 
shown). Reducing the concentration of compound 65 resulted in an increase in the dark/light 
ratio. Inhibition by 65 in the dark likely indicates that inhibitor 64 is partially released over the 
timescale of the experiment (4 days), consistent with the shorter half-life of 65 (t1/2 ~ 10 days) as 
compared to other RuII(bpy)2 caged inhibitors we have examined thus far.146,171 Therefore, further 
optimization of the caging group and/or inhibitor may be necessary to achieve higher dark to 
light ratios in these assays. Nonetheless, the live-cell proteolysis assay demonstrated that the 
caged inhibitor was more potent than the uncaged inhibitor and can be used at a much lower 
concentration, an advantage for use of the caged inhibitor in vivo. 
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Figure 25. The caged inhibitor 65 (ruthenium-caged compound, 1 µM) when uncaged by 
light exposure reduces degradation of DQ-collagen IV (green) by MAME cultures of 
MDA-MB-231 and Hs578T breast carcinoma cells. Structures treated with 65 were 
incubated in the dark (no irradiation) or light (λirr = 395-750 nm) for 45 min. Top views at 
4 days of culture were reconstructed in 3D. Fluorescent intensity per cell (C) was 
quantified in the entire volume; nuclei were stained with Hoechst 33342 (blue) at the time 
of imaging and counted. DMSO was used as a negative control. Data shown are from 3 
independent experiments; *p ≤ 0.05; **p ≤ 0.005; mean ± SD. 
 
Having established that caged inhibitor 65 was able to block proteolysis in a light 
activated fashion, experiments with only the ruthenium caging group, i.e., cis-
[Ru(bpy)2(MeCN)2](PF6)2, were carried out in the absence and presence of light to determine the 
							65	(1	μM) 							65	(1	μM) 
							65	(1	μM) 
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ability of cis-[Ru(bpy)2(MeCN)2](PF6)2 to reduce proteolysis. Control experiments on 3D 
MAME cultures with a 1 µM concentration of inhibitor under light vs. dark conditions proved 
that cis-[Ru(bpy)2(MeCN)2](PF6)2 did not inhibit proteolysis (Figure 26A and B) as no 
differences on fluorescence were observed in the images. Furthermore, quantification established 
that the amount of green fluorescence per cell was the same as in the vehicle control (1% 
DMSO) (Figure 26C). Previous studies had described the successful use of caged-ruthenium 
compounds of the inhibitory neurotransmitter GABA37 and a cathepsin K inhibitor.146,171 We did 
not observe any toxicity of compound 65 as determined by cell viability assays of MDA-MB-231 
and Hs578T 3D MAME cultures in the dark or the light. Our results are consistent with data 
from the literature demonstrating that the caging fragment Ru(bpy)2 does not exhibit side effects 
or toxicity.38,146,171 
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Figure 26. The ruthenium complex cis-[Ru(bpy)2(MeCN)2](PF6)2 used to cage the 
inhibitor did not affect degradation of DQ-collagen IV (green) by 3D MAME cultures of 
MDA-MB-231 and Hs578T breast carcinoma cells. Top views at 4 days of culture were 
reconstructed in 3D. Structures were incubated in the dark (no irradiation) and light (λirr = 
395-750 nm) for 45 min. Fluorescent intensity per cell (C) was quantified in the entire 
volume; nuclei were stained with Hoechst 33342 (blue) at the time of imaging and 
counted. DMSO was used as a negative control. Data shown are from 3 independent 
experiments; mean ± SD. 
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3.3 Discussions and Conclusions 
 
Cathepsin B, one of the most abundant cysteine cathepsins, is upregulated in breast and 
other cancers and considered to be an attractive molecular target for cancer therapy. Though a 
potential chemotherapy target, no small molecule CTSB inhibitor has been FDA approved due to 
many off target toxicity profiles. Here we report the successful application of a photoactivated 
cathepsin B inhibitor (65) to block proteolysis not only in 2D assays but also in live-cell assays 
of 3D MAME TNBC models, which offer a unique system for dynamic imaging of proteolysis. 
These models mimic the in vivo microenvironment of human breast cancers and allow us to 
visualize, localize and quantify collagen IV degradation in real time. Our data indicate that 
compound 64 is as effective as the highly selective cathepsin B inhibitor CA-074 at blocking 
pericellular proteolysis. Positive results were also obtained in activity assays of purified 
cathepsin B and lysates of the 3D MAME TNBC models. These data also provide evidence that 
the ruthenium caging strategy can be used to garner control over inhibition with light. Although 
further optimization of caged inhibitors will be necessary to afford compounds with high 
stability and better dark to light ratios, our complexes were not toxic and the caging group did 
not inhibit proteolysis. Importantly, this example serves as a prototype for development of 
biochemical tools for further analysis of proteases in cancer and clinically relevant, 
photoactivated inhibitors of cathepsin B with red-shifted absorbance to facilitate tissue 
penetration by low energy light for in vivo applications. Also, by increasing our understanding of 
the role played by ECM components in the tumor microenvironment and their potential impact 
on protease inhibition, we can provide more reliable and better data for further assays. This is the 
first report to demonstrate proteolysis inhibition of TNBC cell lines grown in 3D MAME models 
by a strategy using photoactivation of a caged CTSB inhibitor. 
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3.4 Experimental procedures 
 
3.4.1 Cathepsin B activity assay 
Purified human liver cathepsin B was purchased from Athens Research & Technology 
(Athens, GA, USA). The enzyme activity was determined from kinetic measurements performed 
by fluorimetric detection of the hydrolysis product AMC at 37 °C for 30 min at one-minute 
intervals using a Tecan SpectraFluor Plus plate-reader. The excitation and emission wavelengths 
were 360 and 485 nm, respectively. The fluorescent substrate Z-Arg-Arg-AMC (Bachem, 
Torrance, CA, USA) was used at a final concentration of 150 µM. 
The enzyme was activated for 15 minutes with activator buffer (100 µl) containing 5 mM 
EDTA, 10 mM DTT (pH 5.2) at 37 ºC. The sample (1 µl) was added and the reaction mixtures 
were conducted during 45 min under dark (no irradiation) and light (irradiation at 250 W, 395-
750 nm) conditions with a tungsten halogen lamp and H2O filter on separate plated. The plate 
containing dark compound was wrapped in aluminum foil, and the other plate was exposed to 
visible light for the same time period. The irradiation wavelength was selected by placing a 395 
long-pass filter between the lamp and the sample, along with a 10 cm water cell to absorb 
infrared light. After photolysis, the reaction was initiated by addition of 200 µl of assay buffer 
(0.6 mM CaCl2, 0.6 mM MgCl2, 25 mM piperazin-N-N‘-bis[2-ethanosulfonic acid] (disodium 
salt)), pH 7.3 containing 150 µM Z-Arg-Arg-AMC substrate solution. Enzyme concentration 
was 10 nM. The experiments were carried out in triplicate in 96-well flat bottom black plates at 
pH 6.0. Enzyme activities are expressed as a percentage, with 100% equal to activity in the 
absence of inhibitor. IC50 values were determined by plotting percent activity vs. log (inhibitor 
concentration). 
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3.4.2 Inhibition of cellular cathepsin activity. 
Cell lines purchased from American type culture collection (Rockville, MD, USA) were 
cultured in basal medium supplemented with 10 % fetal bovine serum (MDA-MB-231, DMEM; 
Hs578T, DMEM + 10 µg/ml bovine insulin). To prepare cell lysates, cells were grown on 100 
mm dishes to ~80 % confluency, washed twice with PBS (phosphate buffered saline), scraped 
and lysed in SME buffer (250 mM sucrose, 25 mM MES, 1 mM EDTA, pH 6.5, and 0.1 % 
Triton X-100) and then sonicated on ice three times for 10 sec each. Cathepsin B activity was 
measured as previously described.185 Briefly, 50 µl of cell lysate was incubated with 300 µl of 
activator buffer (5 mM EDTA, 10 mM DTT (pH 5.2) at 37 ºC during 15 min. The sample (1 µl) 
was added to 100 µl of the activator buffer containing cell lysate and the reaction mixtures were 
conducted during 45 min under dark (no irradiation) and light (irradiation at 250 W, 395-750 
nm) conditions with a tungsten halogen lamp and H2O filter on separate plates as described 
above. The experiments were carried out in triplicate (on 96-well flat bottom black plates) at pH 
6.0. 
3.4.3 Live-cell proteolysis assay. 
Proteolytic cleavage of DQ-collagen IV substrate (Invitrogen, Carlsbad, CA, USA) by 
live TNBC cells was imaged in real time and quantified as previously described.186,190,191 Briefly, 
glass coverslips were coated with 50 µl of 16.4 mg/ml CultrexTM containing 25 µg/ml DQ-
collagen IV and incubated for 15 min at 37 °C to solidify. TNBC cells (1.0 × 104) were seeded 
onto coated glass coverslips and incubated for 60 min. Medium containing 2 % CultrexTM was 
added to the cells. The sample was added every 48 h. After 4 days of culture, proteolysis of DQ-
collagen IV (green fluorescence) was observed in live cells with a Zeiss LSM 780 confocal 
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microscope with a 20X water immersion objective. Where indicated, assays were performed in 
the presence of CA-074 and CA-074Me (5 µM each) (Peptides International, Louisville, KY, 
USA), compound 64 or compound 65. 
For experiments with the caged inhibitor, cells were exposed to dark (no irradiation) and 
light (irradiation at 250 W, 395-750 nm) conditions for 45 min with a tungsten halogen lamp and 
H2O filter on separate plates. After 4 day of culture, optical sections through the entire depth of 
the 3D structures were acquired on a confocal microscope, reconstructed in 3D and quantified 
using Volocity software. 
3.4.4 Cell viability assay. 
3D cultures of TNBC cells were established, grown and treated with compound 65 as 
described above. After 4 days, a cell viability assay was performed to assess the cytotoxic effects 
of compound 65. The assay has two components: Calcein AM that fluoresces green when 
cleaved by intracellular esterases, thereby labeling live cells, and Ethidium Homodimer-1 that 
fluoresces red when incorporated in the DNA of dead cells. A solution of 4 μM Ethidium 
Homodimer-1 and 2 µM Calcein AM was prepared in sterile PBS. Cultures were incubated for 
30 minutes at 37 °C, washed once with warm PBS and replenished with warm MEGM media for 
live cell imaging. The samples were then imaged at 10X magnification using a Zeiss 510 META 
confocal microscope. Tiled 16-panel images and z-stacks through the depth of structures were 
captured. The images were processed to show top views using Volocity software. Statistics were 
performed using the data analysis package within GraphPad Prism 6.0 (GraphPad Sofware, San 
Diego, CA, USA). Unless otherwise stated, tests comparing two means are Student’s t-test, with 
equal variance assumed. 
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3.4.5 Synthesis of Δ- and Λ-cis-[Ru(bpy)2(64)2](BF4)2 (65): 
In the glove box, a sealable tube was charged with cis-Ru(bpy)2Cl2 (0.062 mmol, 30 mg), 
AgBF4 (0.24 mmol, 47.9 mg) and (S)-3,4-dichloro-N-(1-((cyanomethyl)amino)-1-oxo-3-(m-
tolyl)propan-2-yl)benzamide131 (64) (0.37 mmol, 145.3 mg) and freshly distilled EtOH (15 mL). 
The resulting solution was wrapped in aluminum foil and refluxed for 6 h during which time it 
turned from dark violet to bright orange. After cooling the crude solution to RT, it was placed in 
the freezer at –20 °C for 16 h. The precipitated silver salts were filtered off using celite and the 
filter cake was washed with cold EtOH (190 proof). The solvents were removed under reduced 
pressure and the crude mixture was analyzed by 1H NMR spectroscopy. The resulting yellow 
solid was dissolved in acetone (2 mL) and layered with Et2O (10 mL) and placed in the freezer at 
–20 °C for 16 h. The solution was decanted, and the solid was suspended in acetone (5 mL), then 
treated with Ag-scavenging silica gel (QuadraSil® MP, 20 mg). After 15 min, the suspension 
was filtered and the solution was concentrated. The resulting solid was stirred with EtOAc (15 
mL) for 4 h. The orange solid was centrifuged and the resulting filtered cake was washed with 
Et2O (3 ×15 mL) and dried under reduced pressure to give the title compound 65 as a yellow 
solid in analytically pure form as a hydrate salt (47 mg, 55 %). Mp = 178 oC (decomp); 1H NMR 
(400MHz C3D6O) δ 9.51 (m, 2H), 8.79-8.75 (m, 2H), 8.66 (d, 2H, J = 8.4 Hz), 8.37-8.20 (m, 
6H), 8.08 (t, 2H, J = 7.2 Hz), 7.89-7.70 (m, 8H), 7.62-7.61(m, 2H), 7.41-7.40 (m, 2H), 7.12-7.06 
(m, 6H), 6.98 (t, 2H, J = 7.2 Hz), 4.80-4.75 (m, 2H), 4.58-4.55 (m, 1H), 4.47-4.44 (m, 3H), 3.21-
3.18 (m, 2H), 3.07-3.00 (m, 2H), 2.22 (s, 3H), 2.19 (s, 3H); IR (KBr) νmax (cm-1) 3618, 3567, 
3374, 3083, 2921, 2278, 1664, 1606, 1591, 1526, 1467, 1447, 1426, 1379, 1340, 1312, 1276, 
1242, 1161, 1125, 1009, 1062, 1032, 895, 834, 767, 731, 701, 675. ESMS calculated for 
C58H50BCl4F4N10O4Ru (M+1 65-BF4) 1281.18, found 1281.23; UV-Vis λmax = 420 nm (ε = 10,360 
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M-1cm-1); Anal. Calculated for C58H60B2Cl4F8N10O9Ru (65·5H2O): C, 47.79; H, 4.15; N, 9.61. 
Found: C, 47.45; H, 4.20; N, 9.62, water content was confirmed by 1H NMR spectroscopy. 
3.4.6 Photoinduced ligand exchange. 
Electronic absorption spectra were measured with a Hewlett-Packard 8453 diode array 
spectrophotometer. The ligand exchange quantum yield experiments were performed with a 150 
W Xe arc lamp (USHIO) in a Milliarc lamp housing unit with an LPS-220 power supply and an 
LPS-221 igniter (PTI). A bandpass filter (Thorlabs) and long-pass filter (CVI Melles Griot) were 
used to select the appropriate irradiation wavelengths. 
The photolysis experiments were performed in H2O with 2 % acetone and in an acetone 
solution containing 0.25 M tetrabutylammonium chloride (TBACl) in a 1 × 1 cm quartz cuvette, 
and the irradiation wavelengths were selected with a 395 nm long-pass filter. The photon flux of 
the arc lamp with a 335 nm long-pass filter and a 400 nm bandpass filter was determined to be 
4.30 ± 0.25 × 10−8 mol photons/min by ferrioxalate actinometry as previously described in 
detail.168 The quantum yields (Φ) for ligand dissociation of 65 were determined in each of the 
solvent systems in a 1 × 1 cm quartz cuvette. The decrease in the MLCT absorption maximum of 
the reactant with ε = 10,360 M–1cm–1 at 412 nm as a function of time was monitored at early 
irradiation times to calculate the rate of moles of reactant converted to intermediate, I. The 
increase of the MLCT absorption maximum of the product at 490 nm (ε = 9,300 M–1cm–1)158 was 
monitored at irradiation times after the formation of the intermediate to determine the rate of 
moles of product P formed. These rates along with the photon flux were used to calculate the 
quantum yields for the first and second steps, ΦR→I and ΦI→P, respectively. 
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CHAPTER 4. CAGED NITRILE-BASED CA-074 ANALOG FOR 
INHIBITION OF CATHEPSIN B ACTIVITY 
4.1 Introduction 
Proteases play a dynamic role in tumor invasion and metastasis.180 The role of proteases 
in tumors changes with the type of tumor and also by stages of tumor growth. The interactions of 
normal cells with cancer cells also have an effect on protease expression.85,192,193 Cathepsin B, one 
of the eleven-cysteine proteases found in humans, is an intracellular lysosomal protease.  CTSB 
acts as both an exo- and endo-peptidase and is associated with the degradation and processing of 
proteins.194,195 Normal functions of CTSB include antigen processing, apoptosis and proenzyme 
activation.196 Aberrant CTSB activity is related to numerous human diseases such as tumors, 
neurodegenerative disorders and rheumatoid arthritis.197,198 Thus, CTSB is considered as an 
important therapeutic target in tumors, arthritic conditions and other pathological disease states.  
Specific inhibitors of CTSB would serve as a powerful tool in studying their role in 
cancer, and in this context numerous research articles are dedicated towards developing selective 
inhibitors of CTSB.102,106,107,114,131,132,138,145,199,200 A new type of irreversible inhibitor of cysteine 
proteases i.e. E-64 was first reported in 1977.201 E-64 is a thiol protease inhibitor consisting of an 
active trans-epoxysuccinyl moiety, which selectively binds to an active thiol group found in 
many cysteine proteases, generating a thioether bond.202 But E-64 and its derivatives lack 
selectivity both in vitro and in vivo among different types of cathepsins. For developing selective 
CTSB inhibitors, X-ray structure analysis of cathepsin enzymes and a cathepsin-E-64 complex 
showed that L-trans-epoxy-succinic acid group is useful for distinguishing cathepsin B from 
other relative enzymes.199 Based on this study, CA-074 (43 Figure 11, Chapter 1) (N-(L-3trans-
propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline), a selective CTSB inhibitor, was 
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developed.199 CA-074 showed an IC50 value of 2.24 nM for cathepsin B and the relative IC50 ratio 
for cathepsin B: L: H was 1: 77000: 188000.199 As stated in the previous chapters, CA-074, like 
other cathepsin inhibitors, lacks the ability to specifically target cathepsin activity in the tumor 
microenvironment and cannot be used as therapeutic agent. So new compounds may be useful 
for specific delivery of CA-074 in the tumor region.  
Controlled delivery of drugs can be achieved by using one of the numerous external 
stimulation methods.43 Photoexcitation is one such method where light is used as external 
stimulation for controlled cleavage of prodrugs. Photocaging provides a unique mechanism that 
allows control over drug release. Numerous photolabile molecules based on organic and 
inorganic caging groups are routinely developed and used for biomedical release 
applications.43,203,204 In the previous chapters we have caged numerous nitrile based cathepsin 
inhibitors and we envisioned that a nitrile-based analog of CA-074 (66) (Figure 27) could be 
used in photocaging application using Ru(bpy)2 caging groups. The nitrile functionality was not 
introduced as a warhead towards CTSB; instead it was a molecular replacement for the methyl 
group that can be used for caging applications.  
 
Figure 27: Structure of CA-074 (43) and its corresponding nitrile-based analog (66).  
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4.2 Results and discussions 
4.2.1 Synthesis of nitrile-based CA-074 analog (66) and its Ru(bpy)2 caged 
complex (73) 
 
Scheme 8: Synthesis of nitrile-based analog of CA-074 (66)  
Synthesis of 66 started from a diester (67), which was synthesized from D-Tartaric acid 
using a literature protocol.214 The diester was then converted into the activated ester (68) in 2 
steps using standard KOH saponification followed by DCC coupling. The activated ester was 
reacted with 3-aminopropionitrile to give an amide compound (69). The ethyl ester of 69 was 
cleaved using KOH saponification to give the free acid (70). Boc-Ile-Pro-OBn205 71 was 
subjected to Boc-deprotection using a 1:1 mixture of TFA: DCM. The formed free amine was 
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used without further purification and was coupled with 70 using HBTU to give compound 72, 
which upon LiOH saponification gave the final nitrile-based analog 66 (Scheme 8).  
 
Scheme 9: Synthesis of Ru(bpy)2-based caged complex (73).  
Complex 73 was synthesized as an orange solid by refluxing [Ru(bpy)2(OTf)2]206 in EtOH 
in the presence of 6 equiv. of the nitrile-based CA-074 analog 66 (Scheme 9).	 The reaction 
mixture was cooled to room temperature and concentrated under reduced pressure to obtain an 
orange solid. Spectroscopic analysis of the crude reaction mixture confirmed that 66 was bound 
to ruthenium with high conversion, as there was no metal-based byproducts. To remove excess 
of 66 and purify the complex, the crude product was washed with ethyl acetate and diethyl ether 
multiple times. Subsequent precipitation (layering) from acetone and diethyl ether, followed by 
drying in vacuum, gave the caged inhibitor 73 in pure form. Caged inhibitor 73 was 
characterized by 1H NMR, IR and UV-Vis spectroscopies and mass spectrometry. Spectroscopic 
data were consistent with 73 being isolated as a 1:1 mixture of Δ- and Λ stereoisomers; 
consistent with other previously synthesized complexes.146,171 The IR spectrum of 73 shows a νCN 
stretch at 2278 cm-1, diagnostic of nitrile binding to Ru(II). The electrospray ionization mass 
spectrum of 73 shows prominent peaks at m/z = 1201.3, along with a suitable isotopic pattern, 
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consistent with a monocation of the formula [M –(HOTf + OTf)]+. The electronic absorption 
spectrum of 73 is highly consistent with other dications of the general formula cis-
[Ru(bpy)2(RCN)2]2+, where RCN is MeCN, 5-cyanouracil, and protease inhibitors structurally 
related to 73.42,148 Data for 73 in water containing 2 % acetone show a maximum at 423 nm (ε = 
9,800 M-1cm-1) assigned to a singlet metal-to-ligand charge transfer (1MLCT) transition.  
4.2.2 Stability and photolysis of [Ru(bpy)2(66)2](OTf)2 (73) 
The half-life for 73 in the dark was determined spectrophotometrically using the rate 
constant for decomposition, obtained from the slope of a ln A vs. t graph in DMSO (kobs = 1.6 ± 
0.1 × 10-7 s-1) and in phosphate buffered saline (PBS, pH 6.5, kobs = 7.5 ± 0.1 × 10-7 s-1) as 
described previously,146,171 to be ~50 and ~11 days, respectively at 293 ± 2 K.  
The photochemical reactivity of the ruthenium-caged complex 73 was evaluated by 
monitoring the changes to the electronic absorption spectrum of the complex as a function of 
irradiation time (λirr ≥ 395 nm) in a 2 % acetone aqueous solution (Figure 28). The changes to the 
absorption spectrum of 73 are consistent with those of the related [Ru(bpy)2(L)2]2+ 
complexes.47,75,146,171 A decrease of the reactant 1MLCT transition at 410 nm and evolution of a 
new transition at 446 nm at early irradiation times (up to 3 min) can be assigned as arising from 
the photoinduced substitution of one nitrile ligand, 66, by a solvent H2O molecule to form a 
mono-aqua intermediate, [Ru(bpy)2(66)(H2O)]2+ (I). This process exhibits an isosbestic point at 
427 nm indicative that consumption of the reactant is directly correlated to intermediate 
formation. Further irradiation up to 15 min results in formation of the bis-aqua product, 
[Ru(bpy)2(H2O)2]2+ (P) via substitution of the remaining 66 ligand with H2O. This process is 
indicated by a decrease of the peak of the intermediate at 446 nm, the appearance of a new 
transition at 487 nm, and isosbestic points at 383 and 460 nm. The quantum yield of ligand 
  
	
80 
exchange for the first step, reactant R to intermediate I (ΦR→I) and second step i.e., from 
intermediate I to product P (ΦI→P) will be measured by the Turro group.  
 
Figure 28: Changes to the electronic absorption of 73 in a 2 % acetone aqueous solution 
at irradiation times, tirr, of 0, 1, 3, 5, 7, 10, and 15 min (λirr ≥ 395 nm); the * denotes the 
mono-aqua intermediate. Inset: tirr = 0, 1, and 3 min. 
 
4.2.3 Isolated CTSB enzyme inhibition by 66 and 73. 
Compound 66 acts as a potent CTSB inhibitor and complex 73 acts as a potent, 
photoactivated inhibitor of human cathepsin B. IC50 values were determined for 66 and 73 under 
dark and light conditions and upon irradiation with >395 nm light (Figure 29).  
 
Figure 29: IC50 curves for ruthenium-caged inhibitor 73 (blue with irradiation and black 
without) and uncaged inhibitor 66 (red with irradiation and green without) against human 
cathepsin B.  
* 
* 
  
	
81 
 
Enzyme inhibition for 73 was enhanced by a factor of 5 upon exposure to light with IC50 
values of 15 nM and 78 nM, for light and dark conditions respectively. In contrast, inhibition by 
the free inhibitor 66 was identical under light and dark conditions, 21 nM and 30 nM, 
respectively; confirming that irradiation with 395 nm light has no effect on inhibition under the 
assay conditions.  
4.3 Discussions and conclusions 
Cathepsin B, one of the most abundant cysteine cathepsins, is upregulated in numerous 
diseases and is considered to be an attractive molecular target for cancer therapy.106 Though a 
potential chemotherapy target, no small molecule CTSB inhibitor such as CA-074 has been FDA 
approved due to many off target toxicity profiles. Thus new methods for drug delivery are 
needed for selective inhibition of enzymes in specific locations. Here we report the synthesis of a 
new nitrile-based CA-074 analog (66) and its corresponding Ru(bpy)2 caged complex which 
could be used for light activated inhibition of CTSB. Upon 15 min of visible light irradiation 
(>395 nM) the caged complex 73 releases 2 molecules of 66. Our data indicate that enzyme 
inhibition decreased by 7 fold upon introduction of nitrile group in CA-074 with the IC50 values 
of 3 nM and 21 nM for 43 and 66 respectively. Also a 5-fold increase of enzyme inhibition was 
observed when light was used for photoactivation of complex 73 with IC50 values of 15 nM and 
78 nM under light and dark respectively. The stability data of complex 73 and the previously 
performed SAR studies on CA-074 and its analogs199 indicate that complex 73 can itself act as 
CTSB inhibitor leading to high enzyme inhibition even in the dark conditions. New analogs of 
43 and new caging groups for 66 should be developed for reducing the enzyme inhibition by the 
caged complex in dark.     
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4.3 Experimental procedures 
 
4.4.1 Synthesis of CA-O74 analog (66) 
 Compound 68 (4.20 g, 14.9 mmol) was dissolved in DCM (80 mL) at RT and to the flask 
3-aminopropionitrile (1.56 g, 22.4 mmol) was added dropwise over a period of 15 min. The 
reaction mixture was stirred for an additional 2 h at RT and then concentrated under reduced 
pressure to give crude yellow oil. The compound was then purified by silica gel flash 
chromatography (Rf = 0.4 with 50% EtOAc:Hexane) to give 69 as a white solid (2.8 g, 91%). 
M.p = 128 oC; 1H NMR (400 MHz, Chloroform-d) δ 6.60 (s, 1H), 4.35-4.18 (m, 2H), 3.73-3.42 
(m, 4H), 2.74-2.53 (m, 2H), 1.37-1.26 (m, 3H). 13C NMR (400 MHz, Chloroform-d) δ 166.0, 
166.3, 117.5, 62.5, 53.7, 53.0, 35.1, 18.2, 14.0. HRMS calculated for  (M+Na)+ 235.0695, found 
235.0696. 
 Compound 69 (2.6 g, 12.3 mmol) was subjected to saponification. Compound 69 was 
dissolved in THF (25 mL) and EtOH (13 mL) at 0 oC. To this a suspension of KOH (0.69 g, 12.6 
mmol) in EtOH (12 mL) was added dropwise and the reaction mixture was allowed to stir at 0 oC 
for an additional 1 h. The reaction mixture was then concentrated under reduced pressure, 
dissolved in water (30 mL) and acidified to pH 3 using 1M HCl solution. The aqueous layer was 
then extracted with EtOAc (3 × 30 mL) and the combined organic layer was dried over Na2SO4 
and concentrated under reduced pressure to give compound 70 as a white solid which was used 
without further purification.  
 In a flask, compound 71205 (1.3 g, 3.1 mmol) was dissolved in DCM (2.4 mL) at RT and 
to this TFA (2.4 mL, 3.54 g, 31.1 mmol) was added slowly and reaction mixture was stirred 
overnight. The reaction mixture was concentrated under reduced pressure to give the 
corresponding free amine as a colorless oil which was used without further purification and was 
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dissolved in DMF (30 mL) at 0 oC under inert atmosphere. To the flask, compound 70 (0.6 g, 3.1 
mmol), HBTU (1.4 g, 3.7 mmol) and DIPEA (0.8 g, 6.2 mmol) was added and stirred for 12 h at 
0 oC. The reaction mixture was diluted with EtOAC (300 mL) and the organic layer was washed 
with 10% NH4Cl (2 × 100 mL), 10% NaHCO3 (2 × 100 mL), water (2 × 100 mL) and brine (2 × 
100 mL). The organic layer was dried over Na2SO4 and concentrated under reduced pressure to 
obtain the crude compound as a colorless oil. The crude was purified by silica gel flash 
chromatography (Rf = 0.45 in 100% EtOAc) to give compound 72 as a colorless oil (1.0 g, 64%). 
1H NMR (400 MHz, Chloroform-d) δ 7.39-7.32 (m, 5H), 7.05 (t, J = 6.2 Hz, 1H), 5.21-5.08 (m, 
2H), 4.60 (t, J = 8.8 Hz, 1H), 4.51-4.47 (m, 1H), 3.88-3.82 (m, 1H), 3.70-3.60 (m, 1H), 3.61-3.36 
(m, 4H), 2.62-2.51 (m, 2H), 2.26-2.22 (m, 1H), 2.05-1.93 (m, 3H), 1.82 (d, J = 11.4 Hz, 2H), 
1.51-1.41 (m, 1H), 1.11-1.03 (m, 1H), 0.92 (d, J = 6.7 Hz, 3H), 0.84 (t, 3H). 13C NMR (400 
MHz, Chloroform-d) δ 171.5, 170.6, 166.9, 165.5, 135.3, 128.6, 128.5, 128.3, 117.6, 77.2, 67.0, 
59.2, 54.7, 54.5, 47.6, 45.1, 37.5, 35.1, 29.1, 28.5, 24.8, 24.5, 17.9, 14.9, 10.8. HRMS calculated 
for  (M+Na)+ 507.2220, found 507.2216. 
 Compound 72 (1.0 g, 2.1 mmol) was dissolved in THF (10 mL) MeOH (10 mL) at 0 oC 
and to this LiOH (0.25 g, 10.3 mmol) aqueous solution (10 mL) was added dropwise over a 
period of 30 min and the reaction mixture was allowed to stir at 0 oC for an additional 5 h. The 
reaction mixture was then concentrated under reduced pressure and diluted with water (50 mL). 
The aqueous layer was acidified to pH = 3 using a 10% KHSO4 solution and extracted with 
EtOAc (3 × 50 mL). The combined organic layer was dried over Na2SO4 and concentrated under 
reduced pressure to give a colorless oil which was purified using silica gel flash chromatography 
(Rf = 0.3 with 90:9:1 DCM:MeOH:AcOH) to give the compound 66 as a colorless oil (0.60 g, 74 
%). 1H NMR (400 MHz, Chloroform-d) δ 9.49 (s, 1H), 7.85 (d, J = 8.9 Hz, 1H), 7.30 (t, J = 6.2 
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Hz, 1H), 4.60 (t, J = 8.8 Hz, 1H), 4.54-4.42 (m, 1H), 3.92-3.86 (m, 1H), 3.73-3.59 (m, 3H), 3.54-
3.45 (m, 2H), 2.68-2.56 (m, 2H), 2.30-2.21 (m, 1H), 1.85-1.81 (m, 1H), 1.55-1.43 (m, 1H), 1.14-
1.03 (m, 1H), 0.96 (d, J = 6.7 Hz, 3H), 0.84 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 176.74, 175.32, 171.19, 167.38, 166.16, 117.96, 59.31, 54.89, 54.43, 54.24, 
47.84, 37.27, 35.27, 28.94, 24.87, 24.52, 20.80, 17.98, 14.90, 10.76. HRMS calculated for  
(M+Na)+ 417.1750, found 417.1764. 
4.4.2. Synthesis of caged complex 73 
In the glove box, a sealable tube was charged with cis-Ru(bpy)2(OTf)2 (0.042 mmol, 30 
mg), and  66 (0.252 mmol, 99.6 mg) and freshly distilled EtOH (15 mL). The resulting solution 
was wrapped in aluminum foil and refluxed for 6 h during which time it turned from dark red to 
bright orange. After cooling the crude solution to RT, the solvents were removed under reduced 
pressure and the crude mixture was analyzed by 1H NMR spectroscopy. The resulting yellow 
solid was dissolved in acetone (2 mL) and layered with Et2O (10 mL) and placed in the freezer at 
–20 °C for 16 h. The solution was decanted the resulting solid was stirred with EtOAc (15 mL) 
for 4 h. The orange solid was centrifuged and the resulting filter cake was washed with Et2O (3 × 
15 mL) and dried under reduced pressure to give the title compound 73 as a yellow solid in 
analytically pure form (31 mg, 49 %). Mp = 184 oC (decomp); 1H NMR (600 MHz, Acetone-d6) 
δ 11.14 (s, 1H), 9.53 (d, J = 5.5 Hz, 1H), 8.78 (d, J = 7.9 Hz, 2H), 8.65 (t, J = 7.3 Hz, 2H), 8.10-
8.02 (m, 2H), 8.00-7.91 (m, 2H), 7.90 (q, J = 6.8, 6.1 Hz, 2H), 7.81 (q, J = 10.2, 8.1 Hz, 3H), 
7.40 (tdd, J = 5.9, 4.8, 4.1, 2.5 Hz, 2H), 4.62 (dt, J = 21.9, 7.9 Hz, 1H), 4.48-4.41 (m, 2H), 4.00-
3.87 (m, 2H), 3.75-3.63 (m, 3H), 3.60-3.53 (m, 1H), 3.39 (qd, J = 6.9, 1.6 Hz, 2H), 3.14-3.06 (m, 
2H), 2.26 (q, J = 12.2, 9.9 Hz, 2H), 2.08 (d, J = 1.7 Hz, 32H), 2.05-1.95 (m, 5H), 1.64 (s, 2H), 
1.10 (td, J = 7.0, 1.6 Hz, 2H), 1.02 (dd, J = 8.7, 6.9, 1.7 Hz, 5H), 0.95-0.83 (m, 5H).; IR (KBr) 
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νmax (cm-1) 3618, 3567, 3374, 3083, 2921, 2278, 1664, 1606, 1591, 1526, 1467, 1447, 1426, 
1379, 1340, 1312, 1276, 1242, 1161, 1125, 1009, 1062, 1032, 895, 834, 767, 731, 701, 675. 
ESMS calculated for C56H67N12O12Ru [M –(HOTf + OTf)]+ 1201.40, found 1201.3; UV-Vis λmax 
= 423 nm (ε = 9,800 M-1cm-1). 
4.4.3 Isolated CTSB enzyme inhibition by 66 and 73  
Purified human cathepsin B was purchased from Athens Research & Technology 
(Athens, GA, USA). Cathepsin enzyme activity was determined from kinetic measurements 
performed by fluorimetric detection of the hydrolysis product AMC at 37 °C every 2 min for 14 
min (8 measures). The excitation and emission wavelengths were 360 and 485 nm respectively. 
The selective fluorescent substrate Z-Arg-Arg-AMC was used at a final concentration of 100 μM 
(obtained from Bachem, Torrance, CA). Enzyme activities are expressed as a percentage, with 
100% equal to activity in the absence of inhibitor. 
Recombinant cathepsin B (human) was obtained from Enzo Life Sciences (Farmingdale, 
NY). For each experiment the stock solution 5 μM was diluted 625 times and activated for 15 
min at 37 °C with a 400 mM sodium acetate, pH 5.5, 4 mM EDTA, 8 mM DTT assay buffer 
solution. The inhibitor was prepared as a 1% DMSO solution in the buffer solution (400 mM 
sodium acetate, pH 5.5, 4 mM EDTA, 0.01 % Triton X -100) and plated (Corning® 96 Well Flat 
Clear Bottom Black Polystyrene TC-Treated Microplates, 50 μL/well). Three experiments in 
triplicates (66 and 73, light or dark) were carried out on the different 96 well plates. The wells 
containing “dark” were carefully wrapped in aluminum foil for 15 min and the light plate was 
exposed to 365 nm light (8W) for the same time period. The photolysis was conducted for 15 
min  (with gentle shaking of the plate every 2-3 min) using a 250W tungsten halogen lamp 
(Osram Xenophot HLX) powered by a 24V power supply, using bandpass and water filters, as 
  
	
86 
described in the previous chapters. Both the plates were then left in dark for additional 30 min as 
the inhibitor is irreversible inhibitor. After photolysis, the reaction was initiated by addition of 50 
μL of 200 μM Z-Arg-Arg-AMC solution in the assay buffer (final volume 100 μL, final enzyme 
concentration 2 nM). Cathepsin enzyme activity was determined from kinetic measurements 
performed by fluorimetric detection of the hydrolysis product AMC at 37 °C every 2 min for 14 
min (8 measures) and MAX RFU slope values used for plotting. 
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CHAPTER 5. RUTHENIUM TRIS(2-PYRIDYLMETHYL)AMINE AS 
AN EFFECTIVE PHOTOCAGING GROUP FOR NITRILES2 
5.1 Introduction 
Caged small molecules with photolabile groups are being developed as remotely 
controllable tools for understanding the spatial and temporal aspects of biological activity.149 
Light-activated Ru-based compounds have been used in numerous biological applications. 
Ruthenium compounds are used both as caging groups for small molecules36,37,40,146,151,171 and 
also as biomolecules. The photodissociation generates open coordination sites on the metal 
center, which can be used in DNA binding.15,77,207 First examples of Ru-caged protease 
inhibitors are discussed in the previous chapters of this dissertation where we have used 
Ru(bpy)2 caging group for nitriles.146,171 
Uncaging of metal-based compounds involves two important transformations; i) 
excitation of the caged molecule by absorption of light and ii) conversion of the 1MLCT state 
to a ligand dissociation excited state. Ligand structure plays an important role in both of these 
steps. Despite numerous applications, ligands used for developing Ru-based photocages have  
focused mainly on bi- or tri-dentate planar heteroaromatic groups such as bpy or terpy. To 
date, Ru(bpy)2 is the most widely used inorganic photolabile protecting group used for 
caging neurotransmitters,38,151 anticancer agents47 and enzyme inhibitors.146,171 Classical 
photodissociation of Ru(bpy)3+2 and more recent examples of dissociation of bidentate 
ligands from the Ru-based photocages147,208 (Figure 30) guided us in developing ligands of 
greater dentisity to prevent possible in vivo photo-degradation of the caging group. Past 																																																								2	Portions of the text in this chapter were reprinted and adapted with permission from Sharma,	R.;	
Knoll, J. D.; Martin, P. D.; Podgorski, I.; Turro, C.; Kodanko, J. J. Inorg. Chem. 2014, 53, 3273. 	
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research from our group has shown that these tertiary amine-based ligands can be used in 
peptide ligand conjugates. They can also be attached to drug delivering vectors such as 
LHRH, where there distribution could also be controlled.209,210 Also we wanted to study the 
effects of ligand structure on the properties of the caged complex.  
 
Figure 30: Structures of complexes releasing bidentate ligands on photolysis. 
This chapter describes a new caging group Ru(TPA) for caging nitriles distinct from the 
established Ru(bpy)2, where we have used a tertiary amine based tetradentate tri(2-
pyridylmethyl)amine (TPA) ligand. Two caged nitriles of the general formula 
[Ru(TPA)(RCN)2](PF6)2 were prepared for this study (Figure 31). The complex 
[Ru(TPA)(MeCN)2](PF6)2 (76) contains two caged MeCN ligands, whereas the complex 
[Ru(TPA)(60)2](PF6)2 (77) contains 2 equiv. of the cysteine protease inhibitor Cbz-Leu- 
NHCH2CN (60), a potent and selective inhibitor of human cathepsin K.127 
 
Figure 31: Structures of new nitrile-based Ru(TPA) complexes 76 and 77. 
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5.2 Results and discussions 
5.2.1 Synthesis and characterization of [Ru(TPA)(RCN)2](PF6)2 (76 and 77). 
 
Scheme 10: Synthesis of nitrile-based Ru(TPA) complexes 76 and 77. 
Complex 76 was synthesized as a yellow solid by heating 
[Ru(TPA)(Me2SO)Cl]Cl211,212 in 1:1 H2O/MeCN, followed by precipitation with NH4PF6 
(Scheme 10). UV-vis spectra of 76 showed peak maxima at 380 nm (ε = 11,200 M-1 cm-1) 
associated with metal-to-ligand charge transfer (MLCT) transition. 1H NMR spectroscopic 
analysis indicated the presence of two distinct MeCN ligands, with singlets at 2.88 and 2.47 
ppm, separated by approximately 0.4 ppm, consistent with the expected structure with one of 
the MeCN ligand trans to the basic nitrogen and other in cis position. IR spectroscopy of 
complex 76 showed at υCN stretch at 2276 cm-1consistant with nitriles bound to ruthenium. 
Mass spectra of 76 showed a prominent peak at m/z 619.1, along with a suitable isotopic 
pattern, consistent with the monocation of the formula [Ru(TPA)(MeCN)2](PF6)+. Based on 
COSY and NOESY spectroscopic analysis, the peak at 2.88 ppm was assigned to trans-
MeCN where as the peak at 2.47 corresponded to the cis-MeCN. Complex 76 was further 
characterized by X-ray crystallography. Diffusing Et2O into a solution of 76 in MeCN 
[Ru(TPA)(Me2SO)Cl]Cl
1:1 H2O/MeCN
reflux, 2 h
[Ru(TPA)(MeCN)2](PF6)2
RuCl3 ·  3H2O
1) TPA, AgCF3SO3
    3:2 EtOH/H2O
    24 h, 90 oC
2) Cbz-Leu-NHCH2CN (60)
    EtOH, 
    24 h, 80 oC
    then NH4PF6
[Ru(TPA)(60)2](PF6)2
76
77
then NH4PF6
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yielded small yellow blocks of 76 suitable for crystallographic analysis. The structural 
parameters of 76 were similar to those of  [Ru(TPA)(MeCN)2](SbF6)2 which was reported 
while our studies were underway.211 
 
Figure 32: ORTEP diagram of dication [Ru(TPA)(MeCN)2]+2. Thermal ellipsoids are 
shown at 50% probability. Hydrogen atoms are omitted for clarity. 
 
Complex 77 was synthesized by heating [Ru(TPA)(H2O)2](OTf)2213 in the presence of 
5 equiv. of the protease inhibitor 60 in EtOH (Scheme 10). UV-vis spectra of 77 showed 
peak maxima at 375 nm (ε = 12,000 M-1 cm-1) consistent with a metal-to-ligand charge 
transfer (MLCT) transition. 1H NMR spectroscopic analysis indicated the presence of 
inhibitor in two distinct environments, with α-CN methylene unit multiplets at 4.9 and 4.5 
ppm, separated by approximately 0.5 ppm, consistent with the expected structure with one of 
the inhibitor ligand trans to the basic nitrogen and other in cis position. IR spectrum of 
complex 77 showed at υCN stretch at 2269 cm-1 consistent with nitrile binding to Ru(II).  Mass 
spectra of 70 showed a prominent peak at m/z 1143, along with a suitable isotopic pattern, 
consistent with the monocation of the formula [Ru(TPA)(60)2](PF6)+. Based on COSY and 
NOESY spectroscopic analysis, the multiplet at 4.9 ppm was assigned to the α-CN 
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methylene unit of trans-inhibitor whereas the peak at 4.5 corresponded to the α-CN 
methylene unit of cis-inhibitor molecule. 
5.2.2 Photolysis studies of 76 and 77 
Complexes 76 and 77 show the release of a single nitrile upon relatively short 
irradiation times with 365 nm light.214 A decrease in the absorption peak at 370 and 365 nm 
for 76 (Figure 33A) and 77 (Figure 33B) respectively, is observed within 10-15 min of 
irradiation with λ > 345 nm in 2% acetone in H2O solutions, with the concomitant 
appearance of a new band at 395 and 390 nm, respectively (Figure 33). The quantum yields 
for decomposition of 76 and 77 are 0.012(1) and 0.011(1) respectively (λirr = 350 nm) and 
were determined by the Turro group. 
 
Figure 33: Changes in the electronic absorption spectra upon irradiation with λ > 350 
nm in H2O (2% acetone) of 76 (A) for 0, 1, 2, 3, 5, and 10 min and 77 (B) for 0, 1, 3, 
7, 10, and 15 min. 
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To better understand the photochemical changes, the same reactions were followed in 
deuterated solvents by 1H NMR spectroscopy. Experiments suggested exchange of only one 
nitrile-based ligand with solvent molecules from 76 (Figure 34) and 77 (Figure 35). The 
intensities of upfield resonances, assigned to methyl and methylene protons of α-CN of 76 
and 77, decreases as the peaks associated with free MeCN (2.05 ppm) and free 60 (4.16 ppm) 
increase. Released nitriles are assigned as cis to the basic nitrogen based on COSY and 
NOESY spectroscopic analysis data. This structural assignment is further supported by the 
fact that upfield shifts for resonances of α-CN protons in 76 and 77 would be expected 
because of shielding by two cis-pyridine rings of the TPA ligand, whose π systems are 
orthogonal to the Ru-N vector of the nitrile that is released upon photolysis. 
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Figure 34: Photochemical reaction of 76 (0, 120 and 240 min) in C6D6O: D2O – 9: 1 
showing the release of cis-MeCN (2.47 ppm) and formation of free MeCN (2.05 
ppm). 
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Figure 35: Photochemical reaction of 77 (0, 120 and 240 min) in C6D6O: D2O – 9: 1 
showing the release of cis-60 (4.40 ppm) and formation of free 60 (4.16 ppm). 
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5.2.3 Stability studies of 76 and 77 
Complexes 76 and 77 showed excellent stability in solution in the dark. The 
decomposition rates for 76 and 77 in DMSO and phosphate-buffered saline (pH = 6.5) were 
determined spectrophotometrically. The rate constants were calculated from linear ln A vs t 
plots and ranged from 1.1(3) × 10-8 to 6(2) × 10-9 s-1. These values correspond to half-lives of 
>730 days in solution, confirming that 76 and 77 are stable towards the release of their bound 
nitrile ligands in aqueous media.  
5.2.4 Isolated CTSK enzyme inhibition by 77 
Complex 77 acts as a potent, photoactivated inhibitor of human cathepsin K. IC50 
values were determined for 60 and 77 under dark and light conditions and upon irradiation 
with 365 nm light (Figure 36).  
 
Figure 36: IC50 curves for ruthenium-caged inhibitor 77 (blue with irradiation and 
black without) and uncaged inhibitor 60 (red with irradiation and green without) 
against human cathepsin K.  
Log	[Inhibitor] 
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Enzyme inhibition for 77 was enhanced by a factor of 89 upon exposure to light with 
IC50 values of 63 nM and 5.6 μM, respectively. In contrast, inhibition by the free inhibitor 60 
was identical under light and dark conditions, 27 nM and 34 nM, respectively; confirming 
that irradiation with 365 nm light has no effect on inhibition under the assay conditions. Also 
complex 77 is as potent as 60 in light conditions indicating the release of only one nitrile 
ligands on exposure to light. Control experiments with 76 showed no inhibition of CTSK 
under light and dark conditions at 500 μM, the highest concentration surveyed for 77, 
confirming that neither the ruthenium complex nor its byproducts is responsible for CTSK 
inhibition observed for 77 upon irradiation.    
5.2.5 Discussions and conclusions 
This study establishes Ru(TPA) as a new caging group for bioactive nitriles distant 
from standard planar, heteroaromatic caging groups such as Ru(bpy)2 which are mostly used 
for photocaging purposes. Two new complexes were synthesized using the Ru(TPA) caging 
group. Both the complexes showed release of only one nitrile ligand on photolysis by UV 
light. This study also shows that ligand structure plays an important in photochemical 
properties of the complex. We have demonstrated that caged inhibitor complex 77 can be 
used for efficient photoactivated enzyme inhibition against human CTSK.  
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5.3 Experimental procedures 
5.3.1 Synthesis and characterization of [Ru(TPA)(RCN)2](PF6)2 (76 and 77). 
Synthesis of [Ru(TPA)(CH3CN)2](PF6)2 (76): [Ru(TPA)(DMSO)Cl)]Cl (200.0 mg, 0.370 
mmol) as a 2:1 mixture of stereoisomers, was dissolved in a 1:1 mixture of H20 and CH3CN (20 
mL) under argon atmosphere and the resulting solution was refluxed for 2 h under inert 
atmosphere. Ice cold water (20 mL) was added to the reaction mixture followed by a saturated 
solution of aqueous NH4PF6 (5 mL), resulting in a pale yellow precipitate that was isolated by 
filtration, washed with ice-cold H2O and dried under reduced pressure to get the title complex as 
a yellow solid (136 mg, 48%). Crystals suitable for X-ray crystallographic analysis were 
obtained by diffusing Et2O into a solution of 76 in MeCN: Mp = 190 °C (decomp); 1H NMR 
(400MHz C3D6O:D2O - 9:1) δ 9.18 (d, 1H, J = 5.9 Hz), 8.83 (d, 2H, J = 5.9 Hz), 7.85 (t, 2H, J = 
7.8 Hz), 7.68-7.56 (m, 3H), 7.41 (t, 2H,  J  = 6.8 Hz), 7.25 (t, 1H, J  = 6.8 Hz), 7.18 (d, 1H, J  = 
7.8 Hz), 5.25 (d, 2H, J  = 15.6 Hz), 5.15 (d, 2H, J  = 15.6 Hz), 4.86 (s, 2H), 2.88 (s, 3H), 2.47 (s, 
3H); IR (KBr) νmax (cm-1) 3666, 3592, 3418, 3119, 2935, 2856, 2276, 1729, 1609, 1481, 1461, 
1448, 1311, 1289, 1160, 992, 838, 767, 739. ESMS calculated for C22H24F6N6PRu (M+1) 619.1, 
found 619.3; UV-vis λmax = 380 (ε = 11,200 M-1cm-1); Anal. Calculated for C22H24F12N6P2Ru: C, 
34.61; H, 3.17; N, 11.01. Found: C, 34.70; H, 3.20; N, 10.82.  
Synthesis of [Ru(TPA)(RCN)2](PF6)2 (77): A solution of [Ru(TPA)(H2O)2](CF3SO3)2213  
(540 mg, 0.72 mmol) and dry EtOH (40 mL) was deoxygenated by bubbling Ar through a 
submerged needle for 10 min. Cbz-Leu-NHCH2CN (1.09 g, 3.6 mmol) was added and the 
reaction mixture was refluxed for 24 h at 80 °C under Ar atmosphere. The reaction mixture was 
cooled to room temperature and concentrated under reduced pressure. The green oil was 
extracted with Et2O (3 × 20 mL) to get a dark green solid, which was dissolved in minimum 
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amount of CH2Cl2 and washed with water (3 × 30 mL). The organic layer was dried (NaSO4) and 
concentrated under reduced pressure to get a dark green solid (501 mg). The dark green solid 
was dissolved in MeOH (10 mL) and H2O (10 mL) was added. The insoluble green oil was 
removed by centrifugation. A saturated solution aqueous solution of NH4PF6 (2 mL) was added 
to the clear pale green supernatant solution, resulting in formation of a precipitate that was 
isolated by filtration, washed with water (3 × 20 mL) and dried under reduced pressure to get the 
title compound as a pale yellow solid in analytically pure form (290 mg, 53%): Mp = 210 °C 
(decomp); 1H NMR (400MHz C3D6O) δ 9.19 (d, 1H, J = 5.6 Hz), 8.85 (d, 1H, J  = 6.1 Hz), 8.84 
(d, 1H, J  = 6.1 Hz), 8.50 (t, 1H, J = 5.1 Hz), 8.16 (t, 1H, J  = 4.7 Hz), 7.92-7.87 (m, 2H), 7.71-
7.62 (m, 3H), 7.43-7.22 (m, 14H), 6.96 (d, 1H, J  = 7.3 Hz), 6.79 (d, 1H, J  = 7.1 Hz), 5.32 (d, 
1H, J  = 15.7 Hz), 5.31 (d, 1H, J  = 15.7 Hz), 5.20-5.14 (m, 3H), 5.07-4.96 (m, 4H), 4.90-4.88 
(m, 2H), 4.81 (d, 1H, J  = 12.7 Hz), 4.57-4.45 (m, 2H), 4.36-4.32 (m, 1H), 4.16-4.11 (m, 1H), 
1.86-1.65 (m, 3H), 1.61-1.42 (m, 3H), 0.97-0.84 (m, 12H); IR (KBr) νmax (cm-1) 3417, 3319, 
2959, 2873, 2265, 1717, 1684, 1608, 1519, 1451, 1406, 1340, 1312, 1254, 1160, 1121, 1044, 
844, 769, 740, 699; ESMS calculated for C50H60 F6N10O6PRu (M+1) 1143.3, found 1143.9; UV-
vis λmax = 375 (ε = 12,000 M-1cm-1); Anal. Calculated for C50H61F12N10O6.5P2Ru (77·0.5 H2O): C, 
46.30; H, 4.74; N, 10.80. Found: C, 46.21; H, 4.79; N, 10.78. 
5.3.2 Photochemical quantum yields of 76 and 77 
The Turro group, using ferrioxalate actinometry as previously described in detail 
determined photosubstitution quantum yields.168 A 150 W Xe lamp housed in a Milliarc compact 
arc lamp housing (PTI) and powered by a PTI model LPS-220 power supply was used in the 
steady-state photolysis experiments; the wavelength of the light reaching the sample was 
controlled with colored glass long-pass (295 nm) and band-pass (350 nm) filters (Newport). 
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5.3.3 Stability studies of 76 and 77 
Solutions of 76 and 77 in 0.1 M pH 6.5 phosphate buffer (1.0% DMSO) were monitored 
by UV-Vis spectroscopy for 24 h. Ln A was plotted vs time and the line was fit to give a first 
order reaction rate constants.  
Compound and 
condition 
76 (DMSO) 76 (PBS) 77 (DMSO) 77 (PBS) 
Rate constant k 
(s-1) 
8(2) × 10-9 6(2) × 10-9 7(3) × 10-9 1.2(2) × 10-8 
t1/2 (days) 1.07 × 103 1.33 × 103 1.25 × 103 7.35 × 103 
 
Table 2: Observed rate constants for decomposition of 76 and 77 in 100% DMSO or pH 
6.5 phosphate buffer (1.0% DMSO) at 298±2K. 
 
5.3.4 Cathepsin K inhibition studies 
Cathepsin enzyme activity was determined from kinetic measurements performed by 
fluorimetric detection of the hydrolysis product AMC at 37 °C every 2 min for 14 min (8 
measures). The excitation and emission wavelengths were 360 and 485 nm respectively. The 
selective fluorescent substrate Z-Gly-Pro-Arg-AMC was used at a final concentration of 100 μM 
(obtained from Bachem, Torrance, CA). Enzyme activities are expressed as a percentage, with 
100% equal to activity in the absence of inhibitor 60. 
Recombinant cathepsin K (human) was obtained from Enzo Life Sciences (Farmingdale, 
NY). An 880 nM stock solution was prepared in 50 mM sodium acetate, pH 5.5, 50 mM NaCl, 
0.5 mM EDTA and 5 mM DTT and kept at –80 °C. For each experiment the stock solution was 
diluted 440 times and activated for 15 min at 37 °C with a 400 mM sodium acetate, pH 5.5, 4 
mM EDTA, 8 mM DTT assay buffer solution. The inhibitor was prepared as a 1% DMSO 
solution in the buffer solution (400 mM sodium acetate, pH 5.5, 4 mM EDTA, 0.01 % Triton X -
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100) and plated (Corning® 96 Well Flat Clear Bottom Black Polystyrene TC-Treated 
Microplates, 50 μL/well). Three experiments in triplicates (60 and 77, light or dark) were carried 
out on the different 96 well plates. The wells containing “dark” were carefully wrapped in 
aluminum foil for 15 min and the light plate was exposed to 365 nm light (8W) for the same time 
period. The photolysis was conducted for 15 min  (with gentle shaking of the plate every 2-3 
min) using a long wavelength (UV-365 nm) Black Ray Lamp (8W) held at distance of 18 cm 
from the plate. After photolysis, the reaction was initiated by addition of 50 μL of 200 μM Z-
Gly-Pro-Arg-AMC solution in the assay buffer (final volume 100 μL, final enzyme 
concentration 2 nM). Cathepsin enzyme activity was determined from kinetic measurements 
performed by fluorimetric detection of the hydrolysis product AMC at 37 °C every 2 min for 14 
min (8 measures) and MAX RFU slope values used for plotting. 
5.3.5 X-ray Crystallographic analysis of 76 
A specimen of C49.50H57F24N15.50P4Ru2 was used for the X-ray crystallographic analysis. 
The X-ray intensity data were measured. The total exposure time was 56.65 hours. The frames 
were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The 
integration of the data using a triclinic unit cell yielded a total of 65934 reflections to a 
maximum θ angle of 26.37° (0.80 Å resolution), of which 12628 were independent (average 
redundancy 5.221, completeness = 95.9%, Rint = 3.66%) and 10076 (79.79%) were greater than 
2σ(F2). The final cell constants of a = 12.1129(8) Å, b = 12.2928(8) Å, c = 21.8490(15) Å, α = 
94.436(3)°, β = 97.000(3)°, γ = 91.324(3)°, volume = 3217.7(4) Å3, are based upon the 
refinement of the XYZ-centroids of 9922 reflections above 20 σ(I) with 4.669° < 2θ < 58.65°. 
Data were corrected for absorption effects using the multi-scan method (SADABS). The ratio of 
minimum to maximum apparent transmission was 0.923.  
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The final anisotropic full-matrix least-squares refinement on F2 with 863 variables 
converged at R1 = 5.79%, for the observed data and wR2 = 19.52% for all data. The goodness-
of-fit was 1.413. The largest peak in the final difference electron density synthesis was 1.728 e-
/Å3 and the largest hole was -1.368 e-/Å3 with an RMS deviation of 0.130 e-/Å3. On the basis of 
the final model, the calculated density was 1.704 g/cm3 and F(000), 1653 e-. 
Table 3: Crystal data and structure refinement for [RuII(TPA)(CH3CN)2](PF6)2. (76) 
Identification code rs01147_rework 
Chemical formula C49.50H57F24N15.50P4Ru2 
Formula weight 1651.12 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 12.1129(8) Å α = 94.436(3)° 
 b = 12.2928(8) Å β = 97.000(3)° 
 c = 21.8490(15) Å γ = 91.324(3)° 
Volume 3217.7(4) Å3  
Z 2 
Density (calculated) 1.704 g/cm3 
Absorption coefficient 0.688 mm-1 
F(000) 1653 
Theta range for data collection 0.94 to 26.37° 
Index ranges -15<=h<=15, -15<=k<=15, -26<=l<=27 
Reflections collected 65934 
Independent reflections 12628 [R(int) = 0.0366] 
Coverage of independent reflections 95.9% 
Absorption correction multi-scan 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2013 (Sheldrick, 2013) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 12628 / 0 / 863 
Goodness-of-fit on F2 1.413 
Δ/σmax 0.001 
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Final R indices 
 
Weighting scheme 
 
Largest diff. peak and hole 
R.M.S. deviation from mean 
10076 data; I>2σ(I) R1 = 0.0579, wR2 = 0.1853 
all data                     R1 = 0.0771, wR2 = 0.1952 
w=1/[σ2(Fo2)+(0.1000P)2+0.5098P 
where P=(Fo2+2Fc2)/3 
1.728 and -1.368 eÅ-3 
0.130 eÅ-3 
 
 
Table 4: Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
 
  ___________________________________________  
   
                     x /a            y/b             z/c                    U(eq)  
  ___________________________________________  
   
Ru1 0.34193(3) 0.02767(3) 0.71876(2) 0.01620(14) 
Ru2 0.12463(3) 0.48193(3) 0.22502(2) 0.01489(13) 
P1 0.37972(15) 0.73310(15) 0.44715(8) 0.0404(4) 
P2 0.28898(12) 0.70587(12) 0.94526(7) 0.0277(4) 
P3 0.88862(12) 0.78405(12) 0.06745(7) 0.0257(3) 
P4 0.93103(12) 0.79375(12) 0.55563(7) 0.0264(3) 
F1 0.4210(4) 0.8474(4) 0.4811(2) 0.0693(14) 
F2 0.4994(4) 0.7224(4) 0.4218(3) 0.0834(17) 
F3 0.3461(5) 0.6162(4) 0.4136(3) 0.0880(18) 
F4 0.3476(6) 0.7906(4) 0.3881(3) 0.115(3) 
F5 0.4298(7) 0.6761(5) 0.5073(3) 0.120(3) 
F6 0.2729(5) 0.7372(6) 0.4762(4) 0.148(4) 
F7 0.3609(3) 0.7878(3) 0.99661(16) 0.0380(9) 
F8 0.1842(3) 0.7210(3) 0.98206(18) 0.0399(9) 
F9 0.2158(3) 0.6253(3) 0.89461(18) 0.0459(10) 
F10 0.3934(3) 0.6912(3) 0.9086(2) 0.0549(11) 
F11 0.3242(3) 0.6056(3) 0.98446(19) 0.0448(10) 
F12 0.2524(3) 0.8083(3) 0.90713(18) 0.0468(10) 
F13 0.8923(4) 0.9144(3) 0.0769(2) 0.0526(11) 
F14 0.9894(3) 0.7860(4) 0.02752(19) 0.0589(13) 
F15 0.9728(3) 0.7802(3) 0.12922(17) 0.0486(10) 
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F16 0.7868(3) 0.7824(3) 0.10735(17) 0.0429(9) 
F17 0.8828(3) 0.6543(3) 0.05812(19) 0.0463(10) 
F18 0.8035(3) 0.7885(3) 0.00615(16) 0.0327(8) 
F19 0.0131(3) 0.6939(3) 0.5556(2) 0.0549(11) 
F20 0.0171(3) 0.8643(4) 0.52577(17) 0.0530(11) 
F21 0.9894(3) 0.8369(3) 0.62285(16) 0.0383(9) 
F22 0.8449(3) 0.7215(3) 0.58718(18) 0.0445(9) 
F23 0.8496(3) 0.8925(3) 0.55660(19) 0.0499(10) 
F24 0.8735(3) 0.7499(3) 0.48833(16) 0.0354(8) 
N1 0.3677(3) 0.0445(3) 0.8127(2) 0.0181(9) 
N2 0.4968(3) 0.9698(3) 0.7064(2) 0.0175(9) 
N3 0.3176(3) 0.9989(4) 0.6242(2) 0.0197(9) 
N4 0.1820(3) 0.0846(3) 0.7047(2) 0.0180(9) 
N5 0.2782(3) 0.8705(3) 0.7151(2) 0.0172(9) 
N6 0.4043(3) 0.1828(4) 0.7180(2) 0.0199(10) 
N7 0.0664(3) 0.3229(3) 0.2107(2) 0.0171(9) 
N8 0.1535(4) 0.4530(4) 0.1348(2) 0.0215(10) 
N9 0.1947(3) 0.6320(3) 0.2138(2) 0.0152(9) 
C57 0.2406(4) 0.7078(5) 0.2576(3) 0.0242(12) 
N11 0.2788(3) 0.4218(3) 0.2439(2) 0.0171(9) 
N12 0.9689(3) 0.5378(3) 0.2050(2) 0.0197(9) 
N13 0.0982(3) 0.5129(3) 0.3146(2) 0.0185(9) 
N14 0.7548(6) 0.5979(6) 0.3667(4) 0.0591(18) 
N15 0.5099(5) 0.4123(6) 0.8779(3) 0.0523(17) 
N16 0.3473(5) 0.0853(6) 0.1038(3) 0.0565(18) 
C1 0.3849(4) 0.0464(4) 0.8657(3) 0.0184(11) 
C2 0.4082(5) 0.0460(5) 0.9327(3) 0.0284(13) 
C3 0.5182(4) 0.9722(4) 0.6470(3) 0.0241(12) 
C4 0.4302(4) 0.0213(5) 0.6038(3) 0.0260(12) 
C5 0.2341(5) 0.0768(5) 0.6002(3) 0.0291(13) 
C6 0.1449(4) 0.0898(5) 0.6437(3) 0.0233(12) 
C7 0.1134(4) 0.1090(4) 0.7464(2) 0.0202(11) 
C8 0.0048(4) 0.1401(5) 0.7293(3) 0.0245(12) 
C9 0.9645(5) 0.1411(4) 0.6673(3) 0.0273(13) 
C10 0.0393(5) 0.1152(5) 0.6237(3) 0.0298(13) 
C11 0.2795(5) 0.8834(5) 0.6044(3) 0.0337(14) 
C12 0.2610(4) 0.8206(4) 0.6585(3) 0.0211(12) 
C13 0.2592(4) 0.8185(4) 0.7643(3) 0.0242(12) 
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C14 0.2195(4) 0.7095(5) 0.7570(3) 0.0289(13) 
C15 0.2006(4) 0.6559(5) 0.6994(3) 0.0282(13) 
C16 0.2232(4) 0.7115(5) 0.6488(3) 0.0280(13) 
C17 0.6185(5) 0.9368(5) 0.6295(3) 0.0299(13) 
C18 0.6991(5) 0.9016(5) 0.6724(3) 0.0297(14) 
C19 0.6775(5) 0.8995(4) 0.7324(3) 0.0250(12) 
C20 0.5748(4) 0.9316(4) 0.7483(3) 0.0212(11) 
C21 0.4421(4) 0.2689(4) 0.7190(3) 0.0221(12) 
C22 0.4892(5) 0.3799(5) 0.7204(3) 0.0290(13) 
C23 0.0531(4) 0.2511(4) 0.2533(3) 0.0183(11) 
C24 0.0232(4) 0.1414(4) 0.2366(3) 0.0222(12) 
C25 0.0051(4) 0.1065(4) 0.1745(3) 0.0246(12) 
C26 0.0160(4) 0.1805(4) 0.1305(3) 0.0244(12) 
C27 0.0481(4) 0.2893(4) 0.1499(2) 0.0203(11) 
C28 0.0636(4) 0.3730(4) 0.1051(3) 0.0235(12) 
C29 0.1466(4) 0.5599(4) 0.1070(2) 0.0233(12) 
C30 0.2047(4) 0.6462(4) 0.1536(3) 0.0211(11) 
C31 0.2941(4) 0.8008(4) 0.2436(3) 0.0220(12) 
C32 0.3064(5) 0.8149(5) 0.1823(3) 0.0298(13) 
C33 0.2608(5) 0.7364(4) 0.1368(3) 0.0262(13) 
C34 0.2675(4) 0.4052(5) 0.1313(3) 0.0254(13) 
C35 0.3290(4) 0.3898(4) 0.1937(3) 0.0175(11) 
C36 0.3316(4) 0.4090(4) 0.3009(3) 0.0226(12) 
C37 0.4346(4) 0.3636(4) 0.3093(3) 0.0289(14) 
C38 0.4865(5) 0.3319(4) 0.2583(3) 0.0301(14) 
C39 0.4331(4) 0.3445(4) 0.1999(3) 0.0288(14) 
C40 0.8781(4) 0.5651(5) 0.2009(3) 0.0251(12) 
C41 0.7630(5) 0.5956(5) 0.1984(3) 0.0395(17) 
C42 0.0771(4) 0.5367(4) 0.3638(3) 0.0217(12) 
C43 0.0503(5) 0.5689(6) 0.4250(3) 0.0357(15) 
C44 0.6871(7) 0.5614(7) 0.4713(4) 0.063(2) 
C45 0.7249(6) 0.5799(6) 0.4128(4) 0.050(2) 
C46 0.4140(5) 0.3682(5) 0.9730(3) 0.0404(16) 
C47 0.4678(5) 0.3930(5) 0.9197(4) 0.0400(16) 
C48 0.1739(5) 0.9740(5) 0.0515(3) 0.0364(15) 
C49 0.2709(5) 0.0371(5) 0.0807(3) 0.0335(14) 
           _______________________________________________________________________ 
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Table 5: Bond lengths (Å).  
_______________________________________________________________________ 
 
Ru1-N1 2.031(5) Ru1-N6 2.037(5)     
Ru1-N3 2.053(4) Ru1-N5 2.056(4)     
Ru1-N2 2.062(4) Ru1-N4 2.071(4)     
Ru2-N13 2.030(5) Ru2-N12 2.031(4)     
Ru2-N11 2.032(4) Ru2-N8 2.048(4)     
Ru2-N7 2.051(4) Ru2-N9 2.057(4)     
P1-F6 1.510(5) P1-F4 1.532(6)     
P1-F1 1.579(4) P1-F3 1.583(5)     
P1-F5 1.599(6) P1-F2 1.618(5)     
P2-F10 1.583(4) P2-F8 1.590(4)     
P2-F11 1.592(4) P2-F9 1.594(4)     
P2-F12 1.604(4) P2-F7 1.605(4)     
P3-F14 1.585(4) P3-F17 1.591(4)     
P3-F18 1.593(4) P3-F15 1.594(4)     
P3-F16 1.595(4) P3-F13 1.598(4)     
P4-F20 1.574(4) P4-F23 1.582(4)     
P4-F21 1.596(4) P4-F24 1.596(4)     
P4-F19 1.597(4) P4-F22 1.606(4)     
N1-C1 1.151(7) N2-C20 1.353(7)     
N2-C3 1.357(7) N3-C5 1.487(7)     
N3-C11 1.498(7) N3-C4 1.511(6)     
N4-C7 1.327(7) N4-C6 1.360(7)     
N5-C12 1.328(7) N5-C13 1.333(7)     
N6-C21 1.141(7) N7-C23 1.351(7)     
N7-C27 1.352(7) N8-C29 1.490(7)     
N8-C28 1.501(7) N8-C34 1.521(7)     
N9-C57 1.342(7) N9-C30 1.359(7)     
C57-C31 1.375(8) C57-H57 0.95     
N11-C36 1.350(7) N11-C35 1.355(7)     
N12-C40 1.152(7) N13-C42 1.152(7)     
N14-C45 1.146(11) N15-C47 1.137(9)     
N16-C49 1.130(8) C1-C2 1.456(7)     
C2-H1 0.98 C2-H3 0.98     
C2-H2 0.98 C3-C17 1.387(7)     
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C3-C4 1.503(8) C4-H17 0.99     
C4-H16 0.99 C5-C6 1.526(7)     
C5-H8 0.99 C5-H9 0.99     
C6-C10 1.352(7) C7-C8 1.393(7)     
C7-H7 0.95 C8-C9 1.384(8)     
C8-H4 0.95 C9-C10 1.417(8)     
C9-H5 0.95 C10-H6 0.95     
C11-C12 1.498(8) C11-H14 0.99     
C11-H15 0.99 C12-C16 1.398(8)     
C13-C14 1.404(8) C13-H13 0.95     
C14-C15 1.365(8) C14-H10 0.95     
C15-C16 1.396(9) C15-H11 0.95     
C16-H12 0.95 C17-C18 1.371(8)     
C17-H21 0.95 C18-C19 1.370(8)     
C18-H20 0.95 C19-C20 1.389(7)     
C19-H19 0.95 C20-H18 0.95     
C21-C22 1.463(8) C22-H24 0.98     
C22-H23 0.98 C22-H22 0.98     
C23-C24 1.397(7) C23-H25 0.95     
C24-C25 1.381(8) C24-H26 0.95     
C25-C26 1.389(8) C25-H42 0.95     
C26-C27 1.402(8) C26-H41 0.95     
C27-C28 1.498(7) C28-H39 0.99     
C28-H40 0.99 C29-C30 1.511(8)     
C29-H27 0.99 C29-H32 0.99     
C30-C33 1.383(8) C31-C32 1.388(8)     
C31-H28 0.95 C32-C33 1.385(8)     
C32-H30 0.95 C33-H29 0.95     
C34-C35 1.500(8) C34-H37 0.99     
C34-H38 0.99 C35-C39 1.386(7)     
C36-C37 1.377(7) C36-H36 0.95     
C37-C38 1.379(9) C37-H33 0.95     
C38-C39 1.380(9) C38-H35 0.95     
C39-H34 0.95 C40-C41 1.448(7)     
C41-H43 0.98 C41-H44 0.98     
C41-H45 0.98 C42-C43 1.442(8)     
C43-H47 0.98 C43-H46 0.98     
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C43-H48 0.98 C44-C45 1.442(13)     
C44-H49 0.98 C44-H51 0.98     
C44-H50 0.98 C46-C47 1.450(10)     
C46-H52 0.98 C46-H53 0.98     
C46-H54 0.98 C48-C49 1.446(9)     
C48-H58 0.98 C48-H55 0.98     
C48-H56 0.98       
  
Table 6: Bond angles (o) 
_______________________________________________________________________ 
 
N1-Ru1-N6 88.80(17) N1-Ru1-N3 175.88(16)     
N6-Ru1-N3 94.79(17) N1-Ru1-N5 93.86(17)     
N6-Ru1-N5 177.34(17) N3-Ru1-N5 82.55(17)     
N1-Ru1-N2 96.35(16) N6-Ru1-N2 89.14(16)     
N3-Ru1-N2 81.70(17) N5-Ru1-N2 90.43(16)     
N1-Ru1-N4 99.50(16) N6-Ru1-N4 89.73(16)     
N3-Ru1-N4 82.57(17) N5-Ru1-N4 89.96(15)     
N2-Ru1-N4 164.09(18) N13-Ru2-N12 84.79(17)     
N13-Ru2-N11 95.87(17) N12-Ru2-N11 178.38(17)     
N13-Ru2-N8 178.94(17) N12-Ru2-N8 95.59(17)     
N11-Ru2-N8 83.77(18) N13-Ru2-N7 99.34(17)     
N12-Ru2-N7 91.47(16) N11-Ru2-N7 86.96(16)     
N8-Ru2-N7 81.64(17) N13-Ru2-N9 97.26(17)     
N12-Ru2-N9 91.30(16) N11-Ru2-N9 90.08(15)     
N8-Ru2-N9 81.75(17) N7-Ru2-N9 163.35(17)     
F6-P1-F4 101.5(5) F6-P1-F1 91.4(3)     
F4-P1-F1 88.6(3) F6-P1-F3 91.5(3)     
F4-P1-F3 92.8(3) F1-P1-F3 176.4(3)     
F6-P1-F5 85.7(5) F4-P1-F5 172.5(4)     
F1-P1-F5 89.0(3) F3-P1-F5 89.2(3)     
F6-P1-F2 174.3(5) F4-P1-F2 84.2(4)     
F1-P1-F2 88.8(3) F3-P1-F2 88.1(3)     
F5-P1-F2 88.6(4) F10-P2-F8 179.8(2)     
F10-P2-F11 90.9(2) F8-P2-F11 89.2(2)     
F10-P2-F9 90.5(2) F8-P2-F9 89.5(2)     
F11-P2-F9 90.2(2) F10-P2-F12 90.2(2)     
F8-P2-F12 89.7(2) F11-P2-F12 178.7(2)     
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F9-P2-F12 90.5(2) F10-P2-F7 90.3(2)     
F8-P2-F7 89.6(2) F11-P2-F7 90.1(2)     
F9-P2-F7 179.1(2) F12-P2-F7 89.2(2)     
F14-P3-F17 89.7(2) F14-P3-F18 89.9(2)     
F17-P3-F18 89.6(2) F14-P3-F15 90.7(2)     
F17-P3-F15 90.7(2) F18-P3-F15 179.4(2)     
F14-P3-F16 179.7(3) F17-P3-F16 90.5(2)     
F18-P3-F16 89.9(2) F15-P3-F16 89.6(2)     
F14-P3-F13 91.1(3) F17-P3-F13 179.1(2)     
F18-P3-F13 90.0(2) F15-P3-F13 89.7(2)     
F16-P3-F13 88.7(2) F20-P4-F23 90.5(2)     
F20-P4-F21 89.8(2) F23-P4-F21 89.8(2)     
F20-P4-F24 90.1(2) F23-P4-F24 90.6(2)     
F21-P4-F24 179.5(2) F20-P4-F19 90.0(3)     
F23-P4-F19 179.2(2) F21-P4-F19 89.6(2)     
F24-P4-F19 90.0(2) F20-P4-F22 178.9(2)     
F23-P4-F22 90.1(2) F21-P4-F22 89.3(2)     
F24-P4-F22 90.8(2) F19-P4-F22 89.5(2)     
C1-N1-Ru1 175.1(4) C20-N2-C3 118.8(4)     
C20-N2-Ru1 129.1(4) C3-N2-Ru1 112.1(3)     
C5-N3-C11 111.0(4) C5-N3-C4 111.8(4)     
C11-N3-C4 109.9(4) C5-N3-Ru1 107.2(3)     
C11-N3-Ru1 111.9(3) C4-N3-Ru1 104.8(3)     
C7-N4-C6 119.0(4) C7-N4-Ru1 128.4(4)     
C6-N4-Ru1 112.4(3) C12-N5-C13 121.1(5)     
C12-N5-Ru1 114.2(3) C13-N5-Ru1 124.7(4)     
C21-N6-Ru1 177.7(4) C23-N7-C27 119.6(4)     
C23-N7-Ru2 128.4(4) C27-N7-Ru2 111.8(3)     
C29-N8-C28 112.1(4) C29-N8-C34 110.7(4)     
C28-N8-C34 110.3(4) C29-N8-Ru2 106.8(3)     
C28-N8-Ru2 106.0(3) C34-N8-Ru2 110.7(3)     
C57-N9-C30 118.7(5) C57-N9-Ru2 128.4(4)     
C30-N9-Ru2 112.5(3) N9-C57-C31 122.3(5)     
N9-C57-H57 118.8 C31-C57-H57 118.8     
C36-N11-C35 119.1(4) C36-N11-Ru2 125.8(4)     
C35-N11-Ru2 115.1(3) C40-N12-Ru2 171.3(4)     
C42-N13-Ru2 174.4(4) N1-C1-C2 178.4(6)     
C1-C2-H1 109.5 C1-C2-H3 109.5     
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H1-C2-H3 109.5 C1-C2-H2 109.5     
H1-C2-H2 109.5 H3-C2-H2 109.5     
N2-C3-C17 120.7(5) N2-C3-C4 115.7(5)     
C17-C3-C4 123.4(5) C3-C4-N3 109.0(4)     
C3-C4-H17 109.9 N3-C4-H17 109.9     
C3-C4-H16 109.9 N3-C4-H16 109.9     
H17-C4-H16 108.3 N3-C5-C6 109.6(4)     
N3-C5-H8 109.8 C6-C5-H8 109.8     
N3-C5-H9 109.8 C6-C5-H9 109.8     
H8-C5-H9 108.2 C10-C6-N4 122.4(5)     
C10-C6-C5 122.2(5) N4-C6-C5 115.1(4)     
N4-C7-C8 121.8(5) N4-C7-H7 119.1     
C8-C7-H7 119.1 C9-C8-C7 119.8(5)     
C9-C8-H4 120.1 C7-C8-H4 120.1     
C8-C9-C10 117.4(5) C8-C9-H5 121.3     
C10-C9-H5 121.3 C6-C10-C9 119.5(5)     
C6-C10-H6 120.2 C9-C10-H6 120.2     
N3-C11-C12 111.7(5) N3-C11-H14 109.3     
C12-C11-H14 109.3 N3-C11-H15 109.3     
C12-C11-H15 109.3 H14-C11-H15 107.9     
N5-C12-C16 121.0(5) N5-C12-C11 119.2(5)     
C16-C12-C11 119.8(5) N5-C13-C14 120.2(6)     
N5-C13-H13 119.9 C14-C13-H13 119.9     
C15-C14-C13 120.2(5) C15-C14-H10 119.9     
C13-C14-H10 119.9 C14-C15-C16 118.5(5)     
C14-C15-H11 120.8 C16-C15-H11 120.8     
C15-C16-C12 119.1(6) C15-C16-H12 120.5     
C12-C16-H12 120.5 C18-C17-C3 120.5(6)     
C18-C17-H21 119.8 C3-C17-H21 119.8     
C19-C18-C17 118.7(5) C19-C18-H20 120.6     
C17-C18-H20 120.6 C18-C19-C20 119.7(5)     
C18-C19-H19 120.2 C20-C19-H19 120.2     
N2-C20-C19 121.5(5) N2-C20-H18 119.3     
C19-C20-H18 119.3 N6-C21-C22 179.2(6)     
C21-C22-H24 109.5 C21-C22-H23 109.5     
H24-C22-H23 109.5 C21-C22-H22 109.5     
H24-C22-H22 109.5 H23-C22-H22 109.5     
N7-C23-C24 122.1(5) N7-C23-H25 118.9     
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C24-C23-H25 118.9 C25-C24-C23 118.4(5)     
C25-C24-H26 120.8 C23-C24-H26 120.8     
C24-C25-C26 119.7(5) C24-C25-H42 120.1     
C26-C25-H42 120.1 C25-C26-C27 119.4(5)     
C25-C26-H41 120.3 C27-C26-H41 120.3     
N7-C27-C26 120.6(5) N7-C27-C28 117.0(5)     
C26-C27-C28 122.4(5) C27-C28-N8 107.9(4)     
C27-C28-H39 110.1 N8-C28-H39 110.1     
C27-C28-H40 110.1 N8-C28-H40 110.1     
H39-C28-H40 108.4 N8-C29-C30 108.2(4)     
N8-C29-H27 110.1 C30-C29-H27 110.1     
N8-C29-H32 110.1 C30-C29-H32 110.1     
H27-C29-H32 108.4 N9-C30-C33 121.6(5)     
N9-C30-C29 115.5(5) C33-C30-C29 122.9(5)     
C57-C31-C32 119.2(5) C57-C31-H28 120.4     
C32-C31-H28 120.4 C33-C32-C31 118.8(5)     
C33-C32-H30 120.6 C31-C32-H30 120.6     
C30-C33-C32 119.3(5) C30-C33-H29 120.4     
C32-C33-H29 120.4 C35-C34-N8 112.9(4)     
C35-C34-H37 109.0 N8-C34-H37 109.0     
C35-C34-H38 109.0 N8-C34-H38 109.0     
H37-C34-H38 107.8 N11-C35-C39 121.1(5)     
N11-C35-C34 117.4(4) C39-C35-C34 121.4(5)     
N11-C36-C37 121.8(5) N11-C36-H36 119.1     
C37-C36-H36 119.1 C36-C37-C38 119.3(6)     
C36-C37-H33 120.4 C38-C37-H33 120.4     
C37-C38-C39 119.3(5) C37-C38-H35 120.3     
C39-C38-H35 120.3 C38-C39-C35 119.3(5)     
C38-C39-H34 120.3 C35-C39-H34 120.3     
N12-C40-C41 176.8(6) C40-C41-H43 109.5     
C40-C41-H44 109.5 H43-C41-H44 109.5     
C40-C41-H45 109.5 H43-C41-H45 109.5     
H44-C41-H45 109.5 N13-C42-C43 178.7(6)     
C42-C43-H47 109.5 C42-C43-H46 109.5     
H47-C43-H46 109.5 C42-C43-H48 109.5     
H47-C43-H48 109.5 H46-C43-H48 109.5     
C45-C44-H49 109.5 C45-C44-H51 109.5     
H49-C44-H51 109.5 C45-C44-H50 109.5     
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H49-C44-H50 109.5 H51-C44-H50 109.5     
N14-C45-C44 178.0(9) C47-C46-H52 109.5     
C47-C46-H53 109.5 H52-C46-H53 109.5     
C47-C46-H54 109.5 H52-C46-H54 109.5     
H53-C46-H54 109.5 N15-C47-C46 179.9(10)     
C49-C48-H58 109.5 C49-C48-H55 109.5     
H58-C48-H55 109.5 C49-C48-H56 109.5     
H58-C48-H56 109.5 H55-C48-H56 109.5     
N16-C49-C48 179.1(7)       
 
Table 7: Anisotropic displacement parameters (Å2).    
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... 
+ 2 h k a* b* U12 ] 
 
______________________________________________________________________  
   
                U11           U22              U33            U23                    U13                 U12  
    _______________________________________________________________________  
   
Ru1 0.0147(2) 0.0168(2) 0.0175(3) 0.00155(18) 0.00313(15) 0.00220(16) 
Ru2 0.0125(2) 0.0153(2) 0.0171(2) -0.00021(17) 0.00365(15) 0.00086(16) 
P1 0.0521(11) 0.0404(10) 0.0282(10) -0.0096(8) 0.0145(8) -0.0165(8) 
P2 0.0273(8) 0.0273(8) 0.0293(9) 0.0024(7) 0.0063(6) 0.0020(6) 
P3 0.0241(8) 0.0286(8) 0.0239(8) -0.0033(7) 0.0036(6) 0.0044(6) 
P4 0.0287(8) 0.0282(8) 0.0229(8) 0.0020(7) 0.0056(6) 0.0038(6) 
F1 0.099(4) 0.059(3) 0.050(3) -0.023(2) 0.037(3) -0.035(3) 
F2 0.076(3) 0.059(3) 0.126(5) 0.012(3) 0.051(3) 0.010(3) 
F3 0.150(5) 0.043(3) 0.075(4) -0.026(3) 0.054(3) -0.034(3) 
F4 0.214(7) 0.061(3) 0.054(4) 0.003(3) -0.046(4) -0.007(4) 
F5 0.199(7) 0.086(4) 0.071(4) 0.032(4) -0.001(4) -0.046(5) 
F6 0.087(4) 0.148(6) 0.209(9) -0.104(6) 0.102(5) -0.070(4) 
F7 0.033(2) 0.046(2) 0.033(2) 0.0027(17) -0.0022(15) -0.0098(16) 
F8 0.0267(19) 0.046(2) 0.049(2) 0.0016(19) 0.0120(16) -0.0003(16) 
F9 0.055(2) 0.045(2) 0.036(2) -0.0081(18) 0.0052(17) -0.0148(18) 
F10 0.035(2) 0.065(3) 0.069(3) -0.004(2) 0.028(2) -0.0010(19) 
F11 0.043(2) 0.029(2) 0.062(3) 0.0117(19) -0.0014(18) 0.0074(16) 
F12 0.063(3) 0.034(2) 0.043(3) 0.0136(19) -0.0018(19) 0.0001(18) 
F13 0.073(3) 0.030(2) 0.048(3) -0.0107(19) -0.007(2) -0.0065(19) 
F14 0.029(2) 0.099(3) 0.045(3) -0.028(2) 0.0174(17) -0.023(2) 
F15 0.042(2) 0.068(3) 0.032(2) -0.007(2) -0.0090(16) 0.0236(19) 
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F16 0.036(2) 0.056(2) 0.039(2) 0.0004(19) 0.0152(16) 0.0021(17) 
F17 0.054(2) 0.0281(19) 0.056(3) 0.0042(19) -0.0013(19) 0.0150(17) 
F18 0.041(2) 0.0268(18) 0.028(2) -0.0003(15) -0.0015(14) -0.0050(15) 
F19 0.052(2) 0.057(3) 0.051(3) -0.011(2) -0.0071(19) 0.028(2) 
F20 0.054(2) 0.079(3) 0.025(2) 0.006(2) 0.0051(17) -0.022(2) 
F21 0.054(2) 0.037(2) 0.023(2) -0.0015(16) 0.0051(16) -0.0046(17) 
F22 0.049(2) 0.047(2) 0.038(2) 0.0033(18) 0.0114(17) -0.0122(18) 
F23 0.064(3) 0.041(2) 0.047(3) 0.0077(19) 0.0077(19) 0.0254(19) 
F24 0.0323(19) 0.043(2) 0.032(2) 0.0049(17) 0.0033(14) 0.0038(15) 
N1 0.010(2) 0.017(2) 0.027(3) -0.001(2) 0.0022(17) 0.0018(17) 
N2 0.015(2) 0.014(2) 0.024(3) 0.0007(19) 0.0070(17) 0.0009(17) 
N3 0.019(2) 0.021(2) 0.020(2) 0.004(2) 0.0058(17) 0.0017(18) 
N4 0.018(2) 0.013(2) 0.023(3) 0.0029(19) 0.0027(17) 0.0010(17) 
N5 0.0050(19) 0.019(2) 0.028(3) 0.002(2) 0.0018(16) 0.0027(16) 
N6 0.017(2) 0.022(3) 0.021(3) 0.002(2) 0.0059(17) 0.0027(19) 
N7 0.013(2) 0.017(2) 0.021(3) -0.0020(19) 0.0028(16) -0.0004(17) 
N8 0.029(3) 0.019(2) 0.017(2) 0.0022(19) 0.0024(18) 0.0007(19) 
N9 0.013(2) 0.012(2) 0.021(2) -0.0004(18) 0.0028(16) 0.0036(16) 
C57 0.021(3) 0.031(3) 0.020(3) -0.001(3) 0.000(2) 0.007(2) 
N11 0.014(2) 0.010(2) 0.027(3) 0.0013(19) 0.0048(17) 0.0006(16) 
N12 0.020(2) 0.020(2) 0.020(3) 0.0003(19) 0.0041(17) 0.0003(18) 
N13 0.016(2) 0.016(2) 0.024(3) 0.0009(19) 0.0022(18) -0.0012(17) 
N14 0.058(4) 0.053(4) 0.062(5) -0.008(4) -0.004(3) 0.015(3) 
N15 0.027(3) 0.069(5) 0.062(5) 0.012(4) 0.000(3) 0.014(3) 
N16 0.060(4) 0.070(5) 0.036(4) 0.019(3) -0.015(3) -0.012(3) 
C1 0.011(2) 0.020(3) 0.024(3) 0.001(2) 0.002(2) 0.003(2) 
C2 0.035(3) 0.032(3) 0.017(3) 0.003(3) 0.000(2) 0.005(3) 
C3 0.026(3) 0.020(3) 0.027(3) 0.002(2) 0.006(2) 0.001(2) 
C4 0.019(3) 0.037(3) 0.024(3) 0.002(3) 0.010(2) 0.002(2) 
C5 0.026(3) 0.042(4) 0.020(3) 0.007(3) 0.004(2) 0.010(3) 
C6 0.020(3) 0.028(3) 0.022(3) 0.006(2) 0.001(2) 0.006(2) 
C7 0.022(3) 0.020(3) 0.018(3) 0.002(2) 0.002(2) -0.004(2) 
C8 0.023(3) 0.026(3) 0.026(3) 0.000(3) 0.006(2) 0.006(2) 
C9 0.020(3) 0.023(3) 0.040(4) 0.008(3) 0.003(2) 0.007(2) 
C10 0.028(3) 0.041(4) 0.021(3) 0.008(3) -0.003(2) 0.002(3) 
C11 0.044(4) 0.035(3) 0.023(3) 0.001(3) 0.005(3) -0.010(3) 
C12 0.010(2) 0.025(3) 0.027(3) 0.001(3) 0.003(2) 0.002(2) 
C13 0.018(3) 0.022(3) 0.033(3) 0.005(3) 0.003(2) 0.008(2) 
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C14 0.024(3) 0.030(3) 0.035(4) 0.013(3) 0.010(2) 0.003(2) 
C15 0.021(3) 0.018(3) 0.045(4) 0.001(3) 0.004(2) 0.000(2) 
C16 0.024(3) 0.025(3) 0.033(4) -0.005(3) 0.000(2) -0.001(2) 
C17 0.025(3) 0.034(3) 0.033(4) 0.001(3) 0.014(2) 0.008(3) 
C18 0.023(3) 0.028(3) 0.039(4) -0.007(3) 0.014(2) 0.004(2) 
C19 0.023(3) 0.017(3) 0.035(4) 0.005(2) 0.005(2) 0.002(2) 
C20 0.016(3) 0.019(3) 0.028(3) 0.001(2) 0.002(2) 0.000(2) 
C21 0.015(3) 0.020(3) 0.032(3) 0.002(2) 0.004(2) 0.005(2) 
C22 0.025(3) 0.022(3) 0.040(4) 0.002(3) 0.006(2) -0.002(2) 
C23 0.016(3) 0.016(3) 0.024(3) 0.002(2) 0.005(2) 0.002(2) 
C24 0.022(3) 0.020(3) 0.025(3) 0.001(2) 0.005(2) -0.001(2) 
C25 0.025(3) 0.017(3) 0.031(3) -0.006(3) 0.005(2) 0.000(2) 
C26 0.026(3) 0.024(3) 0.022(3) -0.002(2) 0.001(2) 0.000(2) 
C27 0.015(3) 0.027(3) 0.018(3) 0.001(2) 0.0034(19) 0.002(2) 
C28 0.024(3) 0.023(3) 0.023(3) -0.003(2) 0.004(2) -0.003(2) 
C29 0.029(3) 0.024(3) 0.017(3) 0.004(2) 0.003(2) 0.001(2) 
C30 0.019(3) 0.019(3) 0.026(3) 0.002(2) 0.006(2) 0.006(2) 
C31 0.024(3) 0.014(3) 0.027(3) 0.000(2) 0.000(2) 0.000(2) 
C32 0.033(3) 0.026(3) 0.029(4) -0.004(3) 0.005(2) -0.003(2) 
C33 0.034(3) 0.021(3) 0.026(3) 0.011(3) 0.010(2) -0.001(2) 
C34 0.018(3) 0.032(3) 0.028(3) -0.003(3) 0.012(2) -0.001(2) 
C35 0.016(3) 0.006(2) 0.033(3) 0.003(2) 0.008(2) -0.0014(19) 
C36 0.021(3) 0.015(3) 0.031(3) 0.002(2) 0.000(2) 0.000(2) 
C37 0.020(3) 0.018(3) 0.047(4) 0.007(3) -0.002(3) -0.003(2) 
C38 0.018(3) 0.010(3) 0.063(5) 0.005(3) 0.004(3) 0.004(2) 
C39 0.022(3) 0.017(3) 0.050(4) 0.000(3) 0.016(3) -0.001(2) 
C40 0.022(3) 0.027(3) 0.028(3) 0.008(3) 0.005(2) 0.007(2) 
C41 0.015(3) 0.044(4) 0.062(5) 0.023(4) 0.004(3) 0.008(3) 
C42 0.012(3) 0.024(3) 0.029(3) 0.000(3) 0.005(2) -0.001(2) 
C43 0.035(3) 0.048(4) 0.025(4) -0.006(3) 0.011(3) -0.003(3) 
C44 0.055(5) 0.050(5) 0.081(7) 0.016(5) -0.007(4) -0.010(4) 
C45 0.037(4) 0.041(4) 0.066(6) -0.001(4) -0.016(4) 0.002(3) 
C46 0.020(3) 0.038(4) 0.062(5) -0.001(3) 0.002(3) -0.003(3) 
C47 0.029(4) 0.035(4) 0.052(5) -0.003(3) -0.005(3) 0.005(3) 
C48 0.034(3) 0.029(3) 0.046(4) 0.003(3) 0.004(3) 0.005(3) 
C49 0.036(4) 0.031(3) 0.035(4) 0.015(3) 0.001(3) 0.003(3) 
_______________________________________________________________________  
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Table 8: Hydrogen coordinates ( x) and isotropic atomic displacement parameters (Å2). 
  _______________________________________________________________  
  x            y                 z      U(eq)   
________________________________________________________________  
   
H57 0.2359 0.6968 0.2998 0.029 
H1 0.3901 -0.0266 0.9451 0.043 
H3 0.3631 0.1002 0.9525 0.043 
H2 0.4873 0.0639 0.9456 0.043 
H17 0.4318 -0.0111 0.5610 0.031 
H16 0.4446 0.1010 0.6045 0.031 
H8 0.1993 0.0494 0.5584 0.035 
H9 0.2710 0.1486 0.5972 0.035 
H7 0.1391 0.1052 0.7890 0.024 
H4 -0.0414 0.1605 0.7602 0.029 
H5 -0.1104 0.1584 0.6545 0.033 
H6 0.0154 0.1157 0.5807 0.036 
H14 0.3361 -0.1529 0.5816 0.04 
H15 0.2094 -0.1168 0.5759 0.04 
H13 0.2725 -0.1446 0.8045 0.029 
H10 0.2057 -0.3271 0.7922 0.035 
H11 0.1727 -0.4175 0.6939 0.034 
H12 0.2131 -0.3242 0.6083 0.034 
H21 0.6314 -0.0631 0.5875 0.036 
H20 0.7686 -0.1209 0.6608 0.036 
H19 0.7325 -0.1238 0.7630 0.03 
H18 0.5591 -0.0734 0.7896 0.025 
H24 0.4315 0.4280 0.7038 0.044 
H23 0.5507 0.3799 0.6952 0.044 
H22 0.5168 0.4061 0.7631 0.044 
H25 0.0645 0.2760 0.2959 0.022 
H26 0.0156 0.0920 0.2673 0.027 
H42 -0.0148 0.0323 0.1619 0.03 
H41 0.0019 0.1576 0.0877 0.029 
H39 -0.0066 0.4111 0.0951 0.028 
H40 0.0853 0.3375 0.0663 0.028 
H27 0.0677 0.5781 0.0963 0.028 
H32 0.1828 0.5562 0.0687 0.028 
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H28 0.3223 0.8549 0.2754 0.026 
H30 0.3454 0.8774 0.1718 0.036 
H29 0.2679 0.7443 0.0946 0.031 
H37 0.2582 0.3338 0.1067 0.031 
H38 0.3124 0.4542 0.1095 0.031 
H36 0.2968 0.4321 0.3361 0.027 
H33 0.4696 0.3540 0.3498 0.035 
H35 0.5583 0.3018 0.2633 0.036 
H34 0.4674 0.3224 0.1643 0.035 
H43 -0.2849 0.5379 0.1747 0.059 
H44 -0.2467 0.6639 0.1783 0.059 
H45 -0.2572 0.6058 0.2405 0.059 
H47 0.1035 0.6262 0.4447 0.054 
H46 0.0545 0.5057 0.4498 0.054 
H48 -0.0251 0.5968 0.4221 0.054 
H49 0.6848 0.6312 0.4959 0.094 
H51 0.7384 0.5135 0.4938 0.094 
H50 0.6125 0.5267 0.4641 0.094 
H52 0.4131 0.2892 0.9765 0.061 
H53 0.3375 0.3933 0.9680 0.061 
H54 0.4551 0.4053 1.0105 0.061 
H58 0.1974 0.9098 0.0276 0.055 
H55 0.1282 1.0189 0.0239 0.055 
H56 0.1302 0.9503 0.0833 0.055 
 
  ________________________________________________________________  
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CHAPTER 6. SOLID PHASE SYNTHESIS AS A PLATFORM FOR 
DEVELOPING NEW CAGING GROUPS3 
6.1 Introduction 
Numerous inorganic complexes have been developed as therapeutics and tools for 
chemical biology after the discovery and success of cisplatin.18,28,53 Despite their success in these 
two arenas, our ability to rapidly synthesize, screen and identify metal complexes with desired 
properties has not evolved at the same pace as organic molecules, which are synthesized 
routinely by solid phase in large libraries and screened in high throughput assays.215 
Notwithstanding a few notable exceptions, metal complexes for biological applications are 
mostly synthesized and evaluated one molecule at a time.216-219 Thus new methods of 
synthesizing and screening of metal-based compounds are to be developed if they are to compete 
with their organic counterparts as tool compounds and therapeutics. Given the fact that structure 
activity relationships are notoriously difficult to predict, more rapid methods are clearly needed 
to access diverse libraries of metal complexes.  
One area of biology where metal complexes have made an important impact is 
photocaging.42,148,220 Photocaging has revolutionized our ability to study living systems, by 
allowing researchers to control spatial and temporal aspects of biological activity.149 Metal 
complexes have emerged more recently as an important class of photocaging groups. They are 
attractive because they bind to a variety of different functional groups, including groups that 
can’t be protected with organic-based cages such as nitriles,47,48,75,146,171,221 nitrogen-containing 
heteroaromatics38 or thioethers.49 Metal-based caging groups also carry the advantage of being 
																																																								3	Portions of the text in this chapter were reprinted and adapted with permission from Sharma,	R.;	Ancona,	N.;	Kodanko,	J.	J.	Inorg.	Chem.	2015,	54,	1901	
  
	
117 
labile with visible light under single-photon excitation,151 which is rare for organic photolabile 
protecting groups that are usually cleaved with UV light.222,223 
 Of the various classes of metal-based photocaging groups, ruthenium complexes based on 
planar, heteroaromatic ligands have been the most widely used (Figure 37). Pioneering work in 
the neuroscience area showed that Ru(bpy)2 can be used to achieve high spatial and temporal 
control over receptor activity in live neuronal cells. Importantly, no toxic effects were observed 
from the caged neurotransmitters or their metal-based byproducts. Later work showed that 
Ru(bpy)2 and similar congeners can also be used to cage cytotoxic agents and protease inhibitors 
for cell-based assays.36,38,56,146,171  
 
Figure 37: Ligands used in Ru(II)-based caging groups 
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In the previous chapter we showed that ruthenium tris(2-pyridylmethyl)amine, Ru(TPA), 
is an effective caging group for bioactive nitriles which is distinct from previously developed 
photolabile protecting groups.221 Although complexes of the general formula [Ru(TPA)(RCN)2]2+ 
showed promising activity, including excellent stability in the dark and high levels of selectivity 
for enzyme inhibition under dark vs. light conditions, the potential for improvement remained. 
Most notably, UV light is required for rapid release of nitrile because singlet metal-to-ligand 
charge transfer (1MLCT) bands for these complexes occur at < 400 nm. Moreover, only one of 
the two potentially labile nitrile molecules was released upon irradiation. 
 This chapter is dedicated towards developing a library approach for accessing ruthenium 
complexes by solid phase, one that provides rapid access to new derivatives for screening 
photochemical behavior. Ligands designed to tune spectral properties of the ruthenium-based 
photocaging group were synthesized in parallel fashion on resin.  This library was processed to 
form caged ruthenium complexes bound to resin, then subsequently cleaved and analyzed for 
photochemical reactivity. To validate the screening protocol, three compounds identified from 
this screen were synthesized by solution phase and fully characterized. Data were in good 
agreement with compounds from solid phase, thus validating the predictive power of our library 
approach. Data from solid phase screening indicate a surprisingly wide range of spectral tuning 
and reactivity with light, demonstrating the utility of this screening technology, as well as the 
power it has to identify lead caging groups. 
6.2 Results and discussions 
6.2.1 Synthesis of ligand library 
The strategy for synthesis of the ligand library was based on previous work from our 
laboratory, where a single pyridine precursor bound to resin could be functionalized with two 
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components (R1 and R2) to create a library of polypyridyl ligands.209,210 The pyridine precursor 
chosen for this study was derived from commercially available dimethyl pyridine-2,5-
dicarboxylate (78, Scheme 11). Following a literature protocol, selective reduction of the ester in 
the 2-position furnishes alcohol 79. Amidation of 79 with excess 1,3-propanediamine by heating 
in MeOH at 80 °C provided amine 80 in quantitative yield. Excess of 1,3-propanediamine was 
removed by simple azeotropic distillation using toluene.  
 
Scheme 11. Synthesis of pyridine precursor 80 
To begin our studies with solid phase, Fmoc-protected Rink amide MBHA resin derived 
from polystyrene (81, Scheme 12) was chosen for attachment of pyridine precursor 80. The 
Fmoc group was cleaved from 81 using 1:1 piperidine:DMF, then treatment with succinic 
anhydride in DMF, which furnished acid 82. Acid 82 was coupled to amine 80 using HBTU in 
DMF, giving pyridylmethyl alcohol 83, containing a 10-atom spacer between the pyridine group 
and the amide nitrogen bound to resin. Activation of alcohol 83 was accomplished by either 
mesylation or chlorination using conditions shown in Scheme 12.  Mesylation with MsCl and 
Et3N proceeded smoothly at RT with 100 mg or less of resin to furnish 84 (X = OMs). However, 
upon further scale up, it was difficult to observe full consumption of alcohol 83, as judged by 1H 
NMR and ESMS analysis of product cleaved from resin. Optimal conditions developed later 
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involved heating resin to 50 °C in the presence of excess TsCl, LiCl, iPr2EtN and MeCN, which 
worked routinely on scales of up to 1 g of resin, providing 84 (X = Cl).   
 
 
Scheme 12. Solid phase synthesis of the polypyridyl ligand library (85a-j) 
A library of ten polypyridyl derivatives (85a-j) was accessed in 1-2 steps from 
monopyridine 84 (X = Cl or OMs) using straightforward alkylation chemistry (Scheme 12). Full 
structures of the ligands are shown in Figure 38. In some cases, delivery of the appropriate 
secondary amine resulted in nucleophilic displacement of the leaving group (X = Cl or OMs), 
providing derivatives of 85 in one step (Strategy A). Alternatively, reaction with a primary amine 
(R1NH2) was used to attach one group to the ligand (R1), with a second alkylation reaction with 
R2Cl to complete synthesis of the tertiary amine ligand (Strategy B).   
After ligand syntheses were completed, the library was evaluated by cleaving a small 
amount of each derivative from the resin using 95% TFA in H2O (Figure 38), providing terminal 
amides 86a-j that were characterized by LCMS and 1H NMR spectroscopy. LCMS analysis 
indicated each of the 10 derivatives was furnished in >90% purity, with a few exceptions. 
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Compound 86g, a derivative of the known ligand N4Py, which was produced in <20% purity, 
with the remainder being unreacted 84 (X = Cl).  
 
Figure 38. Structures of polypyridyl ligand library bound to resin (85a-j) and cleaved for 
analysis (86a-j) 
 
f
N N
N
N N
N N
N
NR
g
N
h
N
N
N
N
N
R
N N
R
N
H
O
N
N
i j
N
N
N
NR
R
N N
N
N
R
a
N N
N
COOHR
b
N N
N
R
c
HO
N N
N
NR
d
OH
e
N N
N
N
HN
R
H
N N
H
N
HO
O O H
N N
H
N
HO
O O
95% TFA
H2O
85 86
R =
  
	
122 
In this case, the secondary amine used to synthesize 86g, 1,1-di(pyridin-2-yl)-N-(pyridin-
2-ylmethyl)methanamine, is a hindered nucleophile.209,224 Optimized reaction conditions were 
developed using NaI as a catalyst, MeCN as solvent and iPr2EtN, which raised the level of purity 
of 86g to 88%. Synthesis of compound 86e proceeded smoothly in the first alkylation of 84 (X = 
Cl) with 2-pyridylmethylamine. Subsequent alkylation with 2,6-bis(bromomethyl)pyridine 
followed by aniline proved challenging, resulting in lower conversion to product 86e (52% 
purity) under a variety of conditions, and was not optimized further. 
6.2.2 Synthesis of metal complexes on solid phase. 
With a library of resin-bound polypyridyl ligands 85a-j in hand, conditions were developed 
to generate ruthenium complexes with bound MeCN groups to be released photochemically. 
Ligands 85a-c and 85j contain four donor atoms and were expected to furnish complexes of the 
general formula [Ru(L)(MeCN)2]n+ (n = 1,2) with two molecules of MeCN coordinated to the 
metal. Ligands 85d-i each carry five potential donor atoms, and were expected to result in 
complexes of the general formula [Ru(L)(MeCN)]n+ (n = 1,2) with only one bound nitrile. A 
mixture of neutral and anionic ligands were incorporated that were expected to furnish ruthenium 
(II) complexes as mono- or dicationic species. 
Optimization efforts began by surveying a number of conditions and ruthenium(II) 
precursors for metalation of the resin-bound ligands (Scheme 13, Table 9). Compound 85a, a 
derivative of TPA, was used to develop the protocol because data for ruthenium(II) TPA 
complexes were available to use as benchmarks.211,212,221 Two ruthenium(II) starting materials 
were surveyed initially, cis-[Ru(DMSO)4Cl2], which was expected to give a mixture of 
complexes of the general formula [Ru(85a)(DMSO)Cl]+ that could later be converted into 
[Ru(85a)(MeCN)2]2+, and [Ru(COD)(MeCN)4](OTf)2,225 which could potentially give access to 
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the desired complex [Ru(85a)(MeCN)2]2+ directly in one step. Combining resin-bound 85a with 
2-10 equiv. of these ruthenium salts in the presence of solvent (DMF, EtOH or MeCN) and heat 
(50-80 °C) led to metallation, as judged by UV-vis spectroscopic and ESMS analysis of products 
cleaved from resin using 95% TFA in H2O. Relative yields were approximated by absorbance 
using extinction coefficients of the species [Ru(86a)(DMSO)Cl]+ and [Ru(86a)(MeCN)2]2+. 
Importantly, both species were shown to be stable for > 24 h in the TFA cleavage cocktail in the 
absence of irradiation, indicating decomposition does not occur to a measurable extent during 15 
min cleavage from resin.  
Data indicated a wide range of yields for metallation conditions surveyed. Relative to cis-
[Ru(DMSO)4Cl2] (Table 9, entries 1-3), [Ru(COD)(MeCN)4](OTf)2 is a sluggish ruthenium(II) 
starting material, giving <5% yield after 18 h at 50 °C in MeCN. The choice of solvent was also 
important. DMF, which shows superior swelling of polystyrene resin compared to MeCN, 
MeOH or EtOH, actually showed much lower yields for metallation (entries 1, 2 and 7). We 
considered at this stage that swelling properties could play a key role in optimizing formation of 
the ruthenium complex bound to resin, so compound 85a was also prepared bound to Tenta-Gel 
resin, which shows better swelling properties than polystyrene in protic solvents, where yields 
for binding to Ru(II) were higher. However, use of Tenta-Gel resin did not enhance yields for 
metallation with EtOH (entry 8). Optimal conditions using conventional heating methods were 
identified using polystyrene-based 85a, 4 equiv. of cis-[Ru(DMSO)4Cl2], EtOH as the solvent 
and heating at 80 °C for 18 h (entry 6).  By using microwave heating, reaction timescales were 
cut down from 18 h to 30 min (entry 7). Raising the amount of Ru(II) source to 10 equiv. and 
heating at 120 °C for 1 h in the microwave reactor did not enhance the yield relative to 4 equiv. 
and 80 °C (entry 9). Thus, cis-[Ru(DMSO)4Cl2] (4 equiv.), EtOH as the solvent and heating at 80 
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°C for 30 min with microwave irradiation were deemed optimal for formation of the intermediate 
[Ru(85a)(DMSO)Cl]+.  
 
Scheme 13: Three methods (A-C) explored for synthesis of Ru(II) complexes 
[Ru(86a)(DMSO)Cl]Cl (87a) and [Ru(86a)(MeCN)2]X2 (88a, X = OTf, O2CCF3).  
 
A number of conditions were also surveyed for conversion of the resin-bound 
[Ru(85a)(DMSO)Cl]+ to the caged nitrile species [Ru(85a)(MeCN)2]2+.  Heating the resin in 
MeCN solvent lead to poor conversion to [Ru(85a)(MeCN)2]2+ as judged by UV-vis 
spectroscopic and determined by absorbance at λmax = 348 nm (ε = 9,040 M-1 cm-1) after cleavage 
from resin with 95% TFA in H2O. 
Addition of H2O to the MeCN medium did enhance conversion to [Ru(85a)(MeCN)2]2+, 
however, full conversion was still not observed. We hypothesized at this stage that it could be 
difficult to obtain higher yields of [Ru(85a)(MeCN)2]2+ because the chloride counteranions, 
which are highly polar, show limited ability to solubilize dications in organic media and may not 
be favorable for association of the dicationic complex with the polystyrene polymer. Therefore, 
additives were explored that could potentially exchange with chloride, including NaBF4, NaOAc, 
NaOTf and NH4PF6. However, significant levels of decomposition with little to no formation of 
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product were observed. Considering these facts, an additional ruthenium (II) source was explored 
that already contained less polar anion than chloride. Gratifyingly, heating resin 85a in the 
presence of fac-[Ru(DMSO)3(O2CCF3)2(H2O)]226 (4 equiv.) in EtOH at 80 °C for 30 min under 
microwave irradiation, followed by microwave irradiation in MeCN:H2O (1:1) for 30 min at 80 
°C and cleavage from resin, resulted in good conversion and provided 
[Ru(86a)(MeCN)2](O2CCF3)2 (88a) in 81% yield (Table 9, entry 10). 
With optimal conditions developed, the library of resin-bound ligands 85a-j was processed 
to Ru(II) MeCN complexes (Scheme 14). Conditions for metallation employed fac-
[Ru(DMSO)3(O2CCF3)2(H2O)] (4.0 equiv.) in EtOH with microwave heating at 80 °C for 30 min, 
followed by replacement of the solvent with MeCN:H2O and microwave heating at 80 °C for an 
additional 30 min. In the case of compounds 85b, 85c, 85d, and 85i, 2,6-lutidine (10 equiv.) was 
added during step 1 for deprotonation of acidic protons. Each member of the library was cleaved 
from resin and screened by UV-vis spectroscopy for reactivity with visible light (30 min 
irradiation, λirr ≥ 395 nm) in H2O, with the goal of identifying complexes that exchanged H2O for 
MeCN upon irradiation (Figure 39a-j).  
 
Scheme 14. Synthesis of Ru(II)-MeCN complex library (88a-j) 
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Conditiona,b Ru(II) source 
 (equiv)c 
Solvent Temp (° C)d,e Time (h) % Yieldf,g 
1a A (2) DMF 50d 18 24f 
2a A (2) MeOH 50d 18 35f 
3a B (2) MeCN 50d 18 <5g 
4a B (4) MeCN 80e 0.5 <5g 
5a B (4) EtOH 80e 0.5 <5g 
6a A (4) EtOH 80d 18 70f 
7a A (4) EtOH 80e 0.5 57f 
8b A (4) EtOH 80e 0.5 68f 
9a A (10) EtOH 120e 1 51f 
10a C (4) EtOH, then 
MeCN:H2O 
80e 0.5 × 2 81g 
      
Table 9: Conditions and Ru(II) sources examined for conversion of resin-bound ligand 
85a to Ru(II) complexes [Ru(86a)(DMSO)Cl]Cl (87a) and [Ru(86a)(MeCN)2]X2 (88a, X 
= OTf, O2CCF3). a85a derived from polystyrene resin (0.75 mmol/g); b85a derived from 
Tenta-Gel resin (0.23 mmol/g); cRuthenium(II) sources are cis-[Ru(DMSO)4Cl2] (A), 
[Ru(COD)(MeCN)4](OTf)2 (B) and fac-[Ru(DMSO)3(O2CCF3)2(H2O)] (C); dconventional 
heating; emicrowave heating (50 W); f% yield of [Ru(86a)(DMSO)Cl]+ as determined by 
absorbance at λmax = 345 nm (ε = 10,500 M-1 cm-1) after cleavage from resin with 95% 
TFA in H2O; g% yield of [Ru(86a)(MeCN)2]2+ as determined by absorbance at λmax = 348 
nm (ε = 9,040 M-1 cm-1) after cleavage from resin with 95% TFA in H2O.  
 	 Data from the photochemical screening indicate a range of spectral tuning, as well as 
reactivity with visible light. All of the complexes absorb strongly below 400 nm, with select 
examples showing significant absorbance from 400-500 nm (ex. 88f-g and 88i-j). As expected, 
most of the complexes are slow to react with visible light because their corresponding 1MLCT 
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bands lie below 400 nm (88a-e, 88h).  However, absorbance above 400 nm did not guarantee 
reactivity with visible light. Complex 88f, which absorbs strongly to almost 500 nm, did not 
react with visible light. The N4Py derivative 88g did react slowly with visible light, but did not 
demonstrate the expected bathochromic shift for substitution of H2O for MeCN. Complexes 88i 
and 88j did show the desired shift to longer wavelengths, with 88j showing the most rapid 
spectral change upon irradiation with visible light. 			
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Figure 39: Changes in the electronic absorption spectra upon irradiation with visible 
light (λirr > 400 nm) in H2O of complexes 88a-j for 0 (black), 5 (red), 15 (green) and 30 
(blue) min.  
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In addition to photochemical screening, each of the library members was analyzed by 
ESMS (Table 10). Major peaks were observed for each species, along with suitable isotope 
patterns, corresponding to calculated m/z values for dications. Compounds 88a, 88c-e and 88j all 
showed m/z values consistent with two bound MeCN groups. Data for 88b were consistent with 
three bound nitriles, suggesting that the carboxylic acid group of ligand 86b was not bound to 
ruthenium. Complexes derived from the pentadentate ligands 88f-h all showed major species 
corresponding to one bound MeCN group. 
Compound,b m/z (obs) Formula (calculated)c 
88aa 337 [Ru(86a)(MeCN)2]2+ 
88b a 340 [Ru(86b)(MeCN)3]2+ 
88c a 344 [Ru(86c)(MeCN)2]2+ 
88d a 351 [Ru(86d)(MeCN)2]2+ 
88e a 389 [Ru(86e)(MeCN)2]2+ 
88f a 355 [Ru(86f)(MeCN)]2+ 
88g a 355 [Ru(86g)(MeCN)]2+ 
88h b 382 [Ru(86h)(MeCN)]2+ 
88i a nd nd 
88j a 387 [Ru(86j)(MeCN)2]2+ 
  
Table 10. ESMS data for compounds 88a-j showing major m/z values observed and 
molecular formulas for dications consistent with the data (nd = not detected). 
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6.2.3 Synthesis and Characterization of Complexes by Solution Phase. 
Based on results from our screening, three ligands were chosen for further evaluation in 
Ru(II) MeCN complexes. Ligand 85f, a derivative of the known ligand DPAbpy, was chosen 
because its Ru(II) MeCN complex showed significant absorbance in the visual region, yet no 
reactivity with visible light, a surprising observation that needed to be verified by solution phase. 
Ligand 85g, a derivative of the known ligand N4Py, was chosen because it also showed 
significant absorbance above 400 nm. Unlike 88f, complex 88g did show reactivity with visible 
light, but data were not consistent with substitution of H2O for MeCN, because a bathochromic 
shift was not observed. Therefore a follow up study was warranted. Finally, ligand 85j, which 
contains two isoquinoline donors, was identified as the lead ligand from this study. The UV-vis 
spectrum of 88j showed a significant bathochromic shift in absorbance relative to 88a, as well as 
rapid spectral changes upon irradiation with visible light that were consistent with substitution of 
H2O for MeCN.  However, instead of 86j, we chose to examine the C3 symmetric ligand TQA, 
which replaces the pyridine donor of 86j with isoquinoline. This was expected to simplify our 
analysis, because only one isomer can be formed from TQA, unlike 86j, where quinoline donors 
could adopt either a cis or trans configuration and lead to formation of two isomers.  
 Three Ru(II) complexes were synthesized by solution phase for evaluation against 
compounds from our library screen (Scheme 15). The ligands DPAbpy, N4Py and TQA were 
synthesized using literature procedures.213,227,228 Treating each ligand with one equiv. of cis-
[Ru(DMSO)4Cl2] in MeOH at 80 °C led to rapid metallation.  Concentration and heating in 
MeCN:H2O (1:1), followed by precipitation with NH4PF6 produced [Ru(DPAbpy)(MeCN)](PF6)2 
(89), [Ru(N4Py)(MeCN)2](PF6)2 (90) and [Ru(TQA)(MeCN)2](PF6)2 (91) in yields of 47-75%. 
Complexes 89-91 were characterized by 1H NMR and IR spectroscopies and ESMS. X-ray 
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crystallographic data were collected for complexes 89 and 90 only, data for 91 were described 
previously in in the literature.229  
  
Scheme 15: Synthesis of Ru(II) MeCN complexes 89-91  by solution phase methods. 
 X-ray crystallographic data were obtained for 89 and 91. Diffusion of Et2O into acetone 
solutions provided crystals of 89 and 91 suitable for X-ray crystallographic analysis. Select data 
for 89 and 91 are presented in Figure 40; full tables can be found at the end of Chapter 6.   
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A 
 
B 
Figure 40:  ORTEP diagrams of the dications [Ru(DPAbpy)(MeCN)]2+ (A) and 
[Ru(TQA)(MeCN)2]2+ (B) derived from 89 and 91, respectively. Thermal ellipsoids are 
shown at 50% probability. Hydrogen atoms are omitted for clarity. Select bond lengths 
(Å) and angles (deg) for [Ru(DPAbpy)(MeCN)]2+ (A); Ru–N1, 2.052(11); Ru–N2, 
2.060(12); Ru–N3, 2.085(12); Ru–N4, 1.986(14); Ru–N5, 1.954(11); Ru–N6, 2.052(11); 
N1–Ru–N6, 97.6(4). Select bond lengths (Å) and angles (deg) for [Ru(TQA)(MeCN)2]2+ 
(B); Ru–N1, 2.032(1); Ru–N2, 2.067(1); Ru–N3, 2.052(1); Ru–N4, 2.061(1); Ru–N5, 
2.042(1); Ru–N6, 2.042(1); N1–Ru–N6, 87.50(4). 
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6.2.4 Photolysis of the metal complexes 
The changes to the electronic absorption spectra of 89, 90, and 91 in H2O at room 
temperature were monitored by the Turro group as a function of irradiation time to detect 
generation of any photochemical products. No change in the absorption spectrum of 89 was 
observed following irradiation (λ ≥ 395 nm) for 1 h. The irradiation of 90 in H2O with λ ≥ 395 
nm results in a shift in the absorption maximum from 348 nm to 361 nm, whereas the peak at 420 
nm blue shifts to 408 nm with clear isosbestic points at 368 nm and 412 nm (Figure 41A). This 
process, occurring with Φ400 = 0.019(3), is not consistent with substitution of CH3CN with H2O 
because a shift of the MLCT band at 420 nm to lower energy is expected. Further irradiation 
causes a red shift of the 420 nm peak (Figure 41B), suggesting that substitution of CH3CN may 
occur as a secondary process following the first photoinduced event. The first event is presumed 
to correspond to the substitution of one of the coordinated pyridyl substituents from the N4Py 
ligand with H2O, a point that is explored by 1H NMR spectroscopy with the results described 
below. Irradiation of 91 with λ ≥ 395 nm, Figure 41C, causes a red shift of the absorption 
maximum from 418 nm to 425 nm with an isosbestic point at 420 nm and Φ400 = 0.027(1). This 
red shift of the MLCT band is consistent with formation of the corresponding mono-aqua 
complex upon substitution of one CH3CN. Further irradiation results in a further red shift to 460 
nm (Figure 41D), consistent with substitution of the second CH3CN ligand with H2O. Indeed, a 
second isosbestic point is apparent in Figure 41D for the changes to the absorption spectrum at 
longer irradiation time at 398 nm.    
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Figure 41:  Electronic absorption spectra of 90 irradiated for 0, 0.5, 1, 4, 7, and 15 min 
(A) and 15, 40, and 85 min (B) and 91 irradiated for 0, 0.5, 1, and 2 min (C) and 2, 5, 20, 
and 60 min (D), in H2O upon irradiation with λ ≥ 395 nm. 
 
To confirm the nature of the photoproducts formed during the photolysis of 90 and 91, 
the changes to the 1H NMR spectrum of each complex was monitored as a function of irradiation 
time in D2O with λ ≥ 395 nm. In D2O in the dark, no changes were observed, confirming that the 
complexes are stable in solution in the absence of light. Figure 42A depicts the changes in the 
NMR spectrum of 91 upon irradiation in D2O. In 180 min, a clean progression to a single 
photoproduct is observed, assigned to the mono-aqua species, labeled M in Figure 42A. Most 
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notably, the loss of the singlet at 2.32 ppm concurrent with the evolution of a singlet at 2.06 ppm 
(free CH3CN) indicates substitution of bound CH3CN with D2O. By comparison with the 
previously reported [Ru(TPA)(CH3CN)2]2+ analogue,221 the photosubstituted CH3CN is assigned 
as the ligand trans to the quinoline group (N6, Figure 40B), as this CH3CN chemical shift is 
more shielded than the CH3CN trans to the amine (2.92 ppm). A schematic representation of this 
ligand exchange is shown in Figure 42B. This experiment confirms the ability of 91 to release a 
nitrile ligand and coordinate a solvent molecule when irradiated with visible light at early 
irradiation times. It should be noted that after 180 min of irradiation, the integration of the peak 
corresponding to remaining bound CH3CN ligand begins to decrease, together with a continued 
increase in free CH3CN. At 360 min of irradiation, peaks corresponding to the bis-aqua product 
are discerned in the 1H NMR spectrum, labeled B in Figure 42A. This finding, together with the 
presence of an isosbestic point a longer irradiation times in the absorption spectra (Figure 41B), 
is indicative that the first step shown in Figure 42B is followed by the exchange of the second 
CH3CN ligand with prolonged photolysis.   
The photoproduct(s) formed upon irradiation of 90 in D2O were also studied by 1H NMR 
and the results are shown in Figure 43. Unlike 91, the bound CH3CN singlet at 2.81 ppm does 
not show a clear decrease concurrent with only free CH3CN evolution; instead, as the singlet at 
2.81 ppm decreases, a new peak at 2.86 ppm increases as well as a small increase of free CH3CN 
at 2.06 ppm. Additionally, the singlet at 6.62 ppm, assigned as the methine proton, decreases and 
two new additional singlets at 6.08 and 6.35 ppm appear with irradiation. The aromatic region 
becomes more complicated with new peaks arising at 6.98, 7.80, 8.25, and 8.84 ppm. The shift in 
consistent with a small change in the environment around the CH3CN protons upon exchange of 
one coordinated pyridyl ring for a solvent molecule. The 1H NMR results are consistent with the 
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presence of multiple photoprocesses upon visible light irradiation, where the dominant pathway 
is the dissociation of a coordinated N4Py pyridyl ring from the ruthenium center, but with 
CH3CN exchange for a solvent molecule also operative to a smaller extent, the methine proton 
singlet upfield is consistent with one of the pyridyl rings being released and replaced by solvent.  
 
Figure 42: 1H NMR spectra following irradiation of 91 in D2O with λirr ≥ 395 nm for 0, 
15, 45, 90, and 180 min; the label M indicates signal from the mono-aqua intermediate 
and B from the bis-aqua product formed upon irradiation with selected integrations 
shown parentheses (A) and schematic representation of the first ligand exchange process 
of the complex (B). 
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Figure 43: 1H NMR spectra following irradiation of 90 in D2O with λirr ≥ 395 nm for 0, 
30, 60, and 120 min. Stars indicate new signals evolved upon irradiation. 
 
6.2.5 Discussions. 
 Combinatorial chemistry, diversity-oriented synthesis and other compound library 
approaches have made a major impact in chemical biology and drug discovery.230-236 Methods for 
synthesizing large libraries of organic compounds have advanced to the point where a single 
researcher can synthesize hundreds of thousands of compounds in a week.215 In comparison to 
organic compounds, methods to synthesize libraries of inorganic compounds are grossly 
underdeveloped. Most attention has focused on the discovery of metal-based catalysts for 
organic reactions,237-239 selective metal-binding agents,240-242 and new photosensitizers.243 Peptide- 
and oligonucleotide conjugates of metal complexes have been synthesized by solid phase for 
biological applications, and these compounds have enjoyed great success as biologically active 
agents and tool compounds.244-253 However, their synthesis often involves late-stage attachment 
of the complex (or ligand) to the biomolecule, where the coordination environment of the 
complex is preset. Surprisingly, even though there is an enormous amount of chemical space that 
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remains unexplored, studies that apply combinatorial chemistry to vary and tune the coordination 
sphere of biologically active inorganic compounds are rare. To the best of our knowledge, library 
approaches had not been applied yet towards discovery of new metal-based caging groups, a 
class of inorganic compounds with many important biological applications.36-38,40,56,76,146,150-
152,171,221,254-266 
 The solid phase synthesis and screening platform described in this manuscript allowed us 
to rapidly identify complexes that release their ligands with visible light. Three examples with 
varied reactivity were synthesized and fully characterized, and the photochemical behavior of the 
complexes was in good agreement between solid- and solution-phase compounds. Thus, our 
library approach was validated as a method for identifying lead caging groups. Solid-phase 
synthesis carries numerous advantages over its solution-phase counterpart, including the ability 
to perform reactions on small scale, and isolate compounds by simple filtration, thereby avoiding 
time consuming and often tedious purifications of ligand precursors, ligands and metal 
complexes, which can all be challenging. Removing the need for compound isolation and 
chromatography is a major advantage, especially for researchers that do not carry a strong 
experimental skill set in synthesis. Key to this study, only 1-2 compounds out of the 10 surveyed 
actually reacted with visible light in the desired manner to release bound nitriles. Synthesizing 
and characterizing the photochemistry of each of these 10 complexes would have taken 
considerable effort. The synthesis and screening approach we adopted allowed us to direct our 
efforts in synthesis and full characterization toward the most promising compounds only. 
 The library members from this study displayed a wide range of reactivity with visible 
light. Many of the examples showed little if any photochemical activity, an observation easily 
explained by the fact that most compounds did not absorb strongly in the visible region. Indeed, 
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photochemistry is observed for many of the compounds surveyed when irradiated with in the 
MLCT bands with UV light.267 However, several of the compounds prepared absorb well in the 
visible range, and either do react when irradiated with visible light to follow a non-desired 
pathway, such as the pyridine release observed with complex 90, or are not photoactive with 
visible light at all (ex. 89). Thus, absorbing in the visible range did not guarantee nitrile release 
with visible light, an observation that has been reported with other caging strategies.257 The lead 
compound established from this study was complex 91, which acts much like its congener 
[Ru(TPA)(MeCN)2]2+,221 with the selective release the nitrile ligand positioned trans to quinoline 
upon irradiation with short irradiation times. Complex 91, however, does provide numerous 
advantages over [Ru(TPA)(MeCN)2]2+, including efficient release of MeCN with visible light 
and larger quantum yield, Φ400 = 0.027(1)  for 91 vs. Φ350 = 0.012(1) for [Ru(TPA)(MeCN)2]2+. 
In order to explain the wide range of reactivity with light, computations were carried out with 
compounds 89-91 and other examples.268 Time-dependent density functional theory (TD-DFT) 
calculations, performed by the Schlegel group have provided significant insight into the disparity 
of reactivity for these complexes, which are all derived from very similar ligands.269 These data 
have allowed us to assign many of the optical bands observed in absorption spectra of the 
complexes as 1MLCT transitions, which fall in the UV to visible range. Preliminary assessment 
of the data indicates that the barrier for internal conversion between the lowest energy 3MLCT 
state and the dissociative triplet metal centered (3MC) states is a key factor that controls the 
outcome and selectivity of nitrile release with these complexes. Results of these studies in great 
detail are published and will not be discussed here further.269 
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6.2.6 Conclusions. 
 In conclusion, we have described a new platform for discovering metal-based caging 
groups that provides rapid access to new derivatives for screening photochemical behavior. A 
representative library of 10 compounds was produced that contained a range of different donors, 
denticities and coordination geometries. Absorption and photoreactivity with visible light was 
screened, resulting in the identification of several compounds that demonstrated interesting 
behavior worthy of further investigation. Three new analogs were synthesized by solution phase, 
and data for compounds were in good agreement with the corresponding complexes from solid 
phase, thus validating the predictive power of the library approach. The wide range of reactivity 
with visible light amongst the library of compounds illustrated the need to prescreen compounds 
for their photochemical behavior, before efforts were directed towards solution phase synthesis 
and full characterization, an inherently tedious but necessary process. In general terms, this study 
represents an important example of why combinatorial, library-based approaches should be 
applied towards the development of inorganic complexes for biological applications. Such 
studies are currently underway in our laboratory.  
 
6.3 Experimental procedures for solid phase-based metal complexes 
6.3.1 Synthesis of compound 80 
Compound 80 can be synthesized from compound 79, which is prepared from dimethyl 
pyridine 2-5-dicarboxylate in two steps using a literature protocol.270 Compound 79 (2g, 11.9 
mmol) was dissolved in 160 mL of dry MeOH under inert atmosphere. To this 1,3-
propanediamine (10.6 g, 0.14 mol) was added and the reaction mixture was refluxed for 24 h 
under inert atmosphere. Reaction mixture was concentrated under reduced pressure and excess 
1,3-propanediamine was removed by azeotropic distillation from toluene (3 × 100 mL) to give 
compound 80 as a white solid (2.4 g, 96%). Mp = 122 oC; 1H NMR (400MHz, D2O) δ 8.64 (s, 
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1H), 8.02 (d, 1H, J = 8.8 Hz), 7.46 (d, 1H, J = 8.4 Hz), 3.30 (t, 2H, J = 6.8 Hz), 2.55 (t, 2H, J  = 
7.6 Hz), 1.62 (m, 2H, J  = 7.2 Hz); 13C NMR (400MHz, D2O) δ 168.2, 162.5, 146.9, 136.7, 
128.8, 120.9, 63.6, 37.9, 37.5, 31.1; IR (KBr) νmax (cm-1) 3666, 3592, 3418, 3119, 2935, 2856, 
2276, 1729, 1609, 1481, 1461, 1448, 1311, 1289, 1160, 992, 838, 767, 739. ESMS calculated for  
(M+H)+ 210.1243, found 210.1252. 
 
6.3.2 Synthesis of resin bound pyridine precursor (83 and 84) and ligand library 
(85a-j and 86a-j) 
Commercially available rink amide MBHA resin 81 (Chem-impex, 0.75 mmol) was 
Fmoc deprotected by agitating the resin in a standard peptide synthesizer in the presence of 20% 
piperidine in DMF (20 mL) for 20 min at room temperature (2 cycle). After 2 cycles the resin 
was washed with DMF (3 × 20 mL), IPA (3 × 20 mL) and DCM (3 × 20 mL) and dried under 
reduced pressure. The deprotected resin (0.7 mmol) is then treated with succinic anhydride (2.8 
mmol) in DMF (8 mL) in a peptide synthesizer and agitated for 2 h at RT. Amidation was done 
for two cycles to ensure complete consumption of the amine to give compound 82.  After 2 
cycles the resin was washed with DMF (3 × 20 mL), IPA (3 × 20 mL) and DCM (3 × 20 mL) 
and dried under reduced pressure. Compound 82 (0.7 mmol) was then reacted with compound 80 
(2.8 mmol) in the presence of HBTU (2.8 mmol), DIPEA (0.84 mmol) in DMF (20 mL) in a 
peptide synthesizer at RT for 16 h to give the coupling product 83. Resin was then washed with 
DMF (3 × 20 mL), IPA (3 × 20 mL) and DCM (3 × 20 mL) and dried under reduced pressure.  
Small amount of resin can be cleaved using standard cleaving conditions described below and 
NMR was taken to ensure reaction completion.   
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The alcohol group of compound 83 can be mesylated by treating compound 83 (0.21 
mmol) with MsCl (0.84 mmol), TEA (1.05 mmol) in dry THF (12 mL) for 2h at RT in a peptide 
agitator for 2 cycles. Small amount of resin was cleaved by following standard cleaving 
procedure and NMR of the product was taken to ensure reaction completion.  
Operation Scale Reagent Vol No of 
cycles 
Time/Temp 
Fmoc 
deprotection 
0.7 mmol 20% piperidine in DMF 20 mL 2 20 min/ RT 
Drain and 
wash 
0.7 mmol DMF, iPrOH, DCM 20 mL 3 2 min 
(each)/ RT 
Amidation 0.7 mmol Succinic anhydride (2.8 
mmol) 
8 mL DMF 2 2h / RT 
Coupling with 
80 
0.7 mmol Compound 3 (2.8 mmol), 
HBTU (2.8 mmol), 
DIPEA (0.84 mmol) 
20 mL 
DMF 
1 16 h / RT 
Mesylation 0.21 
mmol 
MsCl (0.84 mmol), TEA 
(1.05 mmol) 
12 mL dry 
THF 
3 2 h / RT 
Chlorination 0.7 mmol TsCl (7 mmol), LiCl (35 
mmol), DIPEA (10.5 
mmol) 
20 mL 
CH3CN 
1 16 h /50 oC 
Table 11: Synthesis of compounds 83 and 84 
The alcohol group of compound 83 can be chlorinated by heating compound 83 (0.7 
mmol) with TsCl (7 mmol), LiCl (35 mmol), DIPEA (10.5 mmol) in acetonitrile (20 mL) for 16 
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h at 50 oC in a vial equipped with slow stirring. After reaction completion, resin was washed with 
DMF (3 × 20 mL), IPA (3 × 20 mL) and DCM (3 × 20 mL) and dried under reduced pressure to 
give compound 84. 1H NMR spectroscopic analysis of product, obtained by cleavage of a small 
amount of resin, was used to measure reaction progress.  
 
Scheme 16a: Synthesis of polypyridyl ligand library (85a-85e) 
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Scheme 16b: Synthesis of polypyridyl ligand library (85f-85j) 
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Standard procedure for resin cleavage is 10 mg of resin was suspended in 1 mL of 95% 
TFA in water and allowed to stand for 15 min at room temperature. The contents of the vial were 
filtered through a cotton plug and concentrated under reduced pressure. The resulting compound 
would be either dissolved in 1 mL D2O for NMR (compounds 83 and 84 and polypyridyl ligands 
86a-j) or 1 mL of H2O (metal complexes 88a-j) for UV spectroscopy and mass spectrometry. 
Synthesis of compound 86a – Resin bound Compound 84 (X = Cl) (100 mg, 0.07 mmol) 
was heated at 50 oC for 16 h in the presence of bis(pyridine-2-ylmethyl)amine271 (70 mg, 0.35 
mmol) in 3 mL DMF under ambient atmosphere in a vial with slow stirring to get resin bound 
85a which was then washed with DMF (3 × 10 mL), IPA (3 × 10 mL) and DCM (3 × 10 mL) 
and dried under reduced pressure. 10 mg of resin was then cleaved using standard cleavage 
condition to get 86a which was analyzed by NMR and HPLC; 1H NMR (400MHz, D2O) δ 8.75 
(s, 1H), 8.66 (d, 2H, J = 6.0 Hz), 8.42 (t, 2H, J = 8 Hz), 8.05 (d, 1H, J = 8.4 Hz), 7.94 (d, 2H, J = 
8 Hz) 7.86(t, 2H, J = 7.6 Hz) 7.46(d, 1H, J = 8.4 Hz) 4.40(s, 4H) 4.11(s, 2H), 3.39 (t, 2H, J = 6.8 
Hz), 2.55 (m, 4H), 1.79 (m, 2H). Calculated mass for  (M+H)+ 490.56, found 491. 
Synthesis of compound 86b – Resin bound Compound 84 (X = Cl) (100 mg, 0.07 mmol) 
was agitated in a standard solid phase peptide synthesizer at room temperature for 16 h in the 
presence of (pyridine-2-ylmethyl)glycine hydrochloride salt272 (141 mg, 0.7 mmol) in 3 mL DMF 
along with DIPEA (90 mg, 0.7 mmol) under ambient atmosphere to get resin bound 85b which 
was then washed with DMF (3 × 10 mL), IPA (3 × 10 mL) and DCM (3 × 10 mL) and dried 
under reduced pressure. 10 mg of resin was then cleaved using standard cleavage condition to get 
86b which was analyzed by NMR and HPLC; 1H NMR (400MHz, D2O) δ 8.93(s, 1H), 8.67(d, 
1H, J = 5.6 Hz), 8.47(d, 1H, J = 8 Hz), 8.41(t, 1H, J = 8 Hz), 7.91-7.86(m, 3H), 4.44(s, 2H), 
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4.39(s, 2H), 3.72(s, 2H), 3.43(t, 2H, J = 6.8 Hz), 3.26(t, 2H, J = 6.8 Hz), 2.55-2.48(m, 4H), 
1.81(t, 2H, J = 6.8 Hz). Calculated mass for  (M+H)+ 457.22, found 457. 
Synthesis of compound 86c – Resin bound Compound 84 (X = OMs) (100 mg, 0.07 
mmol) was slowly stirred in a vial at 55 oC for 16 h in the presence of 2-(((pyridine-2-
ylmethyl)amino)methyl)phenol273 (150 mg, 0.7 mmol) in 3 mL DMF under ambient atmosphere 
to get resin bound 85c which was then washed with DMF (3 × 10 mL), IPA (3 × 10 mL) and 
DCM (3 × 10 mL) and dried under reduced pressure. 10 mg of resin was then cleaved using 
standard cleavage condition to get 86c which was analyzed by NMR and HPLC; 1H NMR 
(400MHz, D2O) δ 8.91(s, 1H), 8.65(d, 1H, J = 5.6 Hz), 8.42(d, 2H, J = 8.4 Hz), 8.28(t, 1H, J = 
8.0 Hz), 7.83(d, 1H, J = 7.6 Hz), 7.78-7.75(m, 2H), 7.21(d, 1H, J = 8 Hz), 7.10(t, 1H, J = 7.6 
Hz), 6.81(t, 1H, J = 7.6 Hz), 6.60(d, 1H, J = 8 Hz), 4.57-4.56(m, 2H), 4.10(s, 2H), 3.47(t, 2H, J 
= 6.8 Hz), 3.30(t, 2H, J = 6.4 Hz), 2.59-2.51(m, 4H), 1.87-1.82(m, 2H). Calculated mass for  
(M+Na)+ 527.24, found 527. 
Synthesis of compound 86d – Resin bound Compound 84 (X = OMs) (100 mg, 0.07 
mmol) was slowly stirred in a vial at 55 oC for 16 h in the presence of (6-(((pyridine-2-
ylmethyl)amino)methyl)pyridine-2-yl)methanol274 (160 mg, 0.7 mmol) in 3 mL DMF under 
ambient atmosphere to get resin bound 85d which was then washed with DMF (3 × 10 mL), IPA 
(3 × 10 mL) and DCM (3 × 10 mL) and dried under reduced pressure. 10 mg of resin was then 
cleaved using standard cleavage condition to get 86d which was analyzed by NMR and HPLC; 
1H NMR (400MHz, D2O) δ 8.85(s, 1H), 8.68(d, 1H, (t, 2H, J = 5.2 Hz), 8.43(t, 1H, J = 7.6 Hz), 
8.34(t, 1H, J = 7.6 Hz), 8.13(d, 1H, J = 8.4 Hz), 7.97(d, 1H, J = 8 Hz), 7.88(t, 1H, J = 7.2 Hz), 
7.81(t, 2H, J = 8.0 Hz), 7.52(d, 1H, J = 8.4 Hz), 4.99(s, 2H), 4.43(s, 2H), 4.39(s, 2H), 4.19(s, 
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2H), 3.46-3.41(m, 2H), 3.30-3.25(m, 2H), 2.57-2.49(m, 4H), 1.86-1.79(m, 2H). Calculated mass 
for  (M+H)+ 519.26, found 520. 
Synthesis of compound 86e – Resin bound Compound 84 (X = OMs) (100 mg, 0.07 
mmol) was agitated in a standard solid phase peptide synthesizer at room temperature for 16 h in 
the presence of pyridine-2-yl-methanamine (2-picolylamine)270 (76 mg, 0.7 mmol) in 6 mL DMF 
under ambient atmosphere to get resin bound secondary amine which was washed with DMF (3 
× 10 mL), IPA (3 × 10 mL) and DCM (3 × 10 mL) and dried under reduced pressure. The 
secondary amine was then alkylated using 2,6-bis(bromomethyl)pyridine274 (186 mg, 0.7 mmol) 
and DIPEA (90 mg, 0.7 mmol) in 6 mL DMF at room temperature  for 6 h. The resin was 
washed using standard washing procedure with DMF, IPA and DCM and further subjected to 
third alkylation using aniline (65 mg, 0.7 mmol) in 3 mL DMF at room temperature for 16 h 
under ambient temperature to give resin bound 85e, which was then washed with DMF (3 × 10 
mL), IPA (3 × 10 mL) and DCM (3 × 10 mL) and dried under reduced pressure. 10 mg of resin 
was then cleaved using standard cleavage condition to get 86e which was analyzed by NMR and 
HPLC; 1H NMR (600MHz, D2O) δ 8.70(s, 1H), 8.45(m, 1H), 8.21-8.18(m, 2H), 7.95-7.93(m, 
1H), 7.73-7.66(m, 3H), 7.55-7.46 (Junk), 7.36-7.33(m, 1H), 7.22-7.21(m, 1H), 7.12-7.10(m, 2H), 
6.87(t, 1H, J = 7.8 Hz), 6.77(d, 2H, J = 7.8 Hz), 4.58(s, 2H), 4.14(s, 2H), 4.05(m, 4H), 3.62(s, 
1H, impurity), 3.26-3.24(m, 2H), 3.08-3.06(m, 2H), 2.36-2.33(m, 4H), 1.65-1.63(m, 2H). 
Calculated mass for  (M+H)+ 594.31, found 595. 
Synthesis of compound 86f – Resin bound Compound 84 (X = OMs) (100 mg, 0.07 
mmol) was agitated in a standard solid phase peptide synthesizer at room temperature for 16 h in 
the presence of pyridine-2-yl-methanamine (2-picolylamine) (76 mg, 0.7 mmol) in 6 mL DMF 
under ambient atmosphere to get a resin bound secondary amine, which was then washed with 
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DMF (3 × 10 mL), IPA (3 × 10 mL) and DCM (3 × 10 mL) and dried under reduced pressure. 
The secondary amine was then alkylated using 6-(chloromethyl)-2,2’-bipyridine275 (143 mg, 0.7 
mmol) and DIPEA (90 mg, 0.7 mmol) in 3 mL DMF at 55 oC for 16 h in a vial with slow 
stirring. The resin was washed using standard washing procedure with DMF, IPA and DCM and 
dried under reduced pressure to get resin bound 85f. 10 mg of resin was then cleaved using 
standard cleavage condition to get 86f which was analyzed by NMR and HPLC; 1H NMR 
(400MHz, D2O) δ 8.91(d, 1H, J = 6.0 Hz), 8.82(s, 1H), 8.72-8.68(m, 1H), 8.64(d, 1H, J = 5.6 
Hz), 8.57-8.55(m, 1H), 8.30(t, 1H, J = 6.4 Hz), 8.25(d, 1H, J = 8.0 Hz), 8.15-8.10(m, 2H), 
8.04(t, 1H, J = 8.0 Hz), 7.90(d, 1H, J = 8.0 Hz), 7.78(t, 1H, J = 8.0 Hz), 7.73(d, 1H, J = 8.4 Hz), 
7.66(d, 1H, J = 8.0 Hz), 4.58(s, 2H), 4.49(s, 2H), 4.38(s, 2H), 3.42(t, 2H, J = 6.8 Hz), 3.30-
3.25(m, 2H), 2.58-2.52(m, 4H), 1.83-1.77(m, 2H). Calculated mass for  (M+H)+ 566.28, found 
567. 
Synthesis of compound 86g – Resin bound Compound 84 (X = Cl) (100 mg, 0.07 mmol) 
was heated at 55 oC for 16 h in the presence of 1,1-di(pyridine-2-yl)-N-(pyridine-2-
ylmethyl)methanamine276 (193 mg, 0.7 mmol) and NaI (10.5 mg, 0.07 mmol) in 3 mL MeCN 
under ambient atmosphere in a vial with slow stirring to get resin bound 85g which was then 
washed with DMF (3 × 10 mL), IPA (3 × 10 mL) and DCM (3 × 10 mL) and dried under 
reduced pressure. 10 mg of resin was then cleaved using standard cleavage condition to get 86g 
which was analyzed by NMR and HPLC; 1H NMR (400MHz, D2O) δ 8.82(s, 1H), 8.55(d, 2H, J 
= 4.8 Hz), 8.48(d, 1H, J = 5.6 Hz), 8.17-8.14(m, 3H), 8.09(d, 1H, J = 8.0 Hz), 7.78(d, 2H, J = 
8.0 Hz), 7.65-7.58(m, 4H), 7.36(d, 1H, J = 8.4 Hz), 4.30(s, 2H), 4.21(s, 1H), 4.14(s, 1H), 3.25-
3.22(m, 2H), 3.09-3.06(m, 2H), 2.36-2.33(m, 4H), 1.64-1.61(m, 2H). Calculated mass for  
(M+H)+ 566.28, found 567. 
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Synthesis of compound 86h – Resin bound Compound 84 (X = Cl) (100 mg, 0.07 mmol) 
was heated at 55 oC for 16 h in the presence of N1-benzyl-N1,N2-bis(pyridine-2-ylmethyl)ethane-
1,2-diamine277 (232 mg, 0.7 mmol) and NaI (10.5 mg, 0.07 mmol) in 3 mL MeCN under ambient 
atmosphere in a vial with slow stirring to get resin bound 85h, which was then washed with 
DMF (3 × 10 mL), IPA (3 × 10 mL) and DCM (3 × 10 mL) and dried under reduced pressure. 10 
mg of resin was then cleaved using standard cleavage condition to get 86h which was analyzed 
by NMR and HPLC; 1H NMR (400MHz, D2O) δ 8.95(s, 1H), 8.89(d, 1H, J = 6.4 Hz), 8.81(d, 
1H, J = 5.2 Hz), 8.64(t, 1H, J = 8.0 Hz), 8.34(d, 1H, J = 8.4 Hz), 8.20-8.06(m, 3H), 7.56(t, 1H, J 
= 7.6 Hz), 7.69(t, 2H, J = 9.6 Hz), 7.61-7.50(m, 5H), 4.66(s, 2H), 4.51(s, 2H), 4.36(s, 2H), 
4.18(s, 2H), 3.73-3.65(m, 4H), 3.51(t, 2H, J = 6.4 Hz), 3.45(t, 2H, J = 6.4 Hz), 2.80-2.74(m, 4H), 
2.09-2.05(m, 2H). Calculated mass for  (M+H)+ 622.34, found 623. 
Synthesis of compound 86i – Resin bound Compound 84 (X = OMs) (100 mg, 0.07 
mmol) was agitated in a standard solid phase peptide synthesizer at room temperature for 16 h in 
the presence of N-(2-aminoethyl)picolinamide278 (115 mg, 0.7 mmol) in 6 mL DMF under 
ambient atmosphere to get resin bound secondary amine which was washed with DMF (3 × 10 
mL), IPA (3 × 10 mL) and DCM (3 × 10 mL) and dried under reduced pressure. The secondary 
amine was then alkylated using 2-(chloromethyl)pyridine hydrochloride salt (115 mg, 0.7 mmol) 
and DIPEA (90 mg, 0.7 mmol) in 3 mL DMF at 55 oC for 16 h in a vial with slow stirring. The 
resin was washed using standard washing procedure with DMF, IPA and DCM and dried under 
reduced pressure to get resin bound 85i. 10 mg of resin was then cleaved using standard cleavage 
condition to get 86i which was analyzed by NMR and HPLC; 1H NMR (400MHz, D2O) δ 8.66-
8.61(m, 3H), 8.34-8.30(m, 1H), 8.10-8.05(m, 2H), 7.98(d, 1H, J = 7.6 Hz), 7.90(d, 1H, J = 8.0 
Hz), 7.79(t, 1H, J = 6.8 Hz), 7.69-7.67(m, 1H), 7.61(d, 1H, J = 8.4 Hz), 4.47(s, 2H), 4.24(s, 2H), 
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3.59-3.55(m, 2H), 3.42-3.48(m, 2H), 3.29-3.25(m, 2H), 3.20-3.18(m, 2H), 2.56-2.53(m, 4H), 
1.84-1.80(m, 2H). Calculated mass for  (M+Na)+ 569.26, found 569. 
Synthesis of compound 86j – Resin bound Compound 84 (X = Cl) (100 mg, 0.07 mmol) 
was heated at 50 oC for 16 h in the presence of bis(isoquinolin-1-ylmethyl)amine (94) (209 mg, 
0.7 mmol) and NaI (10.5 mg, 0.07 mmol) in 3 mL DMF under ambient atmosphere in a vial with 
slow stirring to get resin bound 85j, which was then washed with DMF (3 × 10 mL), IPA (3 × 10 
mL) and DCM (3 × 10 mL) and dried under reduced pressure. 10 mg of resin was then cleaved 
using standard cleavage condition to give 86j which was analyzed by NMR and HPLC; 1H NMR 
(600MHz, D2O) δ 8.57(s, 1H), 8.50(d, 2H, J = 9.0 Hz), 8.19(d, 2H, J = 6.6 Hz), 8.16-8.13(m, 
2H), 8.09(t, 4H, J = 8.4 Hz), 8.00(t, 2H, J = 8.4 Hz), 7.88(d, 2H, J = 7.2 Hz), 7.25(d, 1H, J = 8.4 
Hz), 5.11(s, 4H), 4.39(s, 2H), 3.43-3.41(m, 2H), 3.30-3.28(m, 2H), 2.57-2.54(m, 4H), 1.83(t, 2H, 
J = 6.6 Hz). Calculated mass for  (M+H)+ 589.28, found 590. 
 
6.3.3 Optimization studies for metallation and synthesis of 87 and 88.  
TPA based ligand attached to either polystyrene (a85a - 0.7 mmol/g) or Tenta-gel resin 
(b85a - 0.23 mmol/g) was used for optimization of mettalation conditions. Both compound 84 (X 
= Cl) and compound 86a on tentagel for the optimization steps can be prepared by following the 
same procedure reported for 84 and 86a on polystyrene. Ruthenium starting materials which 
were used are  (A) cis-[Ru(DMSO)4Cl2], (B) [Ru(COD)(MeCN)4](BF4)2279  or (C) fac-
[Ru(DMSO)3(O2CCF3)2(H2O)]280. Different mole ratios of the ruthenium (II) were used for 
different reactions starting from 2 equiv. to 10-equiv. with respect to resin loading. Solvents used 
for the reactions were DMF or MeCN or MeOH or EtOH (1 mL). Reactions carried out by 
conventional heating were done in a vial under inert atmosphere in an oil bath at 50 oC for 18 h 
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with slow stirring of the resin in the solvent in the presence of ruthenium (II) source. The 
microwave reactions were performed in a 2 mL Biotage vial using Biotage microwave reactor 
(Initiator eight microwave system) at 80 oC or 100 oC for 0.5 h or 1 h reaction time. Metal 
complexes [Ru(86a)(DMSO)(Cl)]1+ were then cleaved from the resins using standard cleavage 
procedure and yield was calculated using UV spectroscopy by determining the absorbance at λmax 
= 345 nm (ε = 10,500 M-1 cm-1). For condition 10a yield was calculated based on extinction 
coefficient of [Ru(86a)(MeCN)2] 2+ (ε = 9,040 M-1 cm-1). 
All the solid phase based metallation reactions were carried out in 2 mL microwave glass 
reactors (Biotage). Each microwave vial was charged with 10 mg (0.007 mmol) ligand (85a-j). A 
stock solution of  [Ru(DMSO)3(H2O)(OTFA)2] was prepared by following a known literature 
protocol280 in dry EtOH inside the glove box and 17 mg (0.028 mmol) of the ruthenium complex 
was delivered to each vial inside the glove box. The final volume of EtOH was adjusted to 1 mL 
by adding additional dry EtOH. 2, 6 lutidine (7.5 mg, 0.07 mmol) was added to vials containing 
ligands 85b, 85c, and 85i. All the glass vials were sealed inside the glove box and reacted on an 
Initiator eight microwave system (Biotage microwave reactor) for 30 min at 80 oC. The resin was 
then washed with EtOH (4 × 2 mL) followed by 1:1 MeCN: H2O mixture (4 × 2 mL). Then 1 mL 
of 1:1 MeCN: H2O solution was added to each vial and reacted on Initiator eight microwave 
system (Biotage microwave reactor) for 30 min at 80 oC. Resin was dried under reduced pressure 
and solid-state based metal complex was cleaved from resin using standard cleavage procedure 
to get complexes 88a-j, which were analyzed, by UV spectroscopy and mass spectrometry.  
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6.3.4 Synthesis of metal complexes by solution phase 89-91  
Synthesis of [Ru(DPAbpy)(MeCN)](PF6)2 (89) - DPAbpy (50 mg, 0.14 mmol) that was 
prepared by a known procedure213 was dissolved in dry MeOH (12 mL) under inert atmosphere 
in a pressure flask. To this Ru(DMSO)4Cl2 (65 mg, 0.14 mmol) was added and the solution was 
purged with Ar for 10 min at room temperature. The reaction mixture was refluxed for 5 h under 
inert temperature. Color of the reaction mixture changes from pale yellow to dark red. The 
reaction mixture was cooled to room temperature and concentrated under reduced pressure. To 
the flask 1:1 mixture of MeCN: H2O was added and the reaction mixture was refluxed for 16 h 
under inert atmosphere. Ice cold water (25 mL) was then added to the reaction mixture followed 
by a saturated solution of aqueous NH4PF6 (5 mL), which resulted in the formation of dark red 
precipitate that was filtered, washed with ice cold water (150 mL) and dried under reduced 
pressure to give title complex as a dark red solid (51 mg, 47%). Crystals for X-ray 
crystallographic analysis were obtained by diffusing Et2O into a solution of 89 in acetone: Mp = 
194 oC (decomp); 1H NMR (400MHz C3D6O) δ 9.54(d, 1H, J = 5.6 Hz), 8.86(d, 1H, J = 8.0 Hz), 
8.59(d, 1H, J = 8.8 Hz), 8.43(t, 1H, J = 7.6 Hz), 8.05(t, 1H, J = 6.4 Hz), 8.00(t, 1H, J = 8.0 Hz), 
7.95(t, 2H, J = 7.6 Hz), 7.75(d, 2H, J = 8.0 Hz), 7.61(d, 2H, J = 5.6 Hz), 7.55(d, 1H, J = 8.0 Hz), 
7.29(t, 2H, J = 6.4 Hz), 5.49(s, 4H), 5.43(s, 2H), 2.73(s, 3H); IR (KBr) νmax (cm-1) 3687, 3401, 
3257, 3082, 3005, 2945, 2273, 1983, 1709, 1607, 1568, 1477, 1450, 1408, 1355, 1309, 1295, 
1247, 1162, 1128, 1115, 1092, 1073, 1062, 990, 963, 939, 832, 768, 739, 670, 650, 557, 511, 
465, 450, 425, 391, 353, 337, 330, 313. ESMS calculated for C25H24F6N6PRu (M+1) 655.07, found 
655.00; UV-vis λmax = 371 nm (ε = 10,200 M-1cm-1), 462 nm (ε = 5,850 M-1cm-1); Anal. 
Calculated for C25H24F12N6P2Ru: C, 37.56; H, 3.03; N, 10.51. Found: C, 37.64; H, 3.19; N, 10.42. 
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Synthesis of [Ru(N4py)(MeCN)](PF6)2 (90) - N4py (200 mg, 0.54 mmol) that was 
prepared by a known procedure281 was dissolved in dry MeOH (50 mL) under inert atmosphere 
in a pressure flask. To this Ru(DMSO)4Cl2 (263 mg, 0.54 mmol) was added and the solution was 
purged with Ar for 10 min at room temperature. The reaction mixture was refluxed for 5 h under 
inert temperature. Color of the reaction mixture changes from pale yellow to dark red. The 
reaction mixture was cooled to room temperature and concentrated under reduced pressure. To 
the flask 1:1 mixture of MeCN: H2O was added and the reaction mixture was refluxed for 16 h 
under inert atmosphere. Ice cold water (30 mL) was then added to the reaction mixture followed 
by a saturated solution of aqueous NH4PF6 (20 mL) which resulted in the formation of pale green 
precipitate which was filtered, washed with ice cold water (400 mL) and dried under reduced 
pressure to give title complex as a dark red solid (243 mg, 56%): Mp = 191 oC (decomp); 1H 
NMR (400MHz C3D6O) δ 9.22(d, 2H, J = 5.6 Hz), 9.11(d, 2H, J = 5.6 Hz), 8.18-8.08(m, 4H), 
7.76(t, 2H, J = 7.2 Hz), 7.52(t, 2H, J = 6.4 Hz), 7.41(t, 2H, J = 6.4 Hz), 7.26(d, 2H, J = 8.0 Hz), 
6.97(s, 1H), 4.89(m, 4H), 2.93(s, 3H); IR (KBr) νmax (cm-1) 3692, 3420, 3224, 3113, 3082, 2919, 
2851, 2275, 1991, 1708, 1604, 1564, 1463, 1447, 1358, 1336, 1308, 1289, 1262, 1238, 1199, 
1160, 1076, 1053, 1026, 970, 931, 907, 822, 765, 750, 740, 722, 653, 644, 620, 581, 556, 532, 
514, 426, 373, 353, 337, 331, 313. ESMS calculated for C25H24F6N6PRu (M+1) 655.07, found 
655.00; UV-vis λmax = 355 nm (ε = 11,900 M-1cm-1) 425 nm (ε = 9,880 M-1cm-1). 
Synthesis of [Ru(TQA)(MeCN)2](PF6)2 (91) - TQA (110 mg, 0.25 mmol), which was 
prepared by a known procedure227 was dissolved in dry MeOH (28 mL) under inert atmosphere 
in a pressure flask. To this Ru(DMSO)4Cl2 (121 mg, 0.25 mmol) was added and the solution was 
purged with Ar for 10 min at room temperature. The reaction mixture was refluxed for 5 h under 
inert temperature. Color of the reaction mixture changes from pale yellow to dark red. The 
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reaction mixture was cooled to room temperature and concentrated under reduced pressure. To 
the flask a 1:1 mixture of MeCN: H2O was added and the reaction mixture was refluxed for 16 h 
under inert atmosphere. Ice cold water (20 mL) was then added to the reaction mixture followed 
by a saturated solution of aqueous NH4PF6 (15 mL), which resulted in the formation of pale 
yellow precipitate which was filtered, washed with ice cold water (300 mL) and dried under 
reduced pressure to give title complex as a dark red solid (170 mg, 75%) Crystals for X-ray 
crystallographic analysis were obtained by diffusing Et2O into a solution of 91 in acetone: Mp = 
187 oC (decomp); 1H NMR (600MHz C3D6O) δ 9.26(d, 1H, J = 6.6 Hz), 8.86(d, 2H, J = 6.0 Hz), 
8.25(d, 2H, J = 8.4 Hz), 8.04(d, 2H, J = 7.2 Hz), 7.90-7.82(m, 8H), 7.69(d, 1H, J = 9.0 Hz), 
7.65(t, 1H, J = 7.8 Hz), 7.50(t, 1H, J = 7.8 Hz), 6.40(d, 2H, J = 15.6 Hz), 5.88-5.86(m, 4H), 
3.02(s, 3H), 2.42(s, 3H); IR (KBr) νmax (cm-1) 3665, 3590, 3423, 3222, 3065, 3007, 2942, 2275, 
1922, 1707, 1626, 1596, 1556, 1509, 1456, 1430, 1398, 1378, 1321, 1271, 1239, 1202, 1167, 
1149, 1098, 1081, 1036, 986, 952, 817, 748, 664, 556, 417, 391, 353, 337, 313. ESMS calculated 
for C34H30F6N6PRu (M+1) 769.12, found 769.00; UV-vis λmax = 424 nm (ε = 12,000 M-1cm-1); 
Anal. Calculated for C34H31F12N6O0.5P2Ru: (91·0.5 H2O) C, 44.26; H, 3.39; N, 9.11. Found: C, 
44.16; H, 3.40; N, 9.16. 
 
6.3.5 Synthesis of secondary amine (94) for TQA ligand 
 
Scheme 17: Synthesis of secondary amine (94) for the synthesis of TQA ligand  
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Compound 92282 (1.8 g, 10.2 mmol) was dissolved in DMF (12 mL) and to the flask 
benzene sulfonamide (0.8 g, 5.1 mmol) and K2CO3 (1.7 g, 12.2 mmol) were added and the 
reaction mixture was heated to 50 0C for 16 h. A white precipitate formed in the reaction mixture, 
which was cooled to RT and then dumped in 10% NaCl (30 mL) solution. The solid was then 
filtered, washed with water (30 mL), EtOAc (20 mL) and dried under reduced pressure to get 93 
as a white solid (1.8 g, 94%), which was characterized by NMR. 1H NMR (600MHz CD6O3) δ 
8.30 (d, 2H, J = 8.4 Hz), 8.04 (d, 2H, J = 5.4 Hz), 7.96 (d, 2H, J = 7.2 Hz), 7.79 (d, 2H, J = 8.4 
Hz), 7.69 (t, 1H, J  = 7.8 Hz), 7.64 (t, 2H, J  = 6.6 Hz), 7.59(t, 2H, J  = 8.4 Hz), 7.48(d, 2H, J  = 
6.0 Hz), 7.44(t, 2H, J  = 7.2 Hz), 5.14 (s, 4H), 13 C NMR (600MHz CD6O3) 154.8, 141.2, 136.0, 
132.6, 129.8 128.8, 127.8, 127.0, 126.8, 126.6, 125.0, 120.3, 52.2. 
Compound 93 (1.8 g, 4.8 mmol) was then dissolved in conc H2SO4 (30 mL) and heated to 
120 oC for 2 h under inert atmosphere. The reaction mixture was then cooled and pH was 
adjusted to 11. The amine was then extracted with DCM (3 × 20 mL), dried with Na2SO4 and 
concentrated to get secondary amine 94 as green oil (1.1 g, 78%): 1H NMR (600MHz CDCl3) δ 
8.45 (d, 2H, J = 6.0 Hz), 8.22 (d, 2H, J = 8.4 Hz), 7.80 (d, 2H, J = 8.4 Hz), 7.65 (t, 2H, J =7.8 
Hz), 7.56 (t, 2H, J  = 7.5 Hz), 7.53 (d, 2H, J  = 6.0 Hz), 4.61 (s, 4H), 13 C NMR (600MHz 
CDCl3) 158.4, 141.7, 136.1, 129.9, 127.3, 127.2, 126.7, 124.8, 120.0, 52.4. HRMS calculated for  
(M+H)+ 300.1501, found 300.1508. 
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6.3.6 X-ray crystallographic analysis of 89  
Table 12: Sample and crystal data for [RuII(DPAbpy)(MeCN)](PF6)2. (89) 
Identification code rs350 
Chemical formula C28H35F13N6O3P2Ru 
Formula weight 913.63 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 8.819(3) Å α = 72.241(13)° 
 b = 13.035(5) Å β = 83.765(15)° 
 c = 17.450(7) Å γ = 77.201(15)° 
Volume 1861.1(12) Å3  
Z 2 
Density (calculated) 1.630 g/cm3 
Absorption coefficient 0.611 mm-1 
F(000) 920 
_______________________________________________________________________ 
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Table 13. Data collection and structure refinement  
Theta range for data collection 1.23 to 23.57° 
Index ranges -9<=h<=9, -14<=k<=14, -19<=l<=19 
Reflections collected 18648 
Independent reflections 5276 [R(int) = 0.1206] 
Coverage of independent reflections 95.3% 
Absorption correction multi-scan 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2013 (Sheldrick, 2013) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 5276 / 0 / 483 
Goodness-of-fit on F2 1.071 
Final R indices 3014 data; I>2σ(I) R1 = 0.1116, wR2 = 0.2732 
 all data R1 = 0.1801, wR2 = 0.3116 
Weighting scheme 
w=1/[σ2(Fo2)+(0.1395P)2+20.0036P]  
where P=(Fo2+2Fc2)/3 
Extinction coefficient 0.0076(17) 
Largest diff. peak and hole 1.972 and -1.544 eÅ-3 
R.M.S. deviation from mean 0.179 eÅ-3 
_______________________________________________________________________ 
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Table 14. Atomic coordinates and equivalent isotropic atomic displacement parameters 
(oA2) U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
 
 x/a y/b z/c U(eq) 
Ru1 0.92632(18) 0.77245(9) 0.75269(7) 0.0413(6) 
P1 0.1309(6) 0.7521(3) 0.4314(3) 0.0548(15) 
P2 0.7412(6) 0.8805(3) 0.1070(3) 0.0538(15) 
O4 0.6248(16) 0.7733(10) 0.5144(8) 0.070(4) 
F2 0.0221(16) 0.8376(13) 0.4704(12) 0.145(7) 
F3 0.0301(17) 0.7960(8) 0.3556(8) 0.107(5) 
F4 0.2346(13) 0.8401(7) 0.3926(6) 0.066(3) 
F5 0.2385(14) 0.6655(8) 0.3944(7) 0.087(4) 
F6 0.0266(17) 0.6647(10) 0.4691(7) 0.094(4) 
F7 0.2267(19) 0.7097(11) 0.5094(6) 0.116(5) 
F8 0.9058(15) 0.8360(12) 0.0752(7) 0.115(5) 
F9 0.8059(14) 0.8225(7) 0.1950(5) 0.074(3) 
F10 0.6943(15) 0.7688(8) 0.1074(9) 0.106(5) 
F11 0.7878(13) 0.9913(8) 0.1075(6) 0.067(3) 
F12 0.6831(14) 0.9376(8) 0.0197(6) 0.081(4) 
F13 0.5762(14) 0.9201(8) 0.1453(8) 0.098(5) 
N3 0.0278(14) 0.6699(9) 0.8485(6) 0.032(3) 
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 x/a y/b z/c U(eq) 
N4 0.9667(16) 0.6299(9) 0.7201(7) 0.045(4) 
O3 0.3392(16) 0.5975(8) 0.1271(6) 0.066(4) 
N1 0.7154(14) 0.7535(8) 0.8129(6) 0.028(3) 
N2 0.9099(17) 0.8858(10) 0.8170(7) 0.045(4) 
C11B 0.0778(19) 0.5618(11) 0.8502(8) 0.038(4) 
C17B 0.0411(18) 0.5364(11) 0.7776(8) 0.036(4) 
N5 0.1279(15) 0.8178(9) 0.7123(7) 0.040(3) 
N6 0.8283(16) 0.8767(9) 0.6485(7) 0.042(4) 
C1 0.627(4) 0.6088(17) 0.4906(19) 0.143(13) 
C2 0.626(2) 0.7208(14) 0.4669(12) 0.066(6) 
C3 0.639(2) 0.6712(11) 0.8278(9) 0.039(4) 
C4 0.510(2) 0.6586(11) 0.8817(9) 0.047(5) 
C5 0.461(2) 0.7368(12) 0.9239(9) 0.049(5) 
C6 0.5358(19) 0.8246(11) 0.9078(9) 0.038(4) 
C7 0.6618(19) 0.8349(10) 0.8521(8) 0.035(4) 
C8 0.7433(17) 0.9290(10) 0.8270(9) 0.035(4) 
C9 0.987(2) 0.8273(12) 0.8964(9) 0.051(5) 
C10 0.0502(17) 0.7076(11) 0.9085(7) 0.030(3) 
C11 0.162(2) 0.4891(12) 0.9147(9) 0.047(4) 
C12 0.182(2) 0.5291(13) 0.9780(9) 0.050(5) 
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 x/a y/b z/c U(eq) 
C13 0.123(2) 0.6366(12) 0.9763(9) 0.047(4) 
C14 0.925(2) 0.6108(12) 0.6533(9) 0.049(5) 
C15 0.953(2) 0.5080(12) 0.6424(10) 0.058(5) 
C16 0.020(2) 0.4188(12) 0.7006(9) 0.052(5) 
C17 0.063(2) 0.4344(12) 0.7687(9) 0.046(4) 
C18 0.995(2) 0.9720(13) 0.7666(9) 0.048(5) 
C19 0.143(2) 0.9097(16) 0.7347(10) 0.061(6) 
C20 0.254(2) 0.7666(13) 0.6805(9) 0.046(4) 
C21 0.396(3) 0.8041(16) 0.6670(9) 0.068(6) 
C22 0.413(3) 0.8963(19) 0.6879(10) 0.083(7) 
C23 0.277(3) 0.9509(16) 0.7206(9) 0.060(5) 
C24 0.787(2) 0.9320(12) 0.5889(9) 0.042(4) 
C25 0.737(2) 0.0001(12) 0.5078(8) 0.051(5) 
C26 0.278(3) 0.7609(15) 0.1668(14) 0.086(7) 
C27 0.359(2) 0.6461(12) 0.1725(9) 0.047(4) 
C28 0.471(3) 0.5916(17) 0.2395(11) 0.084(7) 
C2B 0.617(3) 0.775(2) 0.3785(13) 0.104(8) 
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Table 15. Bond lengths (oA2)  
 
Ru1-N3 1.954(11) Ru1-N5 1.986(14) 
Ru1-N4 2.052(11) Ru1-N6 2.052(11) 
Ru1-N1 2.060(12) Ru1-N2 2.085(12) 
P1-F5 1.559(11) P1-F3 1.562(11) 
P1-F6 1.566(13) P1-F7 1.567(11) 
P1-F2 1.571(11) P1-F4 1.571(12) 
P2-F8 1.550(12) P2-F12 1.563(9) 
P2-F13 1.580(12) P2-F11 1.589(10) 
P2-F9 1.595(9) P2-F10 1.597(11) 
O4-C2 1.22(2) N3-C10 1.334(17) 
N3-C11B 1.371(17) N4-C14 1.368(18) 
N4-C17B 1.401(16) O3-C27 1.203(17) 
N1-C3 1.339(19) N1-C7 1.403(16) 
N2-C8 1.464(19) N2-C18 1.49(2) 
N2-C9 1.515(17) C11B-C11 1.391(19) 
C11B-C17B 1.488(19) C17B-C17 1.35(2) 
N5-C20 1.327(19) N5-C19 1.40(2) 
N6-C24 1.116(17) C1-C2 1.39(3) 
C1-H4 0.98 C1-H1 0.98 
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C1-H3 0.98 C2-C2B 1.49(3) 
C3-C4 1.39(2) C3-H6 0.95 
C4-C5 1.40(2) C4-H26 0.95 
C5-C6 1.39(2) C5-H7 0.95 
C6-C7 1.40(2) C6-H8 0.95 
C7-C8 1.49(2) C8-H25 0.99 
C8-H24 0.99 C9-C10 1.493(19) 
C9-H9 0.99 C9-H17 0.99 
C10-C13 1.379(18) C11-C12 1.40(2) 
C11-H10 0.95 C12-C13 1.37(2) 
C12-H12 0.95 C13-H11 0.95 
C14-C15 1.38(2) C14-H13 0.95 
C15-C16 1.35(2) C15-H16 0.95 
C16-C17 1.37(2) C16-H15 0.95 
C17-H14 0.95 C18-C19 1.52(3) 
C18-H22 0.99 C18-H23 0.99 
C19-C23 1.37(3) C20-C21 1.41(3) 
C20-H21 0.95 C21-C22 1.40(3) 
C21-H20 0.95 C22-C23 1.41(3) 
C22-H19 0.95 C23-H18 0.95 
C24-C25 1.475(19) C25-H29 0.98 
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C25-H27 0.98 C25-H28 0.98 
C26-C27 1.49(2) C26-H30 0.98 
C26-H33 0.98 C26-H34 0.98 
C27-C28 1.51(2) C28-H31 0.98 
C28-H32 0.98 C28-H35 0.98 
C2B-H2B1 0.98 C2B-H2B2 0.98 
C2B-H2B3 0.98   
 
 
Table 16. Bond angles (o)  
 
N3-Ru1-N5 89.2(5) N3-Ru1-N4 80.3(4) 
N5-Ru1-N4 98.3(5) N3-Ru1-N6 177.1(5) 
N5-Ru1-N6 89.1(5) N4-Ru1-N6 97.6(4) 
N3-Ru1-N1 88.1(4) N5-Ru1-N1 164.6(4) 
N4-Ru1-N1 96.1(5) N6-Ru1-N1 94.2(5) 
N3-Ru1-N2 83.1(4) N5-Ru1-N2 83.0(5) 
N4-Ru1-N2 163.4(4) N6-Ru1-N2 98.9(4) 
N1-Ru1-N2 81.6(5) F5-P1-F3 90.5(7) 
F5-P1-F6 87.4(7) F3-P1-F6 88.9(7) 
F5-P1-F7 91.4(8) F3-P1-F7 177.9(9) 
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F6-P1-F7 90.4(7) F5-P1-F2 178.9(9) 
F3-P1-F2 90.2(9) F6-P1-F2 91.8(8) 
F7-P1-F2 87.9(9) F5-P1-F4 92.4(6) 
F3-P1-F4 90.4(6) F6-P1-F4 179.2(6) 
F7-P1-F4 90.4(7) F2-P1-F4 88.4(7) 
F8-P2-F12 92.2(7) F8-P2-F13 176.0(7) 
F12-P2-F13 91.7(7) F8-P2-F11 92.4(8) 
F12-P2-F11 89.6(5) F13-P2-F11 88.6(7) 
F8-P2-F9 86.2(6) F12-P2-F9 178.2(8) 
F13-P2-F9 89.9(7) F11-P2-F9 89.7(5) 
F8-P2-F10 87.8(8) F12-P2-F10 91.0(6) 
F13-P2-F10 91.1(8) F11-P2-F10 179.4(7) 
F9-P2-F10 89.8(6) C10-N3-C11B 122.5(11) 
C10-N3-Ru1 119.2(9) C11B-N3-Ru1 118.3(9) 
C14-N4-C17B 115.1(12) C14-N4-Ru1 130.1(9) 
C17B-N4-Ru1 114.7(9) C3-N1-C7 118.3(13) 
C3-N1-Ru1 130.3(10) C7-N1-Ru1 110.7(10) 
C8-N2-C18 112.5(11) C8-N2-C9 113.0(12) 
C18-N2-C9 110.5(13) C8-N2-Ru1 105.8(9) 
C18-N2-Ru1 106.2(8) C9-N2-Ru1 108.5(8) 
N3-C11B-C11 119.4(13) N3-C11B-C17B 114.2(11) 
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C11-C11B-C17B 126.4(13) C17-C17B-N4 122.0(13) 
C17-C17B-C11B 125.3(12) N4-C17B-C11B 112.5(12) 
C20-N5-C19 116.7(16) C20-N5-Ru1 130.5(12) 
C19-N5-Ru1 111.8(12) C24-N6-Ru1 174.4(14) 
C2-C1-H4 109.5 C2-C1-H1 109.5 
H4-C1-H1 109.5 C2-C1-H3 109.5 
H4-C1-H3 109.5 H1-C1-H3 109.5 
O4-C2-C1 123.(2) O4-C2-C2B 121.6(17) 
C1-C2-C2B 115.(2) N1-C3-C4 124.5(13) 
N1-C3-H6 117.7 C4-C3-H6 117.7 
C3-C4-C5 117.3(16) C3-C4-H26 121.3 
C5-C4-H26 121.3 C6-C5-C4 119.2(17) 
C6-C5-H7 120.4 C4-C5-H7 120.4 
C5-C6-C7 121.3(14) C5-C6-H8 119.3 
C7-C6-H8 119.3 C6-C7-N1 119.2(14) 
C6-C7-C8 125.4(13) N1-C7-C8 115.4(14) 
N2-C8-C7 108.2(11) N2-C8-H25 110.1 
C7-C8-H25 110.1 N2-C8-H24 110.1 
C7-C8-H24 110.1 H25-C8-H24 108.4 
C10-C9-N2 114.1(11) C10-C9-H9 108.7 
N2-C9-H9 108.7 C10-C9-H17 108.7 
  
	
166 
N2-C9-H17 108.7 H9-C9-H17 107.6 
N3-C10-C13 120.0(13) N3-C10-C9 115.0(11) 
C13-C10-C9 125.0(13) C11B-C11-C12 117.5(14) 
C11B-C11-H10 121.2 C12-C11-H10 121.2 
C13-C12-C11 121.4(14) C13-C12-H12 119.3 
C11-C12-H12 119.3 C12-C13-C10 118.9(14) 
C12-C13-H11 120.5 C10-C13-H11 120.5 
N4-C14-C15 122.9(13) N4-C14-H13 118.5 
C15-C14-H13 118.5 C16-C15-C14 120.4(15) 
C16-C15-H16 119.8 C14-C15-H16 119.8 
C15-C16-C17 118.3(14) C15-C16-H15 120.8 
C17-C16-H15 120.8 C17B-C17-C16 121.1(14) 
C17B-C17-H14 119.4 C16-C17-H14 119.4 
N2-C18-C19 105.4(13) N2-C18-H22 110.7 
C19-C18-H22 110.7 N2-C18-H23 110.7 
C19-C18-H23 110.7 H22-C18-H23 108.8 
C23-C19-N5 123.1(19) C23-C19-C18 120.0(17) 
N5-C19-C18 116.4(15) N5-C20-C21 122.1(16) 
N5-C20-H21 119.0 C21-C20-H21 119.0 
C22-C21-C20 122.(2) C22-C21-H20 118.9 
C20-C21-H20 118.9 C21-C22-C23 115.(2) 
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C21-C22-H19 122.5 C23-C22-H19 122.5 
C19-C23-C22 121.(2) C19-C23-H18 119.6 
C22-C23-H18 119.6 N6-C24-C25 176.5(15) 
C24-C25-H29 109.5 C24-C25-H27 109.5 
H29-C25-H27 109.5 C24-C25-H28 109.5 
H29-C25-H28 109.5 H27-C25-H28 109.5 
C27-C26-H30 109.5 C27-C26-H33 109.5 
H30-C26-H33 109.5 C27-C26-H34 109.5 
H30-C26-H34 109.5 H33-C26-H34 109.5 
O3-C27-C26 123.1(16) O3-C27-C28 120.5(14) 
C26-C27-C28 116.4(15) C27-C28-H31 109.5 
C27-C28-H32 109.5 H31-C28-H32 109.5 
C27-C28-H35 109.5 H31-C28-H35 109.5 
H32-C28-H35 109.5 C2-C2B-H2B1 109.5 
C2-C2B-H2B2 109.5 H2B1-C2B-H2B2 109.5 
C2-C2B-H2B3 109.5 H2B1-C2B-H2B3 109.5 
H2B2-C2B-H2B3 109.5   
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Table 17. Anisotropic atomic displacement parameters (oA2)  
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k 
a* b* U12 ] 
 
 U11 U22 U33 U23 U13 U12 
Ru1 0.0735(12) 0.0293(7) 0.0225(7) -0.0119(5) -0.0260(6) 0.0047(6) 
P1 0.085(4) 0.044(2) 0.041(2) -0.023(2) -0.022(3) 0.000(3) 
P2 0.081(4) 0.040(2) 0.045(2) -0.0234(19) -0.029(3) 0.008(2) 
O4 0.087(11) 0.067(8) 0.077(9) -0.053(7) 0.010(8) -0.020(7) 
F2 0.077(10) 0.163(13) 0.27(2) -0.192(15) 0.028(11) -0.020(9) 
F3 0.155(13) 0.055(6) 0.119(10) -0.005(6) -0.101(10) -0.018(7) 
F4 0.081(8) 0.045(5) 0.077(7) -0.027(5) -0.021(6) -0.001(5) 
F5 0.096(10) 0.057(6) 0.103(9) -0.037(6) 0.008(7) 0.006(6) 
F6 0.148(12) 0.102(9) 0.067(7) -0.054(7) 0.014(8) -0.064(9) 
F7 0.174(14) 0.134(11) 0.050(7) -0.002(7) -0.057(8) -0.060(10) 
F8 0.084(10) 0.167(13) 0.066(8) -0.040(8) -0.018(7) 0.050(9) 
F9 0.115(9) 0.048(5) 0.043(5) -0.011(4) -0.027(6) 0.023(6) 
F10 0.114(11) 0.035(5) 0.177(13) -0.027(7) -0.103(10) 0.013(6) 
F11 0.092(8) 0.064(6) 0.062(6) -0.016(5) -0.035(6) -0.038(6) 
F12 0.131(10) 0.061(6) 0.056(6) -0.024(5) -0.062(7) 0.011(6) 
F13 0.075(9) 0.045(6) 0.132(11) 0.010(6) 0.008(8) 0.018(6) 
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 U11 U22 U33 U23 U13 U12 
N3 0.031(8) 0.044(7) 0.025(6) -0.016(5) 0.001(5) -0.006(6) 
N4 0.070(10) 0.033(6) 0.025(6) -0.008(5) -0.025(6) 0.013(6) 
O3 0.117(11) 0.039(6) 0.048(7) -0.020(5) -0.053(7) 0.008(6) 
N1 0.042(8) 0.028(6) 0.015(5) -0.012(4) -0.007(5) 0.005(6) 
N2 0.066(11) 0.044(7) 0.021(6) -0.013(5) -0.009(6) 0.006(7) 
C11B 0.055(11) 0.035(8) 0.028(7) -0.015(6) -0.009(7) -0.003(8) 
C17B 0.045(11) 0.033(8) 0.024(7) -0.005(6) -0.007(7) 0.006(7) 
N6 0.069(10) 0.040(7) 0.022(6) -0.015(6) -0.028(7) 0.005(7) 
C1 0.16(3) 0.055(14) 0.21(3) -0.001(17) -0.10(3) -0.024(16) 
C2 0.082(16) 0.040(10) 0.082(14) -0.027(10) -0.002(12) -0.010(10) 
C3 0.064(13) 0.020(7) 0.035(8) -0.007(6) -0.036(9) 0.000(8) 
C4 0.084(15) 0.029(8) 0.029(8) 0.000(6) -0.021(9) -0.016(8) 
C5 0.058(12) 0.049(10) 0.039(9) -0.024(7) -0.011(8) 0.013(9) 
C6 0.049(12) 0.025(8) 0.042(9) -0.008(6) -0.032(9) 0.002(7) 
C7 0.050(11) 0.026(7) 0.027(8) -0.006(6) -0.022(8) 0.002(7) 
C8 0.032(10) 0.026(7) 0.056(9) -0.015(7) -0.016(8) -0.012(7) 
C9 0.076(14) 0.049(9) 0.031(8) -0.021(7) -0.015(8) -0.001(9) 
C10 0.030(9) 0.039(8) 0.019(7) 0.000(6) -0.016(6) -0.008(7) 
C11 0.063(13) 0.042(9) 0.036(9) -0.006(7) -0.013(8) -0.010(8) 
C12 0.058(13) 0.049(10) 0.038(9) 0.001(7) -0.022(8) -0.012(9) 
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 U11 U22 U33 U23 U13 U12 
C13 0.063(13) 0.050(10) 0.039(9) -0.007(7) -0.012(8) -0.035(9) 
C14 0.072(13) 0.037(8) 0.040(9) -0.018(7) -0.028(9) 0.004(8) 
C15 0.093(16) 0.033(8) 0.050(10) -0.019(7) -0.023(10) 0.005(9) 
C16 0.078(14) 0.033(8) 0.047(10) -0.022(7) -0.013(9) 0.004(9) 
C17 0.063(13) 0.031(8) 0.038(9) -0.004(7) -0.003(8) -0.003(8) 
C18 0.068(14) 0.047(9) 0.039(9) -0.017(8) -0.021(9) -0.018(9) 
C19 0.056(14) 0.079(13) 0.052(11) 0.004(9) -0.040(10) -0.038(12) 
C21 0.097(18) 0.072(12) 0.021(8) -0.002(8) -0.024(9) 0.009(12) 
C22 0.092(18) 0.102(17) 0.036(10) 0.009(11) -0.050(11) 0.002(14) 
C23 0.076(16) 0.083(13) 0.030(9) -0.028(9) -0.006(9) -0.013(12) 
C24 0.054(12) 0.039(8) 0.046(10) -0.030(8) -0.016(9) -0.006(8) 
C25 0.082(14) 0.041(8) 0.029(8) -0.012(7) -0.039(9) 0.009(9) 
C26 0.100(19) 0.054(11) 0.111(18) -0.039(12) 0.004(14) -0.009(12) 
C27 0.064(13) 0.039(8) 0.044(9) -0.022(7) -0.015(9) -0.007(8) 
C28 0.12(2) 0.094(15) 0.053(11) -0.041(11) -0.031(12) -0.016(14) 
C2B 0.13(2) 0.13(2) 0.067(15) -0.031(14) 0.000(15) -0.051(18) 
_______________________________________________________________________ 
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Table 18.  Hydrogen coordinates and isotropic atomic displacement parameters (Å2). 
_______________________________________________________________________ 
 x/a y/b z/c U(eq) 
H4 0.7351 0.5679 0.4959 0.215 
H1 0.5779 0.5906 0.4500 0.215 
H3 0.5699 0.5888 0.5425 0.215 
H6 0.6737 0.6176 0.7997 0.046 
H26 0.4586 0.5993 0.8895 0.057 
H7 0.3775 0.7298 0.9631 0.059 
H8 0.5005 0.8789 0.9352 0.046 
H25 0.7033 0.9811 0.7756 0.042 
H24 0.7251 0.9685 0.8684 0.042 
H9 1.0734 0.8631 0.8994 0.061 
H17 0.9105 0.8362 0.9409 0.061 
H10 1.2040 0.4150 0.9158 0.057 
H12 1.2382 0.4810 1.0231 0.059 
H11 1.1324 0.6616 1.0210 0.057 
H13 0.8733 0.6714 0.6125 0.058 
H16 0.9264 0.4995 0.5938 0.07 
H15 1.0369 0.3472 0.6943 0.063 
H14 1.1084 0.3727 0.8104 0.056 
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 x/a y/b z/c U(eq) 
H22 1.0210 1.0154 0.7994 0.058 
H23 0.9317 1.0225 0.7216 0.058 
H21 1.2495 0.7026 0.6664 0.056 
H20 1.4825 0.7655 0.6429 0.082 
H19 1.5089 0.9204 0.6806 0.1 
H18 1.2777 1.0168 0.7329 0.072 
H29 0.8140 1.0454 0.4820 0.076 
H27 0.6357 1.0479 0.5123 0.076 
H28 0.7285 0.9524 0.4753 0.076 
H30 0.1931 0.7825 0.1294 0.13 
H33 0.3514 0.8104 0.1470 0.13 
H34 0.2344 0.7653 0.2201 0.13 
H31 0.4137 0.5832 0.2916 0.126 
H32 0.5482 0.6371 0.2353 0.126 
H35 0.5243 0.5191 0.2349 0.126 
H2B1 0.5788 0.8542 0.3685 0.155 
H2B2 0.5462 0.7444 0.3562 0.155 
H2B3 0.7211 0.7618 0.3525 0.155 
_______________________________________________________________________ 
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6.3.7 X-ray crystallographic analysis of 91  
Table 19. Sample and crystal data for [RuII(TQA)(MeCN)2](PF6)2. (91) 
Identification code rs337    
Chemical formula C22H27F6N3O2PRu0.50    
Formula weight 572.98    
Temperature 100(2) K    
Wavelength 0.71073 Å    
Crystal size 
Crystal system 
0.302 x 0.442 x 0.708 mm 
triclinic 
 
  
Space group P -1    
Unit cell dimensions a = 12.0377(11) Å α = 91.125(5)°    
 b = 14.0264(13) Å β = 90.825(5)°    
 c = 16.2856(16) Å γ = 113.890(4)°    
Volume 2512.9(4) Å3     
Z 4    
Density (calculated) 1.514 g/cm3    
Absorption coefficient 
F(000) 
 
0.469 mm-1 
1172 
 
 
  
_____________________________________________________________________ 
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Table 20. Data collection and structure refinement  
Theta range for data collection 1.25 to 35.66° 
Index ranges -18<=h<=19, -22<=k<=22, -26<=l<=26 
Reflections collected 121269 
Independent reflections 23019 [R(int) = 0.0695] 
Max. and min. transmission 0.8710 and 0.7330 
Absorption correction multi-scan 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2013 (Sheldrick, 2013) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 23019 / 4 / 653 
Goodness-of-fit on F2 0.916 
Final R indices 18642 data; I>2σ(I) R1 = 0.0385, wR2 = 0.0999 
 all data R1 = 0.0510, wR2 = 0.1054 
Weighting scheme 
w=1/[σ2(Fo2)+(0.0647P)2+0.7003P]  
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 1.779 and -1.007 eÅ-3 
R.M.S. deviation from mean 0.092 eÅ-3 
_______________________________________________________________________ 
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Table 21. Atomic coordinates and equivalent isotropic atomic displacement parameters 
(oA2)  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
 
 x/a y/b z/c U(eq) 
C1R 0.89797(11) 0.02036(10) 0.88758(8) 0.0146(2) 
Ru1 0.84333(2) 0.74608(2) 0.74645(2) 0.01102(3) 
N2 0.71452(9) 0.62034(8) 0.68304(7) 0.01360(18) 
P2 0.0 0.5 0.0 0.02257(10) 
P3 0.40262(3) 0.94040(3) 0.77823(2) 0.02251(7) 
P4 0.0 0.5 0.5 0.02738(12) 
N4 0.93183(9) 0.88462(8) 0.81235(6) 0.01314(18) 
F1 0.27282(9) 0.88622(8) 0.73211(6) 0.0311(2) 
F2 0.12186(12) 0.60359(10) 0.00258(10) 0.0575(4) 
F3 0.13674(11) 0.56013(10) 0.47228(9) 0.0530(4) 
F4 0.38419(11) 0.04658(9) 0.78632(8) 0.0402(3) 
F5 0.53202(9) 0.99375(9) 0.82541(7) 0.0370(2) 
F6 0.33779(10) 0.90357(10) 0.86389(7) 0.0400(3) 
F7 0.94677(13) 0.54733(11) 0.92919(7) 0.0493(3) 
F8 0.42150(10) 0.83323(8) 0.76933(7) 0.0350(2) 
F9 0.95786(13) 0.46352(11) 0.40702(7) 0.0505(3) 
F10 0.05788(11) 0.44965(9) 0.93254(7) 0.0362(2) 
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F11 0.46651(10) 0.97495(9) 0.69209(7) 0.0378(2) 
F12 0.97588(11) 0.60281(9) 0.48825(9) 0.0488(3) 
O1 0.15567(15) 0.86795(12) 0.29928(12) 0.0536(4) 
O2 0.46163(12) 0.76937(11) 0.55022(9) 0.0377(3) 
O3 0.38894(14) 0.24063(14) 0.99355(10) 0.0484(4) 
N1 0.97765(10) 0.69264(8) 0.75360(7) 0.01478(18) 
N6 0.77973(10) 0.67193(8) 0.85277(7) 0.01521(19) 
C00 0.41939(13) 0.37880(11) 0.56177(9) 0.0225(3) 
C01 0.85695(11) 0.92796(9) 0.83781(7) 0.0133(2) 
C02 0.81997(12) 0.88737(10) 0.52262(8) 0.0157(2) 
C03 0.91005(12) 0.87812(10) 0.47197(8) 0.0173(2) 
C04 0.72333(11) 0.86768(10) 0.81498(8) 0.0157(2) 
C05 0.59202(11) 0.70872(10) 0.73364(8) 0.0164(2) 
C06 0.73613(13) 0.92463(11) 0.48861(9) 0.0214(3) 
C07 0.63929(13) 0.46268(10) 0.60087(9) 0.0196(2) 
C08 0.1364(2) 0.78328(16) 0.26870(14) 0.0403(4) 
C09 0.06772(13) 0.15964(10) 0.96099(9) 0.0195(2) 
C0E 0.72659(12) 0.86803(10) 0.66416(8) 0.0165(2) 
C0M 0.69216(15) 0.56411(13) 0.98184(10) 0.0273(3) 
C0F 0.73224(12) 0.54235(10) 0.64072(8) 0.0167(2) 
C0Q 0.81467(11) 0.85499(9) 0.60509(8) 0.0136(2) 
  
	
177 
C0O 0.50197(11) 0.54238(10) 0.64339(8) 0.0149(2) 
C0N 0.86389(14) 0.15324(11) 0.96742(9) 0.0227(3) 
C0I 0.81901(13) 0.06531(11) 0.91787(9) 0.0194(2) 
C0B 0.91452(14) 0.90578(11) 0.38828(9) 0.0231(3) 
C0H 0.38510(17) 0.79403(15) 0.52015(12) 0.0357(4) 
C0G 0.05173(12) 0.66194(10) 0.76277(8) 0.0166(2) 
C0R 0.98988(12) 0.83776(10) 0.50665(8) 0.0183(2) 
C011 0.05329(11) 0.93206(10) 0.83323(8) 0.0146(2) 
C0J 0.58124(19) 0.30478(15) 0.06161(13) 0.0380(4) 
C0D 0.97662(11) 0.80641(10) 0.58562(8) 0.0161(2) 
C0S 0.02412(11) 0.06840(10) 0.90961(8) 0.0152(2) 
C0K 0.98941(14) 0.20084(11) 0.98922(9) 0.0219(3) 
C0T 0.52002(12) 0.45974(10) 0.60165(8) 0.0171(2) 
C0C 0.10075(11) 0.02173(10) 0.88014(8) 0.0163(2) 
C0L 0.38348(12) 0.54163(11) 0.64437(9) 0.0196(2) 
C0P 0.14637(13) 0.62365(12) 0.77496(10) 0.0231(3) 
C0V 0.48237(16) 0.22910(14) 0.00895(10) 0.0298(3) 
C0A 0.60410(11) 0.62183(9) 0.68332(8) 0.0140(2) 
C2AN 0.74097(12) 0.62443(10) 0.90945(8) 0.0177(2) 
C10E 0.6929(3) 0.6821(2) 0.20338(15) 0.0675(9) 
C11E 0.3976(4) 0.8345(5) 0.4360(3) 0.160(3) 
  
	
178 
C14E 0.2339(3) 0.7583(2) 0.22979(19) 0.0649(7) 
C15E 0.0133(3) 0.6978(2) 0.2657(2) 0.0809(11) 
C55E 0.4719(3) 0.6640(3) 0.20157(17) 0.0749(9) 
C17E 0.4992(2) 0.13563(18) 0.97648(13) 0.0472(5) 
C18E 0.5627(2) 0.61741(16) 0.18346(11) 0.0392(4) 
C19E 0.27234(19) 0.78177(18) 0.56234(15) 0.0455(5) 
N5 0.71088(9) 0.80262(8) 0.73864(6) 0.01228(17) 
N3 0.88878(9) 0.81392(8) 0.63509(6) 0.01279(17) 
O1S 0.52988(14) 0.53087(12) 0.15400(9) 0.0437(3) 
C56E 0.83057(16) 0.93920(12) 0.35704(10) 0.0280(3) 
C57E 0.74118(15) 0.94824(12) 0.40715(10) 0.0269(3) 
C58E 0.28849(13) 0.46209(12) 0.60532(10) 0.0240(3) 
C59E 0.30700(13) 0.38067(11) 0.56363(10) 0.0239(3) 
 
 
Table 22. Bond lengths (oA2)  
 
 
C1R-C01 1.4175(17) C1R-C0I 1.4252(18) 
C1R-C0S 1.4265(17) Ru1-N6 2.0321(12) 
Ru1-N3 2.0418(11) Ru1-N1 2.0420(11) 
  
	
179 
Ru1-N5 2.0516(10) Ru1-N2 2.0612(11) 
Ru1-N4 2.0666(11) N2-C0A 1.3378(16) 
N2-C0F 1.3715(16) P2-F2 1.5919(13) 
P2-F2 1.5920(13) P2-F7 1.5920(11) 
P2-F7 1.5920(11) P2-F10 1.6067(10) 
P2-F10 1.6067(10) P3-F4 1.5953(11) 
P3-F11 1.5970(11) P3-F6 1.5984(11) 
P3-F1 1.6016(11) P3-F5 1.6048(11) 
P3-F8 1.6129(11) P4-F3 1.5927(12) 
P4-F3 1.5927(12) P4-F12 1.5964(11) 
P4-F12 1.5965(11) P4-F9 1.5967(11) 
P4-F9 1.5967(11) N4-C01 1.3412(15) 
N4-C011 1.3729(16) O1-C08 1.209(2) 
O2-C0H 1.208(2) O3-C0V 1.223(2) 
N1-C0G 1.1457(16) N6-C2AN 1.1394(17) 
C00-C59E 1.364(2) C00-C0T 1.4187(19) 
C00-H00 0.95 C01-C04 1.5196(17) 
C02-C03 1.4173(19) C02-C0Q 1.4201(18) 
C02-C06 1.4217(19) C03-C0R 1.414(2) 
C03-C0B 1.4201(19) C04-N5 1.4969(16) 
C04-H04A 0.99 C04-H04B 0.99 
  
	
180 
C05-N5 1.5015(16) C05-C0A 1.5119(17) 
C05-H05A 0.99 C05-H05B 0.99 
C06-C57E 1.370(2) C06-H06 0.95 
C07-C0F 1.3638(19) C07-C0T 1.4198(19) 
C07-H07 0.95 C08-C15E 1.481(3) 
C08-C14E 1.499(3) C09-C0K 1.370(2) 
C09-C0S 1.4193(18) C09-H09 0.95 
C0E-N5 1.5028(17) C0E-C0Q 1.5042(18) 
C0E-H0E1 0.99 C0E-H0E2 0.99 
C0M-C2AN 1.452(2) C0M-H0M1 0.98 
C0M-H0M2 0.98 C0M-H0M3 0.98 
C0F-H0F 0.95 C0Q-N3 1.3345(16) 
C0O-C0A 1.4195(17) C0O-C0L 1.4224(18) 
C0O-C0T 1.4249(18) C0N-C0I 1.3684(19) 
C0N-C0K 1.419(2) C0N-H0N 0.95 
C0I-H0I 0.95 C0B-C56E 1.370(2) 
C0B-H0B 0.95 C0H-C19E 1.479(3) 
C0H-C11E 1.480(4) C0G-C0P 1.4557(18) 
C0R-C0D 1.3581(19) C0R-H0R 0.95 
C011-C0C 1.3637(18) C011-H011 0.95 
C0J-C0V 1.480(3) C0J-H0J1 0.98 
  
	
181 
C0J-H0J2 0.98 C0J-H0J3 0.98 
C0D-N3 1.3746(16) C0D-H0D 0.95 
C0S-C0C 1.4140(18) C0K-H0K 0.95 
C0C-H0C 0.95 C0L-C58E 1.3691(19) 
C0L-H0L 0.95 C0P-H0P1 0.98 
C0P-H0P2 0.98 C0P-H0P3 0.98 
C0V-C17E 1.493(3) C10E-C18E 1.485(3) 
C10E-H10A 0.98 C10E-H10B 0.98 
C10E-H10C 0.98 C11E-H11A 0.98 
C11E-H11B 0.98 C11E-H11C 0.98 
C14E-H14A 0.98 C14E-H14B 0.98 
C14E-H14C 0.98 C15E-H15A 0.98 
C15E-H15B 0.98 C15E-H15C 0.98 
C55E-C18E 1.514(3) C55E-H55A 0.98 
C55E-H55B 0.98 C55E-H55C 0.98 
C17E-H17A 0.98 C17E-H17B 0.98 
C17E-H17C 0.98 C18E-O1S 1.201(2) 
C19E-H19A 0.98 C19E-H19B 0.98 
C19E-H19C 0.98 C56E-C57E 1.404(3) 
C56E-H56E 0.95 C57E-H57E 0.95 
C58E-C59E 1.413(2) C58E-H58E 0.95 
  
	
182 
C59E-H59E 0.95 
 
 
Table 23. Bond angles (o)  
 
C01-C1R-C0I 123.18(11) C01-C1R-C0S 117.77(11) 
C0I-C1R-C0S 119.03(11) N6-Ru1-N3 173.98(4) 
N6-Ru1-N1 87.50(4) N3-Ru1-N1 96.67(4) 
N6-Ru1-N5 93.32(4) N3-Ru1-N5 82.56(4) 
N1-Ru1-N5 178.86(4) N6-Ru1-N2 88.64(4) 
N3-Ru1-N2 86.47(4) N1-Ru1-N2 98.28(4) 
N5-Ru1-N2 82.53(4) N6-Ru1-N4 89.81(4) 
N3-Ru1-N4 93.90(4) N1-Ru1-N4 97.81(4) 
N5-Ru1-N4 81.41(4) N2-Ru1-N4 163.76(4) 
C0A-N2-C0F 119.84(11) C0A-N2-Ru1 112.70(8) 
C0F-N2-Ru1 127.41(9) F2-P2-F2 180.0 
F2-P2-F7 90.36(8) F2-P2-F7 89.64(8) 
F2-P2-F7 89.64(8) F2-P2-F7 90.36(8) 
F7-P2-F7 180.00(9) F2-P2-F10 89.68(7) 
F2-P2-F10 90.32(7) F7-P2-F10 89.57(6) 
F7-P2-F10 90.44(6) F2-P2-F10 90.32(7) 
  
	
183 
F2-P2-F10 89.68(7) F7-P2-F10 90.43(6) 
F7-P2-F10 89.56(6) F10-P2-F10 180.0 
F4-P3-F11 90.45(7) F4-P3-F6 90.49(7) 
F11-P3-F6 178.92(7) F4-P3-F1 89.67(6) 
F11-P3-F1 90.22(6) F6-P3-F1 89.26(6) 
F4-P3-F5 90.61(6) F11-P3-F5 90.44(6) 
F6-P3-F5 90.08(6) F1-P3-F5 179.28(7) 
F4-P3-F8 179.57(7) F11-P3-F8 89.12(6) 
F6-P3-F8 89.94(6) F1-P3-F8 90.23(6) 
F5-P3-F8 89.49(6) F3-P4-F3 180.0 
F3-P4-F12 90.43(7) F3-P4-F12 89.58(7) 
F3-P4-F12 89.57(7) F3-P4-F12 90.42(7) 
F12-P4-F12 180.0 F3-P4-F9 90.35(7) 
F3-P4-F9 89.65(8) F12-P4-F9 90.71(7) 
F12-P4-F9 89.29(7) F3-P4-F9 89.65(8) 
F3-P4-F9 90.34(7) F12-P4-F9 89.29(7) 
F12-P4-F9 90.71(7) F9-P4-F9 180.0 
C01-N4-C011 119.37(11) C01-N4-Ru1 113.20(8) 
C011-N4-Ru1 127.40(8) C0G-N1-Ru1 175.72(11) 
C2AN-N6-Ru1 175.55(11) C59E-C00-C0T 120.04(13) 
C59E-C00-H00 120.0 C0T-C00-H00 120.0 
  
	
184 
N4-C01-C1R 122.37(11) N4-C01-C04 115.74(10) 
C1R-C01-C04 121.75(10) C03-C02-C0Q 118.09(11) 
C03-C02-C06 119.23(12) C0Q-C02-C06 122.63(12) 
C0R-C03-C02 118.08(12) C0R-C03-C0B 122.43(13) 
C02-C03-C0B 119.45(13) N5-C04-C01 109.85(10) 
N5-C04-H04A 109.7 C01-C04-H04A 109.7 
N5-C04-H04B 109.7 C01-C04-H04B 109.7 
H04A-C04-H04B 108.2 N5-C05-C0A 110.51(10) 
N5-C05-H05A 109.5 C0A-C05-H05A 109.5 
N5-C05-H05B 109.5 C0A-C05-H05B 109.5 
H05A-C05-H05B 108.1 C57E-C06-C02 119.79(14) 
C57E-C06-H06 120.1 C02-C06-H06 120.1 
C0F-C07-C0T 119.80(12) C0F-C07-H07 120.1 
C0T-C07-H07 120.1 O1-C08-C15E 121.7(2) 
O1-C08-C14E 122.7(2) C15E-C08-C14E 115.5(2) 
C0K-C09-C0S 120.33(13) C0K-C09-H09 119.8 
C0S-C09-H09 119.8 N5-C0E-C0Q 112.19(10) 
N5-C0E-H0E1 109.2 C0Q-C0E-H0E1 109.2 
N5-C0E-H0E2 109.2 C0Q-C0E-H0E2 109.2 
H0E1-C0E-H0E2 107.9 C2AN-C0M-H0M1 109.5 
C2AN-C0M-H0M2 109.5 H0M1-C0M-H0M2 109.5 
  
	
185 
C2AN-C0M-H0M3 109.5 H0M1-C0M-H0M3 109.5 
H0M2-C0M-H0M3 109.5 C07-C0F-N2 122.10(12) 
C07-C0F-H0F 119.0 N2-C0F-H0F 119.0 
N3-C0Q-C02 122.30(11) N3-C0Q-C0E 116.33(11) 
C02-C0Q-C0E 121.35(11) C0A-C0O-C0L 122.78(12) 
C0A-C0O-C0T 117.95(11) C0L-C0O-C0T 119.27(12) 
C0I-C0N-C0K 120.52(13) C0I-C0N-H0N 119.7 
C0K-C0N-H0N 119.7 C0N-C0I-C1R 120.31(13) 
C0N-C0I-H0I 119.8 C1R-C0I-H0I 119.8 
C56E-C0B-C03 119.77(14) C56E-C0B-H0B 120.1 
C03-C0B-H0B 120.1 O2-C0H-C19E 123.02(19) 
O2-C0H-C11E 120.8(2) C19E-C0H-C11E 116.1(2) 
N1-C0G-C0P 179.50(16) C0D-C0R-C03 119.95(12) 
C0D-C0R-H0R 120.0 C03-C0R-H0R 120.0 
C0C-C011-N4 122.15(11) C0C-C011-H011 118.9 
N4-C011-H011 118.9 C0V-C0J-H0J1 109.5 
C0V-C0J-H0J2 109.5 H0J1-C0J-H0J2 109.5 
C0V-C0J-H0J3 109.5 H0J1-C0J-H0J3 109.5 
H0J2-C0J-H0J3 109.5 C0R-C0D-N3 122.49(12) 
C0R-C0D-H0D 118.8 N3-C0D-H0D 118.8 
C0C-C0S-C09 122.51(12) C0C-C0S-C1R 118.26(11) 
  
	
186 
C09-C0S-C1R 119.22(12) C09-C0K-C0N 120.59(13) 
C09-C0K-H0K 119.7 C0N-C0K-H0K 119.7 
C00-C0T-C07 122.56(12) C00-C0T-C0O 119.19(12) 
C07-C0T-C0O 118.25(12) C011-C0C-C0S 120.06(12) 
C011-C0C-H0C 120.0 C0S-C0C-H0C 120.0 
C58E-C0L-C0O 119.90(13) C58E-C0L-H0L 120.1 
C0O-C0L-H0L 120.1 C0G-C0P-H0P1 109.5 
C0G-C0P-H0P2 109.5 H0P1-C0P-H0P2 109.5 
C0G-C0P-H0P3 109.5 H0P1-C0P-H0P3 109.5 
H0P2-C0P-H0P3 109.5 O3-C0V-C0J 121.88(18) 
O3-C0V-C17E 120.63(19) C0J-C0V-C17E 117.47(16) 
N2-C0A-C0O 122.00(11) N2-C0A-C05 116.26(11) 
C0O-C0A-C05 121.60(11) N6-C2AN-C0M 179.72(15) 
C18E-C10E-H10A 109.5 C18E-C10E-H10B 109.5 
H10A-C10E-H10B 109.5 C18E-C10E-H10C 109.5 
H10A-C10E-H10C 109.5 H10B-C10E-H10C 109.5 
C0H-C11E-H11A 109.5 C0H-C11E-H11B 109.5 
H11A-C11E-H11B 109.5 C0H-C11E-H11C 109.5 
H11A-C11E-H11C 109.5 H11B-C11E-H11C 109.5 
C08-C14E-H14A 109.5 C08-C14E-H14B 109.5 
H14A-C14E-H14B 109.5 C08-C14E-H14C 109.5 
  
	
187 
H14A-C14E-H14C 109.5 H14B-C14E-H14C 109.5 
C08-C15E-H15A 109.5 C08-C15E-H15B 109.5 
H15A-C15E-H15B 109.5 C08-C15E-H15C 109.5 
H15A-C15E-H15C 109.5 H15B-C15E-H15C 109.5 
C18E-C55E-H55A 109.5 C18E-C55E-H55B 109.5 
H55A-C55E-H55B 109.5 C18E-C55E-H55C 109.5 
H55A-C55E-H55C 109.5 H55B-C55E-H55C 109.5 
C0V-C17E-H17A 109.5 C0V-C17E-H17B 109.5 
H17A-C17E-H17B 109.5 C0V-C17E-H17C 109.5 
H17A-C17E-H17C 109.5 H17B-C17E-H17C 109.5 
O1S-C18E-C10E 121.5(2) O1S-C18E-C55E 120.7(2) 
C10E-C18E-C55E 117.8(2) C0H-C19E-H19A 109.5 
C0H-C19E-H19B 109.5 H19A-C19E-H19B 109.5 
C0H-C19E-H19C 109.5 H19A-C19E-H19C 109.5 
H19B-C19E-H19C 109.5 C04-N5-C05 112.21(10) 
C04-N5-C0E 110.00(10) C05-N5-C0E 110.82(10) 
C04-N5-Ru1 106.64(7) C05-N5-Ru1 106.01(7) 
C0E-N5-Ru1 111.02(7) C0Q-N3-C0D 119.02(11) 
C0Q-N3-Ru1 115.49(8) C0D-N3-Ru1 124.76(8) 
C0B-C56E-C57E 120.80(14) C0B-C56E-H56E 119.6 
C57E-C56E-H56E 119.6 C06-C57E-C56E 120.91(15) 
  
	
188 
C06-C57E-H57E 119.5 C56E-C57E-H57E 119.5 
C0L-C58E-C59E 120.61(13) C0L-C58E-H58E 119.7 
C59E-C58E-H58E 119.7 C00-C59E-C58E 120.99(13) 
C00-C59E-H59E 119.5 C58E-C59E-H59E 119.5 
 
 
Table 24. Anisotropic atomic displacement parameters (oA2)  
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... 
+ 2 h k a* b* U12 ] 
 
 U11 U22 U33 U23 U13 U12 
C1R 0.0140(5) 0.0149(5) 0.0147(5) -0.0009(4) -0.0013(4) 0.0057(4) 
Ru1 0.00887(4) 0.01258(4) 0.01167(5) -0.00078(3) -0.00064(3) 0.00450(3) 
N2 0.0120(4) 0.0135(4) 0.0147(5) -0.0011(3) -0.0002(3) 0.0046(4) 
P2 0.0247(2) 0.0219(2) 0.0265(3) 0.00645(19) 0.0061(2) 0.0145(2) 
P3 0.01966(17) 0.02716(18) 0.02462(18) 0.00682(14) 0.00073(14) 0.01326(15) 
P4 0.0216(2) 0.0354(3) 0.0312(3) -0.0175(2) -0.0075(2) 0.0189(2) 
N4 0.0108(4) 0.0152(4) 0.0129(4) -0.0002(3) -0.0007(3) 0.0048(4) 
F1 0.0207(4) 0.0382(5) 0.0336(5) 0.0028(4) -0.0022(4) 0.0113(4) 
F2 0.0399(7) 0.0344(6) 0.0872(11) -0.0022(6) 0.0180(7) 0.0034(5) 
F3 0.0282(6) 0.0511(7) 0.0765(9) -0.0264(7) 0.0087(6) 0.0139(5) 
F4 0.0423(6) 0.0342(5) 0.0530(7) -0.0030(5) -0.0121(5) 0.0253(5) 
  
	
189 
 U11 U22 U33 U23 U13 U12 
F5 0.0253(5) 0.0464(6) 0.0422(6) -0.0027(5) -0.0100(4) 0.0179(5) 
F6 0.0369(6) 0.0636(7) 0.0275(5) 0.0139(5) 0.0089(4) 0.0280(6) 
F7 0.0677(8) 0.0747(9) 0.0341(6) 0.0146(6) 0.0085(6) 0.0574(8) 
F8 0.0338(5) 0.0310(5) 0.0472(6) 0.0061(4) 0.0027(5) 0.0202(4) 
F9 0.0610(8) 0.0573(8) 0.0347(6) -0.0237(6) -0.0170(6) 0.0272(7) 
F10 0.0494(6) 0.0418(6) 0.0316(5) 0.0058(4) 0.0118(5) 0.0327(5) 
F11 0.0309(5) 0.0485(6) 0.0314(5) 0.0164(5) 0.0088(4) 0.0124(5) 
F12 0.0449(7) 0.0403(6) 0.0710(9) -0.0219(6) -0.0248(6) 0.0293(6) 
O1 0.0404(8) 0.0352(7) 0.0811(12) -0.0084(8) 0.0113(8) 0.0112(6) 
O2 0.0315(6) 0.0399(7) 0.0434(8) 0.0008(6) -0.0042(6) 0.0164(6) 
O3 0.0433(8) 0.0724(11) 0.0463(8) 0.0127(8) 0.0089(7) 0.0402(8) 
N1 0.0133(4) 0.0161(4) 0.0148(5) 0.0001(4) -0.0008(4) 0.0060(4) 
N6 0.0128(4) 0.0156(4) 0.0163(5) -0.0014(4) -0.0006(4) 0.0048(4) 
C00 0.0223(6) 0.0169(6) 0.0225(7) -0.0042(5) -0.0041(5) 0.0022(5) 
C01 0.0120(5) 0.0150(5) 0.0133(5) -0.0005(4) -0.0008(4) 0.0058(4) 
C02 0.0157(5) 0.0126(5) 0.0160(5) 0.0002(4) -0.0026(4) 0.0030(4) 
C03 0.0181(6) 0.0137(5) 0.0148(5) -0.0002(4) 0.0000(4) 0.0011(4) 
C04 0.0127(5) 0.0178(5) 0.0164(5) -0.0061(4) -0.0011(4) 0.0062(4) 
C05 0.0095(5) 0.0168(5) 0.0215(6) -0.0043(4) 0.0004(4) 0.0041(4) 
C06 0.0218(6) 0.0198(6) 0.0218(6) 0.0045(5) -0.0025(5) 0.0074(5) 
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 U11 U22 U33 U23 U13 U12 
C07 0.0192(6) 0.0169(5) 0.0220(6) -0.0046(5) -0.0003(5) 0.0069(5) 
C08 0.0418(10) 0.0348(9) 0.0465(11) 0.0041(8) 0.0092(9) 0.0174(8) 
C09 0.0189(6) 0.0157(5) 0.0200(6) -0.0022(4) -0.0040(5) 0.0033(5) 
C0E 0.0165(5) 0.0191(5) 0.0171(6) 0.0017(4) 0.0004(4) 0.0103(5) 
C0M 0.0269(7) 0.0314(7) 0.0237(7) 0.0126(6) 0.0075(6) 0.0113(6) 
C0F 0.0145(5) 0.0164(5) 0.0193(6) -0.0036(4) 0.0002(4) 0.0065(4) 
C0Q 0.0118(5) 0.0123(5) 0.0151(5) -0.0011(4) -0.0018(4) 0.0035(4) 
C0O 0.0118(5) 0.0151(5) 0.0154(5) -0.0005(4) -0.0008(4) 0.0031(4) 
C0N 0.0234(6) 0.0211(6) 0.0251(7) -0.0069(5) -0.0039(5) 0.0110(5) 
C0I 0.0175(6) 0.0195(6) 0.0220(6) -0.0050(5) -0.0032(5) 0.0087(5) 
C0B 0.0278(7) 0.0191(6) 0.0158(6) 0.0021(5) 0.0023(5) 0.0025(5) 
C0H 0.0271(8) 0.0379(9) 0.0390(10) 0.0075(7) -0.0011(7) 0.0096(7) 
C0G 0.0151(5) 0.0186(5) 0.0168(6) 0.0002(4) -0.0003(4) 0.0076(4) 
C0R 0.0168(5) 0.0186(5) 0.0166(6) -0.0008(4) 0.0040(4) 0.0042(5) 
C011 0.0106(5) 0.0168(5) 0.0156(5) 0.0006(4) -0.0002(4) 0.0046(4) 
C0J 0.0425(10) 0.0324(9) 0.0392(10) 0.0116(7) 0.0057(8) 0.0146(8) 
C0D 0.0136(5) 0.0189(5) 0.0156(5) -0.0006(4) 0.0009(4) 0.0065(4) 
C0S 0.0145(5) 0.0150(5) 0.0144(5) 0.0000(4) -0.0018(4) 0.0042(4) 
C0K 0.0242(7) 0.0163(5) 0.0230(7) -0.0052(5) -0.0050(5) 0.0063(5) 
C0T 0.0162(5) 0.0157(5) 0.0161(6) -0.0014(4) -0.0015(4) 0.0032(4) 
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 U11 U22 U33 U23 U13 U12 
C0C 0.0118(5) 0.0173(5) 0.0174(6) 0.0002(4) -0.0015(4) 0.0035(4) 
C0L 0.0127(5) 0.0193(6) 0.0246(7) -0.0012(5) -0.0030(5) 0.0044(4) 
C0P 0.0195(6) 0.0279(7) 0.0279(7) 0.0036(6) -0.0010(5) 0.0156(6) 
C0V 0.0349(8) 0.0415(9) 0.0219(7) 0.0139(6) 0.0103(6) 0.0237(7) 
C0A 0.0122(5) 0.0138(5) 0.0148(5) -0.0006(4) -0.0001(4) 0.0042(4) 
C2AN 0.0157(5) 0.0187(5) 0.0185(6) 0.0003(4) 0.0006(4) 0.0068(5) 
C10E 0.0713(18) 0.0615(16) 0.0332(11) 0.0052(11) -0.0068(11) -0.0105(13) 
C11E 0.089(3) 0.300(7) 0.121(3) 0.154(4) 0.048(3) 0.103(4) 
C14E 0.0674(17) 0.0621(16) 0.081(2) 0.0074(14) 0.0227(15) 0.0411(14) 
C15E 0.0567(17) 0.0583(16) 0.102(3) -0.0364(17) 0.0141(16) -0.0015(13) 
C55E 0.119(3) 0.091(2) 0.0461(14) 0.0252(14) 0.0357(16) 0.072(2) 
C17E 0.0634(14) 0.0549(13) 0.0372(10) -0.0096(9) -0.0146(10) 0.0393(12) 
C18E 0.0530(12) 0.0399(10) 0.0219(8) 0.0088(7) 0.0105(8) 0.0153(9) 
C19E 0.0362(10) 0.0482(11) 0.0552(13) -0.0120(10) 0.0047(9) 0.0207(9) 
N5 0.0087(4) 0.0138(4) 0.0138(4) -0.0010(3) -0.0012(3) 0.0042(3) 
N3 0.0109(4) 0.0137(4) 0.0130(4) -0.0009(3) -0.0006(3) 0.0043(3) 
O1S 0.0447(8) 0.0430(8) 0.0351(7) 0.0000(6) 0.0050(6) 0.0091(7) 
C56E 0.0372(8) 0.0240(7) 0.0175(6) 0.0057(5) -0.0025(6) 0.0068(6) 
C57E 0.0302(8) 0.0252(7) 0.0233(7) 0.0078(5) -0.0053(6) 0.0090(6) 
C58E 0.0132(6) 0.0226(6) 0.0314(8) -0.0001(5) -0.0046(5) 0.0025(5) 
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 U11 U22 U33 U23 U13 U12 
C59E 0.0183(6) 0.0195(6) 0.0260(7) -0.0025(5) -0.0069(5) -0.0002(5) 
 
 
Table 25.  Hydrogen coordinates and isotropic atomic displacement parameters (Å2). 
_______________________________________________________________________ 
 x/a y/b z/c U(eq) 
H00 0.4303 0.3233 0.5337 0.027 
H04A 0.6815 0.8222 0.8605 0.019 
H04B 0.6847 0.9170 0.8058 0.019 
H05A 0.5290 0.7278 0.7081 0.02 
H05B 0.5662 0.6845 0.7897 0.02 
H06 0.6768 0.9331 0.5223 0.026 
H07 0.6543 0.4093 0.5727 0.023 
H09 1.1516 1.1923 0.9759 0.023 
H0E1 0.7562 0.9423 0.6818 0.02 
H0E2 0.6468 0.8482 0.6358 0.02 
H0M1 0.7568 0.5518 1.0109 0.041 
H0M2 0.6268 0.4971 0.9653 0.041 
H0M3 0.6599 0.6027 1.0183 0.041 
H0F 0.8118 0.5439 0.6391 0.02 
H0N 0.8106 1.1826 0.9874 0.027 
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 x/a y/b z/c U(eq) 
H0I 0.7348 1.0341 0.9036 0.023 
H0B 0.9755 0.9011 0.3541 0.028 
H0R 1.0527 0.8326 0.4747 0.022 
H011 1.1060 0.9014 0.8144 0.018 
H0J1 0.5626 0.3652 0.0747 0.057 
H0J2 0.6580 0.3278 0.0325 0.057 
H0J3 0.5886 0.2715 0.1126 0.057 
H0D 1.0301 0.7782 0.6075 0.019 
H0K 1.0194 1.2618 1.0237 0.026 
H0C 1.1854 1.0529 0.8930 0.02 
H0L 0.3703 0.5962 0.6721 0.024 
H0P1 1.2261 0.6825 0.7760 0.035 
H0P2 1.1421 0.5749 0.7299 0.035 
H0P3 1.1345 0.5878 0.8272 0.035 
H10A 0.7412 0.6422 0.1902 0.101 
H10B 0.7028 0.7013 0.2620 0.101 
H10C 0.7206 0.7454 0.1711 0.101 
H11A 0.4140 0.9088 0.4387 0.239 
H11B 0.3221 0.7963 0.4043 0.239 
H11C 0.4650 0.8250 0.4092 0.239 
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 x/a y/b z/c U(eq) 
H14A 0.3105 0.8207 0.2315 0.097 
H14B 0.2105 0.7352 0.1725 0.097 
H14C 0.2446 0.7026 0.2599 0.097 
H15A -0.0448 0.7230 0.2890 0.121 
H15B 0.0136 0.6393 0.2975 0.121 
H15C -0.0105 0.6745 0.2085 0.121 
H55A 0.3899 0.6133 0.1863 0.112 
H55B 0.4913 0.7272 0.1698 0.112 
H55C 0.4758 0.6818 0.2603 0.112 
H17A 0.4256 0.0896 -0.0541 0.071 
H17B 0.5145 0.0980 0.0224 0.071 
H17C 0.5685 0.1579 -0.0602 0.071 
H19A 0.2732 0.7547 0.6172 0.068 
H19B 0.2019 0.7329 0.5305 0.068 
H19C 0.2672 0.8496 0.5672 0.068 
H56E 0.8329 0.9565 0.3008 0.034 
H57E 0.6834 0.9710 0.3842 0.032 
H58E 0.2094 0.4617 0.6063 0.029 
H59E 0.2402 0.3264 0.5365 0.029 
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6.3.8 HPLC conditions for analysis of purity of 86a-j 
Instrument conditions 
Instrument – LCMS-MS (Schimadzu) Nexera X2 connected to LCMS-8040 mass spectrometry 
Software for data processing – Labsolutions Version 5.55  
LCMS conditions 
Column – Kinetex (Phenomenex) 
P/No – 00A-4496-YO 
Destription – Kinetex 2.6 μ XB – C18 100oA 
Size – 30 X 3.0 mm 
Mobile phase A – 0.1% HCOOH in water 
Mobile phase A – 0.1% HCOOH in acetonitrile 
Gradient program 
Time (min) B conc (%) Command 
0.50 1 Pump B conc 
5.50 90 Pump B conc 
5.51 90 Pump B conc 
8.00 90 Pump B conc 
8.01 90 Pump B conc 
12.0 - Stop 
Flow rate – 0.3 mL/min 
Column temperature – 35oC, sample temperature – 10oC 
Injection volume – 1 μL 
Analysis time – 12 min.	  
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CHAPTER 7. TUNING EXCITED STATE LIFETIMES OF RUTHENIUM 
COMPLEXES 
7.1 Introduction 
Photosensitizers are compounds that absorb light (UV or visible) and transfer it to 
adjacent molecules, which then induce a chemical change in the neighboring molecule. These 
compounds have broad applications in chemistry, biology, materials and medicine.283,284 Triplet 
photosensitizers are the compounds that upon irradiation reach triplet states and then transfer 
their triplet energy to adjacent molecules. For instance, in photodynamic therapy, the triplet 
photosensitizers transfer their energy to triplet oxygen (3O2) to generate singlet dioxygen species 
(1O2) (Figure 9a, chapter 1).58,67,71,283,285 Triplet sensitizers are being used for numerous 
applications such as PDT,286-289 molecular sensing,290-292 light-initiated polymerization, and 
electroluminescence.293,294 Photosensitizers are also used in redox catalysis, as excited states can 
act as strong oxidant or reductant.295-297 A good triplet photosensitizer should have a strong 
visible light absorption (high ε value), effective conversion of singlet excited state to triplet 
excited state (quantum yields) and long-lived triplet excited states.298,299 While transition metal 
complexes absorb visible light, their molar absorption coefficients (ε) and their triplet lifetimes 
are usually small, so most of the complexes are not useful as triplet photosensitizers.283  
Ruthenium-based compounds are an important class of photosensitizers that have 
undergone decades of development to tune their excited state properties.10,284,300-304 The majority 
of the previous studies were largely focusing on ligands with denticities of three or below for the 
ruthenium complexes.305 Figure 44 shows a few examples of Ru-based photosensitizers, where 
95 is considered as a gold standard which has a long-lived excited state of 0.890 μs in ambient 
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H2O when the complex is excited at 452 nm. More recently developed complexes have their 
emission lifetimes in microsecond range.306-308 
 
Figure 44: Examples of Ru-based photosensitizers 
In this chapter, we report a new class of ruthenium-based photosensitizers derived from 
the chromophore Ru(TQA), where TQA (tris(isoquinolin-1-ylmethyl)amine) is a tetradentate 
ligand. The longer a molecule stays at the excited state, the greater is the likelihood of it 
undergoing an electron or energy transfer to its neighboring molecules. Thus excited state 
lifetime plays a key role in the use of compounds as photosensitizers. The [Ru(TQA)(X)2]m+ 
complexes described in this chapter have consistently longer lived emitting triplet metal to ligand 
charge transfer (3MLCT) excited states at 77 K than do their Ru-bipyridine analogs even though 
their lowest energy triplet metal centered (3MC) excited states have energies that are lower than 
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or comparable to the emitting MLCT excited state energies. These observations indicate that the 
longer 3MLCT lifetimes found for these complexes are unique properties of the Ru-TQA 
chromophore and suggest that achieving long lived MLCT excited states depends on the 
optimization of some excited state electronic properties of the complexes and not just finding 
complexes for which the 3MLCT excited state is lower in energy than any 3MC excited state.  
7.2 Results and discussions 
7.2.1 Synthesis and characterization of complexes 101 and 102 
Three compounds were developed and examined in this study. Two new derivatives of 
Ru(TQA) were prepared  (Scheme 18), along with a third compound reported in the previous 
chapter (91).309 Treating the ligand TQA227 with 1 equiv. of cis-[Ru(DMSO)4(Cl)2] in refluxing 
MeOH resulted in formation of [Ru(TQA)(DMSO)(Cl)]Cl, isolated as a mixture of 
stereoisomers. As described previously, treating this intermediate with 1:1 MeCN:H2O at 80 °C, 
followed by precipitation with NH4PF6 provided [Ru(TQA)(MeCN)2](PF6)2 (91).309 Alternatively, 
heating [Ru(TQA)(DMSO)(Cl)]Cl  in 1:1 EtOH:H2O at 80 °C in the presence of 10 equiv. of 
NaCN or KSCN provided [Ru(TQA)(CN)2] (101) and [Ru(TQA)(SCN)2] (102), respectively, in 
59-61% yield. 
 
Scheme 18. Synthesis of Ru(TQA) complexes 101 and 102 
Ru
N N
N
N
X
X
N
NN
N
1) cis-[Ru(DMSO)4(Cl)2]
MeOH, 60 oC
2) MX (10 equiv)
EtOH, H2O, 80 oC
TQA
MX = NaCN or KSCN
[Ru(TQA)(CN)2] (101) (61%)
[Ru(TQA)(SCN)2] (102) (59%)
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Complexes 101 and 102 were characterized by 1H NMR, UV-vis and IR spectroscopies. 
X-ray crystallographic data for 91 is at the end of the previous chapter. Spectroscopic data for 
the three complexes are highly consistent across the series. 1H NMR spectra of all the three 
complexes show two distinct sets of resonances for the 3-isoquinoloyl CH groups, present in a 
2:1 ratio at approximately 9.8-8.6 ppm. UV-vis data indicate strong absorbance in the visible 
region; with metal-to-ligand charge transfer (MLCT) bands occurring with λmax values for MeCN 
(ε424 = 12,000 M-1cm-1), CN (ε470 = 9,600 M-1cm-1) and SCN (ε510 = 9,440 M-1cm-1). The IR 
spectrum of 101 shows diagnostic strong absorbances at 2063 and 2043 cm-1, consistent with CN 
binding to Ru(II). Likewise, the IR spectrum of 102 shows a strong absorbance at 2102 cm-1, 
consistent with N-bound thiocyanate.310,311  
7.2.2 Excited state lifetimes and quantum yield calculations 
The efficiency of the photosensitization process generally depends on the properties of 
the lowest energy photosensitizer excited state (LEES). Since the photosensitized reactions of 
interest occur in competition with intra-sensitizer processes leading to excited state deactivation, 
the intrinsic LEES lifetime (τin) is a critical excited state property, which is inversely dependent 
on the sum of the rate constants for intra-sensitizer deactivation processes: (τin)-1 = (kRAD + kNRD + 
kIC), where the most important deactivation processes are radiative decay (RAD), non-radiative 
population of ground state vibrational modes (NRD) and the population of a shorter lived excited 
state (typically 3MC) with the same spin multiplicity (IC). The new class of ruthenium-quinoline 
based photosensitizers reported in this chapter has values of τin that are an order of magnitude 
larger than those of paradigmatic Ru-bipyridine chromophores (Table 26). Derivatives of 
Ru(TQA) show remarkably long-lived excited states and relatively high emission quantum yields 
with several different ancillary ligands, X, demonstrating that Ru-(TQA) is a special, highly 
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consistent chromophore with unique intrinsic properties. Furthermore, these long 77 K lifetimes 
are observed even though the 3MLCT is not always the lowest energy excited state (contrary to 
Kasha’s rule),312 presumably because of large reorganizational barriers to internal conversion.313 
Excited state lifetime and emission spectrum studies presented in this chapter were performed by 
the Endicott group. 
Ligands 
 L(X)2 
hυmax 
cm-1/103 
τin , 
 µs 
Φem τTQA 
/τbpy 
TQA(MeCN)2 18.3 145 0.45 17 
(bpy)2(MeCN)2 18.5 8.3 0.6  
TQA(CN)2 17.3 78 0.26 22 
 (bpy)2(CN)2 15.9 3.4 0.27  
TQA(NCS)2b 16.0 17.6 0.50 31 
 (bpy)2(NCS)2b 14.9 0.57 0.084  
Table 26. Excited state lifetimes (τin) and emission quantum yields (Φem) of some 
[RuL(X)2]m+ complexes at 77 Ka . a Determined in ethanol/methanol (v/v' = 4/1) solvent 
except as indicated. b Butyronitrile. 	
The emission spectra of the [Ru(TQA)(X)2]m+ complexes in Figure 45 differ from those of 
the Ru-bpy analogs314,315 in Table 26 in that the dominant vibronic feature, the second highest 
energy peak in the spectra, is relatively more intense and suggestive of more configurational 
mixing between the 3MLCT and aromatic ligand-based ππ* excited state.316  
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Figure 45. A) Lifetime determination for 91; B) Emission spectra for [Ru(TQA)(L)2]m+ 
complexes 91 (L = MeCN, black), 101 (L = CN, red) and 102 (L = SCN, blue). 
 
7.2.3 DFT calculations 
DFT calculations were performed by the Schlegel group on the 3MLCT states to 
understand the origins of the longer lifetimes of the Ru(TQA) complexes compared to the 
Ru(bpy)2 species. The 3MLCT state MOs of Ru(TQA) and Ru(bpy)2 complexes (Figure 46) show 
that the metal-based singly occupied MOs (SOMOs) of Ru(TQA) complexes have significant 
contribution (35-54%) from the π orbital of one of the quinoline (Q) moieties and as a result, 
they exhibit significant π -delocalization between Ru d π  and Q π  orbitals. The 
[Ru(TQA)(MeCN)2]2+ (91) complex is particularly striking since the extent of delocalization is 
quite large (Ru d π and quinoline π 54%)  and the Ru spin density of 0.54 is also unusually low. 
In contrast to the Ru(TQA) complexes, the Ru(bpy)2 species show less contribution (11-19%) 
from the bpy ligand in the metal-centered SOMOs as illustrated in Figure 46. These results 
suggest that the emitting excited states of the Ru(TQA) complexes are not pure 3MLCT states, 
but that they have significant contributions from the quinoline 3π,π * states. In contrast, the 
3MLCT states of Ru(bpy)2 complexes have much less contribution from the π,π * states. Since 
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the 3π,π * state is intrinsically longer-lived than a pure 3MLCT state, this greater configurational 
mixing is very likely the origin of the longer excited state lifetimes for the Ru(TQA) species. 
Among the four complexes studied by DFT, [Ru(TQA)(MeCN)2]2+  displays the highest mixing. 
In a previous study of Ru-bpy chromophores316 we showed that variations of the ancillary ligands 
results in variations in the 3MLCT excited state energy and thereby “tunes” the 
3MLCT/3ππ*(bpy) mixing, and the same behavior is apparently the case for the TQA complexes.  
Table 27 lists the relative energies of the 3MLCT and the 3MC states. The 3MC energies 
calculated for the cyanide complexes are close to or slightly higher than those of the 3MLCT 
states, while the MeCN complexes have significantly lower energy 3MC states.  
 
Figure 46. Metal-based SOMOs (corresponding orbitals with isovalue of 0.03 a.u.) and 
orbital contributions (%) of Ru and ligands for A) [Ru(TQA)(MeCN)2]2+ (91); B) 
[Ru(TQA)(CN)2] (101); C) [Ru(bpy)2(MeCN)2]2+; D) [Ru(bpy)2(CN)2] in the 3MLCT 
optimized geometries.  
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ΔE SOMO(1) SOMO(2) 
cm-1 × 103 Ru Ligand Ru Ligand 
A 
3MLCT (T3) 0 45 54 3 97 
3MC (T0) -4.5 78 17 77 17 
3MC (T1) -3.3 77 18 91 8 
3MC (T2) -2.8 75 22 86 9 
B 
3MLCT (T1) 0 62 35 3 97 
3MC (T0) -1.2 75 17 81 8 
C 
3MLCT (T1) 0 78 19 2 98 
3MC (T0) -3.7 92 6 74 16 
D 
3MLCT (T0) 0 81 11 2 98 
3MC (T1) 2.1 91 2 73 22 
 
Table 27. Relative energies of the 3MLCT and 3MC states and orbital contributions (%) 
of Ru and ligands to the SOMOs of A) [Ru(TQA)(MeCN)2]2+(91); B) [Ru(TQA)(CN)2] 
(101); C) [Ru(bpy)2(MeCN)2]2+; D) [Ru(bpy)2(CN)2]. Energies of the 3MLCT states are 
set to be zero. Energies of the 3MC states are compared to those of the 3MLCT states.  
 
The energy barrier for the internal conversion is expected to be small enough so that the 
3MC states can be thermally accessed at ambient temperature in the case of MeCN complexes.313 
These results are in agreement with the difficulty in finding any ambient emission from these 
complexes and with our previous report of CH3CN photodissociation from 
[Ru(TQA)(MeCN))2]2+ at room temperature.309  
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7.3 Discussions and conclusions 
A new class of ruthenium-based photosensitizers was developed and their excited state 
life-times and DFT calculations were performed. Complexes which were part of the study had 
general formula [Ru(TQA)(X2)]n+, where TQA is tris(isoquinoline-1-ylmethyl)amine, and X = 
MeCN (91), CN (101) or SCN (102) with n = 0 or 2. These complexes showed exceptionally 
long-lived excited states (τem = 78-145 μs) and high emission quantum yields (ϕem = 0.26-0.50) 
at 77 K. The chromophore Ru(TQA) furnishes complexes with extremely long-lived excited 
states. Although long lifetimes have been achieved before by appending aromatic acceptors (AA) 
on a Ru-(polypyridine) chromophore,306,308,317 such complexes take advantage of a reversible 
energy transfer equilibrium between a pendant AA moiety with a very long intrinsic lifetime and 
the shorter lived Ru-(polypyridine) 3MLCT state. In marked contrast, the systems in the current 
chapter demonstrate that intrinsic long excited state lifetimes depend on the configurational 
mixing between the 3MLCT excited state of the donor/acceptor complex and a acceptor/ligand 
localized excited state. 
7.4 Experimental procedures 
7.4.1 Synthesis and characterization of complexes 101 and 102 
Synthesis of 101 [Ru(TQA)(CN)2] - TQA (47.2 mg, 0.11 mmol), which was prepared by 
a known procedure227 was dissolved in 10 mL of dry MeOH under inert atmosphere in a pressure 
flask. To this, Ru(DMSO)4Cl2 (52.0 mg, 0.11 mmol) was added and the solution was purged with 
Ar for 10 min at room temperature. The reaction mixture was refluxed for 5 h under inert 
temperature. Color of the reaction mixture changes from pale yellow to dark red. The reaction 
mixture was cooled to room temperature and concentrated under reduced pressure. To the flask, 
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NaCN (53.9 mg, 1.1 mmol) and a 1:1 mixture of EtOH: H2O (10 mL) was added, and the 
reaction mixture was refluxed for 16 h under inert atmosphere. Ice cold water (20 mL) was then 
added to the reaction mixture which resulted in the formation of dark red precipitate, which was 
filtered and washed with ice cold water (300 mL) and dried under reduced pressure to give title 
complex as a dark red solid (39 mg, 61%): Mp = 194 oC (decomp); 1H NMR (400MHz 
(CD3)2SO) δ 9.64(d, 1H, J = 6.0 Hz), 8.66(d, 2H, J = 6.4 Hz), 8.14-8.16(m, 2H), 7.90-7.82(m, 
3Hz), 7.77-7.70(m, 6H), 7.65-7.62(m, 3H), 7.51(t, 1H, J = 8.0 Hz), 5.94(d, 2H, J = 15.6 Hz), 
5.54-5.49(m, 4H); IR (KBr) νmax (cm-1) 3852, 3744, 3726, 3673, 3528, 3432, 3252, 2994, 2947, 
2891, 2063, 2043, 1693, 1650,  1594, 1553, 1503, 1453, 1394, 1376, 1317, 1294, 1262, 1236, 
1198, 1145, 1099, 955, 827, 748, 679, 668, 660; UV-vis λmax = 470 nm (ε = 9,600 M-1cm-1); Anal. 
Calculated for C100H86N18O3Ru3: (3 moles 101·2 moles H2O and 1 mole Et2O) C, 63.51; H, 4.58; 
N, 13.33. Found: C, 63.49; H, 4.54; N, 13.29. 
Synthesis of 102 [Ru(TQA)(SCN)2] - TQA (27.3 mg, 0.06 mmol) was dissolved in 10 
mL of dry MeOH under inert atmosphere in a pressure flask. To this, Ru(DMSO)4Cl2 (30.0 mg, 
0.06 mmol) was added and the solution was purged with Ar for 10 min at room temperature. The 
reaction mixture was refluxed for 5 h under inert temperature. Color of the reaction mixture 
changes from pale yellow to dark red. The reaction mixture was cooled to room temperature and 
concentrated under reduced pressure. To the flask, KSCN (58.2 mg, 0.6 mmol) and a 1:1 mixture 
of EtOH: H2O (10 mL) was added and the reaction mixture was refluxed for 16 h under inert 
atmosphere. Ice cold water (20 mL) was then added to the reaction mixture followed by saturated 
brine solution, which resulted in the formation of dark red precipitate that was filtered and 
washed with ice cold water (300 mL) and dried under reduced pressure to give title complex as a 
dark red solid (24 mg, 59%): Mp = 214 oC (decomp); 1H NMR (400MHz (CD3)2SO) δ 9.03(d, 
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1H, J = 6.4 Hz), 8.55(d, 2H, J = 6.4 Hz), 8.19-8.17(m, 2H), 7.98-7.96(m, 2Hz), 7.84-7.82(m, 
3H), 7.79-7.75(m, 5H), 7.62(t, 2H, J = 6.4 Hz), 7.50(t, 1H, J = 8.0 Hz), 5.92(d, 2H, J = 15.6 Hz), 
5.46(s, 2H), 5.19(d, 2H, J = 15.6 Hz),; IR (KBr) νmax (cm-1) 3901, 3743, 3419, 3261, 2917, 2101, 
1705, 1622, 1593, 1552, 1504, 1451, 1395, 1316, 1224, 1199, 1146, 1093, 1014, 949, 871, 827, 
796, 749, 658, 641, 616; UV-vis λmax = 510 nm (ε = 9,440 M-1cm-1); Anal. Calculated for 
C32H32N6O4RuS2: (102·4 H2O) C, 52.65; H, 4.42; N, 11.52. Found: C, 52.68; H, 4.45; N, 11.49. 
7.4.2 UV-Vis Spectra conditions 
The UV-vis spectra were determined in ethanol-methanol ([Ru(TQA)(NCCH3)2]2+ (91) 
and [Ru(TQA)(CN)2]0) (101) and butyronitrile ([Ru(TQA)(NCS)2]0) (102) (Figures 46-48) 
glasses using a Quartz Tungsten Halogen (QTH) lamp as the light source for low-temperature 
spectroscopic measurements. An Oxford Instruments OptistatCF static exchange gas continuous-
flow cryostat with liquid nitrogen as the cryogen was employed at 90 K with NSG Precision 
Cells, Inc. cryogenic square 1 cm quartz cuvettes. The detection system was an ANDOR 
Shamrock 500 spectrometer with dual exit ports and equipped with a 600 l/mm, 500 nm blaze 
grating. Light was collected with a lens and transmitted by means of Thorlabs 3 mm Core Liquid 
Light Guide LLG0338-4 (wavelength range 340 – 800 nm) to an Andor F/# matcher SR 500i to 
the spectrometers entrance slit. The ANDOR Newton detector and liquid light guide combination 
that was used for spectroscopic determinations has no response to light wavelengths less than ~ 
400 nm. As a result, any response shown less than or equal to 400 nm is the result of partial 90 K 
absorption.  
  
	
207 
400 450 500 550 600 650 700 750 800
-0.2
0.0
0.2
0.4
0.6
0.8
1.0  [Ru(TQA)(NCCH3)2]
2+ Ambient Temp
 [Ru(TQA)(NCCH3)2]
2+ 90 K
 
 
Ab
so
rb
an
ce
Wavelength, nm 	
Figure 47- Absorption spectrum of 91 at RT (black) and at 90 K (red) 
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Figure 48- Absorption spectrum of 101 at RT (black) and at 90 K (red) 
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Figure 49- Absorption spectrum of 102 at RT (black) and at 90 K (red) 
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CHAPTER 8. CONCLUSIONS 
8.1 Goals achieved and future directions 
Light can be controlled both temporally and spatially and it can also be used in 
activation of numerous compounds through energy transfer.2 This ability of light can be 
harnessed to develop new tools for solving problems in biology. Three different projects are 
discussed in this dissertation, so the goals achieved and their corresponding future directions 
are also discussed in three different sections.  
8.1.1 Caging nitrile based inhibitors of cathepsin K and B using Ru(bpy)2 
caging group: 
Light activated compounds can be used as tools for understanding and solving 
numerous biological problems.43,148 To develop metal-based photocages as tools for biology, 
we chose cathepsin enzymes as our initial targets. Cathepsins are required for normal cell 
growth and are involved in numerous physiological functions and are thus called 
housekeeping enzymes.85,93,95,129,196,318,319 Numerous results have shown that these enzymes are 
over expressed in numerous tumors and other pathological problems.83,92,94,99,105,106,109,320,321 
These results suggest that cathepsins could be viable target for cancer chemotherapy and 
treatment of other disorders. Several academic and industrial research groups developed 
numerous inhibitors for targeting cathepsins.93,124,131,132,140,154,201,202,322-326 While these inhibitors 
were both potent and selective towards cathepsins, they could not reach the market due to 
their off-target reactivity and inhibition of cathepsins in normal cells. The photolabile group 
strategy we developed could be useful in achieving spatial control over the activation of these 
inhibitors. We envisioned that these inhibitors can be protected using photolabile-protecting 
groups and be specifically released at the target site. Towards this end, we have developed 
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nitrile-based caged cathepsin inhibitors, which can be released using light. Ru(bpy)2 was 
used as a group for caging numerous nitrile-based cathepsin B and cathepsin K inhibitors. 
Initially we used known nitrile-based inhibitors of CTSK and CTSB for our photolabile 
caging strategy. Later we also synthesized an analog of a known CTSB inhibitor, which was 
caged successfully. These inhibitors are stable in the dark and release the active inhibitor 
when irradiated with light of suitable wavelength. In the first few chapters of this 
dissertation, we have shown that spatial and temporal control can be achieved for enzyme 
inhibitors using photolabile-caging groups. These caged molecules were shown to inhibit 
cathepsin activity in isolated enzyme assays and also in 2D and 3D assays.171 Moreover no 
toxic effects were seen from either the complexes or their corresponding photolysis 
byproducts, which makes us believe that this strategy would be extremely useful in studying 
aberrant proteolysis in tumor models.  
The focus of this dissertation was only on nitrile-based cathepsin B and K inhibitors, 
and current research in our group is directed towards inhibition of other proteases, which are 
over expressed in numerous pathological states. New nitrile-based cathepsin inhibitors or 
their analogs with higher activity and selectivity can be synthesized and caged for developing 
the photocaging applications.  
While only nitriles were used, other functionalities such as pyridines, imidazoles and 
thioethers can also be caged using various ruthenium-caging groups, thus increasing the 
applicability of this method across different inhibitor groups apart from nitriles. Stability of 
caged complexes in different mediums is an important factor that could determine the 
usefulness of our caging strategy. While caged nitriles were successful for preliminary 
studies, where they showed good stability profiles in DMSO, some lacked long-term stability 
  
	
211 
in other biological mediums. Pyridines on the other hand have greater affinity towards 
ruthenium when compared to nitriles, which could be useful for increasing the stability of the 
caged complex in dark. 
Rate of photodissociation is also an important factor in photocaging strategy. The 
quantum yields for the complexes synthesized and studied were low and some compounds 
required a longer irradiation time. New methods could be developed to increase the rate of 
photodissociation. One strategy would be to increase the steric bulk on the metal complex, 
which could assist in ligand release. While the caged complexes are charged, the free 
inhibitors are hydrophobic. Our studies have also shown that the released inhibitors, due to 
their hydrophobic nature, are trapped in the solvent cage, which decreases the overall 
quantum yields. Water-soluble inhibitors with polar groups could increase the quantum 
yields by assisting in inhibitor solubility. 
Enzymes have different functions in various locations of human body. While 
numerous research articles have been dedicated towards studying their functions and 
distribution; it is not completely understood. Photocaging can be used for understanding the 
role of enzymes and other biological molecules in the body. Small molecules can be caged 
and specifically delivered using photocages, and their effects on different physiological 
functions can be studied. 
A combination strategy can also be developed where cathepsin inhibitors with 
different functionalities are caged using suitable metal complexes. Upon photolysis the caged 
complex acts as dual therapeutic agent where the inhibitors interact with the enzymes and the 
metal complex either generates singlet oxygen species through triplet sensitization or induces 
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DNA damage. Both oxygen sensitization and DNA damage can induce cell death, thus 
paving a way for dual strategy. 
8.1.2 Developing new ligands for photocaging applications: 
In the latter part of this dissertation, focus was laid towards developing new caging 
groups for nitriles. Traditionally small, flat heteroaromatic ligands are used as ancillary 
ligands for caging groups. Here we have shown that tertiary nitrogen-based tetra- and 
pentadentate ligands can also be used for caging nitrile groups.221,309 The ligands were 
developed for tuning the MLCT bands more towards the PDT region to decrease the damage 
caused to tissues by light. Also these tertiary amine-based ligands are known to be useful for 
attaching metal complexes to drug delivery vectors, which could provide an additional 
advantage to the caging strategy.209,210 We initially synthesized and studied TPA ligand-based 
acetonitrile-Ru complex and inhibitor-Ru complex. Both complexes showed ligand exchange 
with UV light irradiation where only one potential nitrile based ligand was released on 
photolysis.221  
Usually metal complexes are synthesized and screened one molecule at a time. This 
method is not practical if inorganic molecules are to compete with their organic counterparts 
as therapeutic agents and biochemical tools, which are usually synthesized and screened in a 
library fashion.215,218,231 Towards this end, a new platform for discovering metal-based caging 
groups was developed. We have shown that solid phase synthesis can be used for synthesis 
and screening of ligands and their corresponding metal complexes for the caging 
applications.309 Ten different ligands and their acetonitrile-ruthenium complexes were 
synthesized and their photochemistry was studied. Synthesizing and studying the complexes 
in solution phase verified the results from solid phase. The wide range of photochemical 
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reactivity of the synthesized complexes illustrated the need for prescreening compounds 
using the library approach, as solution phase synthesis is tedious. Several complexes showed 
no photochemical nitrile release, despite having their MLCT bands in the visible region, 
indicating that achieving ligand exchange is much more complex than irradiating into a 
MLCT band. 
This solid phase synthesis approach can be used to screen for caging other functional 
groups such as pyridines, imidazoles and thioethers using the same library instead of making 
them through solution phase. The library can also be extended to study other ligands and 
metal complexes. Toxicity of ruthenium-based metal complexes depends on both the 
structure of the ligand and the structure of the inhibitor. Only photochemical studies were 
performed on the complexes made by solid phase during this dissertation period. Toxicity of 
complexes should also be studied on metal complexes synthesized from the library approach.   
Photocaging provides spatial control over small molecules but current photocages 
cannot affect the distribution of the caged molecules to the target site. Drug delivery vectors 
can be used for achieving control over distribution.209 Ligands with attached delivery vectors 
should be used to synthesize and study metal-based caged complexes. This property would 
be useful if photocages are to be developed as drugs and prodrugs for tumors and other 
pathological conditions, as the overall dose of the inhibitor can be decreased using controlled 
delivery.  
Metal complexes based on TPA and TQA have shown the release of only one nitrile 
group out of the two potential bound nitriles. The released nitriles were assigned cis to the 
basic nitrogen. The non-labile trans nitriles can be replaced by strong sigma-donating groups, 
which could increase the quantum yields for exchange of cis nitriles. Also new complexes 
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with more sterically crowded tetra- and penta-dentate ligands should be used, as steric bulk 
on ligands can accelerate ligand dissociation.     
Energy transfer FRET chemistry can be utilized for inducing ligand dissociation 
using less energetic light. In FRET chemistry, a donor chromophore absorbs light and 
transfers its energy through nonradiative coupling to the acceptor chromophore. While FRET 
chemistry is used in numerous other energy transfer reactions, it has not been applied for 
caged cathepsin inhibitor complexes. Ruthenium complexes with attached organic 
chromophores such as Resorufin, Ampliflu Red and Resazurin can be developed which can 
absorb less energetic light and transfer it to the metal center to induce ligand exchange.  
8.1.3 Developing new ruthenium complexes as photosensitizers: 
In the final part of this dissertation ruthenium complexes were developed as triplet 
sensitizers, which could be used in solar cell applications. We developed ruthenium complexes 
based on the TQA ligand with exceptionally long triplet-excited lifetimes at 77K, which can be 
used for energy transfer reactions. Three complexes with general formula [Ru(TQA)(X)2]n were 
synthesized and studied where X was an ancillary ligand (X = MeCN or CN or SCN). 
Experimental and DFT calculation results suggest that achieving long lived MLCT excited states 
depends on the optimization of some excited state electronic properties of the complexes and not 
just finding complexes for which the 3MLCT excited state is lower in energy than any 3MC 
excited state. Though we achieved exciting results, these were far from practical applicability as 
they were performed at 77K. Other isomers of TQA ligand can be used for tuning the excited 
state properties. Metals like iridium should also be used as numerous Ir complexes have 
relatively longer excited-state lifetimes compared to their Ru counterparts. Also strong donating 
ancillary ligand groups could increase the excited state-lifetimes. 
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    ABSTRACT 
SYNTHESIS AND BIOLOGICAL EVALUATION OF NITRILE-BASED INHIBITORS 
OF CYSTEINE PROTEASES CAGED WITH RUTHENIUM COMPLEXES 
 
by 
RAJGOPAL SHARMA 
     December 2015 
Advisor: Jeremy J. Kodanko, Ph.D. 
Major: Chemistry (Organic) 
Degree: Doctor of Philosophy 
Light activated compounds can be used as tools for understanding and solving numerous 
biological problems. This dissertation focuses on developing ruthenium-based photocages for 
caging nitrile-based cysteine protease inhibitors. Four research areas pertaining to this 
dissertation, i) metals in medicine, ii) photocages in biological applications, iii) photodynamic 
therapy and iv) cysteine cathepsin proteases were briefly surveyed in the introductory chapter. 
Next, Ru(bpy)2 group was utilized for synthesizing nitrile-based caged CTSK and CTSB 
inhibitors. Light activated release of inhibitors, followed by toxicity and stability data were 
studied. Cathepsin enzyme activity inhibition in 2D and 3D assays were established. This work 
showcased the applicability of ruthenium complexes in photocaging cathepsin inhibitors for 
gaining spatiotemporal control over enzyme inhibition. Later we reported that ruthenium (II) 
tri(2-pyridylmethyl)amine, a polypyridyl ligand distinct from the established Ru(bpy)2 class,  is 
an effective caging group for nitriles that provides high levels of control over cathepsin activity 
with light. Also a library approach was developed by solid phase that provides rapid access to 
new complexes for screening photochemical behavior. Ligands designed to tune spectral 
properties of the ruthenium-based photocaging group were synthesized in parallel fashion on 
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resin.  The library was processed to form caged ruthenium complexes bound to resin, then 
subsequently cleaved and analyzed for photochemical reactivity. Three compounds identified 
from this screen were synthesized by solution phase and characterized spectroscopically and 
photochemically. Data were in good agreement with compounds from solid phase, thus 
validating the predictive power of our library approach. Finally new ruthenium complexes based 
on TQA ligand were developed and studied for excited state lifetimes. 
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